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Abstract
Background
Increasing evidence indicates that oxidative injury exists in schizophrenia. Although
it may not be the main cause, oxidative damage has been suggested to contribute to
the pathophysiology and may account for deteriorating course and poor outcome in
schizophrenia. There is increasing interest in the neuroprotective efficacy of
antioxidants in modulating such processes with at least one polyphenolic being
tested as a prophylactic in Alzheimer’s disease. Beneficial effects of adjunctive -3
(n-3 series) polyunsaturated fatty acids with combined intakes of vitamin C and E on
both the positive and negative symptoms of schizophrenia have been reported.
Robust in vitro systems are desirable, enabling a mechanistic investigation of the
molecular mechanisms underpinning such effects and identification of further
potentially efficacious nutraceuticals.
Materials and Method
Comparative studies employing a lymphoblastoid cell line of schizophrenic origin, a
neuroblastoma IMR-32 cell line and the lymphoma U937 cell line was undertaken.
The cytoprotective effects of phenolic antioxidants and essential fatty acids in
affording protection to cellular DNA, protein and lipids from an oxidative challenge
were assessed in the three cell lines. In addition, two human studies were
undertaken. The first study utilised the non-invasive technique of breath hydrocarbon
analysis and the lipid peroxidation products in a population of schizophrenic patients
were compared to a population of apparently healthy aged-matched control subjects,
while the second study investigated possible differences in biomarkers of DNA, lipid
Abstract iv
and protein oxidation in schizophrenic and control subjects. Plasma vitamin C levels
were also compared in both groups.
Results and Conclusion
Cell Culture Studies: Pre-treatment of peripheral and neuronal cells with antioxidant
or -3 fatty acids followed by an oxidative challenge significantly reduced the levels
of DNA damage. Treatment with H2O2 alone and following pre-treatment with EPA
or DHA had no effect on the levels of protein carbonyls in U937 cells, however,
DHA supplementation did appear to reduce endogenous and H2O2-induced protein
carbonylation. Marked differences in the uptake of fatty acids by the cell types were
found and the IMR-32 cell line was most susceptible to the oxidant challenge.
Hydroxytyrosol gave significant cytoprotection in all three cell lines and this
possible neuroprotective efficacy warrants further investigation, both in vitro and in
vivo. Treatment of the three cell lines with a high concentration of H2O2 for 30min or
4 hours did not induce a significant increase in MDA. U937 cells were supplemented
for 24 hours with fatty acids followed by a 4 hour oxidative stress. Both EPA and
DHA treatment appeared to reduce LOOH levels in the U937 cells but not
significantly. Cytoplasmic PLA2 activity in the three human cell lines was examined
and the basal level of cPLA2 activity was found to be comparable in the
lymphoblastoid and IMR-32 cells but significantly lower than that measured in the
U937 cells. Supplementation of the U937 cell line with EPA caused a significant
decrease (p<0.05) in cPLA2 activity relative to the vehicle treated control but neither
EPA nor DHA supplementation appeared to have any significant effect on either
total PLA2 or cPLA2 activity in IMR-32 or lymphoblastoid cell lines.
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Human Studies: No significant difference was found between the levels of ethane
and pentane in the breath from the schizophrenic patients and control samples. In
addition, no significant difference in the levels of plasma MDA between the two
groups was detected. Ethane levels and MDA levels were higher in the male
schizophrenic samples than in the female schizophrenic samples but the results were
not statistically significant. The pentane levels were higher in the female
schizophrenic samples when compared to the male schizophrenia samples but again,
these were not significantly greater. Finally, results of study 2 revealed that cellular
DNA damage and plasma protein carbonyl levels were increased in the
schizophrenic group compared to control subjects but not significantly. However,
DNA damage in lymphocytes from the male schizophrenic group was significantly
higher than the female group. Biomarkers of lipid peroxidation and plasma vitamin
C levels also revealed no significant difference between the two groups under
investigation, although a significant elevation in plasma vitamin C was observed in
the female control group when compared to the male groups.
Treatment of cells with EPA, DHA and hydroxytyrosol to reduce levels of oxidative
damage warrants further investigation. Ultimately, it is important to investigate a
range of biomarkers to determine whether the measurement of oxidative damage to
lipids, proteins and DNA has clinical significance. This will enable better
understanding of the disease of interest and allow these biomarkers to become
potentially useful clinical tools.
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1.1 What is Schizophrenia?
Schizophrenia is a major illness characterised by psychosis, apathy and social
withdrawal and cognitive impairment which results in impaired functioning in work,
school, parenting, self-care, independent living, interpersonal relationships, and
leisure time (Mueser and McGurk 2004). The illness is characterised by three broad
types of symptoms including psychotic symptoms, negative symptoms and cognitive
impairment (Liddle 1987). Psychotic symptoms involve the loss of contact with
reality, including false beliefs (delusions), perceptual experiences not shared by
others (hallucinations) or bizarre behaviours. Negative symptoms are deficit states in
which basic emotional and behavioural processes are diminished or absent.
Cognitive impairment in schizophrenia includes problems in attention and
concentration, psychomotor speed, learning and memory and executive functions
(e.g. abstract thinking, problem solving) (Mueser and McGurk, 2004). The most
common subtype of schizophrenia currently found in the UK is paranoid
schizophrenia, where age of onset occurs later on in life and it has a more insidious
course than the other subtypes (Holtam, 2000).
Diagnosis in psychiatry is not only crucial for understanding the disease process but
also for making judgements about treatment and prognosis. However, for those
psychiatric disorders whereby there are no clear-cut and differentiating biological
markers, there has been less precision and agreement on diagnosis. Consequently
psychiatrists have had to rely mainly on symptom expression and historical data,
information that may vary depending on the skill of the interviewer and the scope
and depth of inquiry (Kay et al 1991). The limitation of categorical diagnosis is most
evident in psychiatric conditions that are heterogeneous and not uniformly
responsive to drug therapy. Schizophrenia is a prime example as it is now accepted
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as encompassing more than one disease process. The data from separate
perspectives, such as premorbid history, genetic study, neurological findings and
drug response, overlap to reveal distinct syndromes, such as those that have different
origins and may require different treatments. The analysis of these syndromes
reveals a profile of symptoms most notably the positive and negative features (i.e.
following PANSS assessment, those patients who are categorized by the negative
subscale and have predominantly negative symptoms as compared to the patients
who fall within the positive subscale and exhibit predominantly positive symptoms,
summarized according to the range of cognitive and emotional domains involved).
As a consequence, the Positive and Negative Syndrome Scales (PANSS) has been
developed as a broad-ranged, operationalized instrument to measure these and other
features of schizophrenic symptomatology (Kay et al 1991).
1.2 Burden of Disease
The global burden of disease (GBD) 2000 methodology reports a point prevalence of
0.4% for schizophrenia. Schizophrenia causes a high degree of disability. In a recent
14-country study on disability associated with physical and mental conditions, active
psychosis was placed as the third most disabling condition, higher than paraplegia
and blindness, by the general population (Üstün et al 1999). In the global burden of
disease study, schizophrenia accounted for 1.1% of the total disability-adjusted life
years and 2.8% of years lost due to disability. The economic cost of schizophrenia to
society is also high. It has been estimated that in 1991, the cost of schizophrenia to
the United States was US$ 19 billion in direct expenditure and US$ 46 billion in lost
productivity (The World Health Organisation Report 2001).
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A study conducted by Guest and Cookson (1999) examining the cost of
schizophrenia to UK society of an annual cohort of newly diagnosed patients with
schizophrenia over the first 5 years following diagnosis, revealed that the total
discounted cost to society was estimated at £862 million. The National Health
Service (NHS) accounted for 38% of the total cost, of which hospital admissions
accounted for 69%, hospital visits a further 26% and drugs accounting for 2%, Local
Authorities for 12% and the Home Office for 1%. Indirect costs due to lost
productivity accounted for 49%. The study concluded that NHS expenditure and lost
productivity costs predominated, irrespective of disease course. The findings suggest
that treatments that reduce hospitalisation and have the potential to enable patients to
return to active employment could drastically reduce the societal burden of
schizophrenia.
1.3 Oxidative Stress
Oxidative stress is implicated in the aetiopathogenesis of numerous diseases and is
defined as “a disturbance in the pro-oxidant-antioxidant balance in favour of the
former, leading to potential damage” (Sies 1991). Oxidative stress often occurs
following an increased production of free radicals, or when the antioxidant defence
system is ineffective or a combination of both events and will lead to a free radical
attack of protein, DNA and lipids. Oxidants comprise reactive oxygen species
(ROS), reactive nitrogen species, sulphur-centred radicals and various others. Not all
reactive species are radicals but the reactive non-radical species often become
radicals damaging biomolecules by (one-electron) oxidation. This type of reaction
results in the formation of oxidation products which are able to propagate the
reaction leading to extensive damage.
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1.3.1 Free Radicals
A free radical is any chemical species that contains one or more unpaired electrons.
Unpaired electrons alter the chemical reactivity of an atom or molecule, usually
making it more reactive than the corresponding non-radical, because they act as
electron acceptors and essentially ‘steal’ electrons from other molecules. This loss of
electrons is called oxidation and free radicals are referred to as oxidizing agents
because they tend to cause other molecules to donate their molecules. When two free
radicals come into contact, their unpaired electrons form a pair and both radicals are
lost. But since most molecules found in living organisms do not have unpaired
electrons, any free radicals that are produced will most likely react with non-radicals,
generating new free radicals and creating a chain reaction (Figure 1.1). Unpaired
electrons can be associated with many different atoms and molecules and so many
different free radicals exist.
(1) ADDITION
x· + y  →  [x-y] ·
(2) ELECTRON DONATION
x· + y  →  y·- + x+
(3) ELECTRON REMOVAL
x· + y  →  x- + y·+
only when two radicals meet can chain reactions be terminated.
x· + x· → x2
x· + y· → xy
Figure 1.1. Free radical chain reaction.
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In biological systems most attention has been focused on the oxygen radicals
(Gutteridge and Halliwell 1994). Reduction of oxygen can produce two free radicals,
superoxide and hydroxyl. If two hydroxyl radicals combine the joining of their
unpaired electrons produce an oxygen-oxygen covalent bond creating hydrogen
peroxide (H2O2), a product with no unpaired electrons:
OH· + OH· → H-O-O-H
Because H2O2 has no unpaired electrons, it is not a free radical. However, if one
extra electron is added, OH· is generated. Although poorly reactive, H2O2 can make
OH· at any time if an electron is supplied to it, for example from iron via the Fenton
reaction.
Free radicals and related molecules are often classified together as reactive oxygen
species to signify their ability to promote oxidative changes within the cell (reviewed
by Gilgun-Sherki et al 2001). Oxidants can be formed in various ways such as by
ionizing radiation, chemical reactions, enzymatically, redox-catalysis involving free
transition metal ions or metal ions bound to enzymes. Important cellular sources of
oxidative stress are: (i) the formation of reactive oxygen species by incomplete
reduction of oxygen in the respiratory chain of mitochondria; and (ii) the host
defence systems which includes the ‘oxidative burst’ mediated by NADPH oxidase,
producing superoxide radical and myeloperoxidase, leading to the formation of
hypochlorous acid.
Monitoring oxidative stress in humans can be done indirectly at best, by assaying
products of oxidative damage or by investigating the potential of an organism, tissue
or body fluids to withstand further oxidation (Abuja and Albertini 2001).
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1.3.2 Oxidative Stress and Neurological Disorders
The nervous system is particularly susceptible to ROS attack because of its high
metabolic rate, its low levels of oxidant defence systems and its moderate cellular
turnovers (Mahadik et al 2001). Oxidative stress, therefore, is currently regarded as a
contributor to the initiation or progression of various neurological illnesses.
Disorders such as Parkinson’s disease, Alzheimer’s disease and amyotrophic lateral
sclerosis have been causally linked to the generation of ROS and oxidative stress and
evidence suggests that oxidative neuronal injury accompanies other neurological
brain disorders including schizophrenia (Mahadik et al 2001). It has also been
reported that free radical-mediated abnormalities may contribute to the development
of a number of clinically significant processes including prominent negative
symptoms, tardive dyskinesia, neurological ‘soft’ signs and parkinsonian symptoms.
Altered membrane dynamics and antioxidant enzyme activities in schizophrenia are
thought to occur because of a free radical-mediated neurotoxicity in schizophrenia
(Yao et al 2001). Earlier studies have also revealed that oxidized metabolites of
catecholamines (aminochrome, derived from dopamine and related compounds)
occur in the human brain and it has been suggested that some of the demonstrated
cellular damage in the schizophrenic brain may be mediated by catecholamine o-
quinones (Smythies 1997).
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1.3.3 Oxidative Stress and Schizophrenia
Increasing evidence supports the view that a number of the neuropathological
changes seen in schizophrenia may be the result of increased free radical-mediated or
ROS-mediated neuronal injury (Mahadik and Mukherjee, 1996). Free radicals are
recognised as causative agents of peroxidative damage to lipids, and numerous lipid
peroxidation biomarkers exist in the majority of human diseases. Polyunsaturated
fatty acids (PUFA), major components of membrane phospholipids, are at high risk
of free radical attack and auto-oxidation to form peroxyradicals and lipid peroxide
intermediates such as aldehydes (malondialdehyde (MDA), 4-hydroxynonenal (4-
HNE)), pentane and ethane, isoprostanes and cholesteroloxides. Altered in vivo and
in vitro phospholipid metabolism has been identified in some patients with
schizophrenia. This altered lipid metabolism has been suggested to be a primary
result of reduced levels of membrane phospholipid PUFAS. From this ‘the
membrane phospholipid hypothesis of schizophrenia’ has arisen which suggests that
altered phospholipid metabolism is the fundamental cause of schizophrenia
(Horrobin, 1994). In particular, it is suggested that, in individuals who develop
schizophrenia, there is an accelerated loss of unsaturated fatty acids, notably
arachidonic acid (AA), docosahexaenoic acid (DHA), eicosapentaenoic acid (EPA)
and dihomogamma-linolenic acid (DGLA) from the Sn2 position of the
phospholipid.
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1.4 The Phospholipid Membrane Hypothesis
Approximately 20% of the brain by weight consists of highly unsaturated fatty acids,
in particular AA and DHA. The specific essential polyunsaturated fatty acid content
of synaptic membranes can modify neuronal functioning and produce clinical effects
through at least 2 mechanisms: changes in membrane EPUFA content alter the
microenvironment and hence structure and function of membrane receptors; ion
channels and enzymes and EPUFAs contribute to cell regulation by acting as a
source of precursors for second messengers in intra- and inter-cellular signal
transduction (Fenton et al 1999).
Feldberg (1976) and Horrobin (1977) introduced the phospholipid membrane
hypothesis of schizophrenia from their findings that schizophrenia might be caused
by a prostaglandin excess or deficiency. In neurones, the outstanding feature of the
phospholipids is that in contrast to other tissues, there are only small amounts of the
EPUFAs linoleic and -linoleic acids. However, there are large amounts of AA and
DHA in the sn2 position of the phospholipid with smaller amounts of dihomo--
linolenic acid, adrenic acid (AdrA), EPA and docosapentaenoic acid (DPA). The
fatty acids may be released from the sn2 position usually by activation of one of the
phospholipase A2 group of enzymes and these then can be converted to a variety of
signalling molecules known as eicosanoids including prostaglandins and
leukotrienes.
This mixture of fatty acids provides the neuronal membranes their specific properties
in relation to cell signalling and to modulation of structures and function of
membrane-bound and membrane-associated proteins. In people who develop
schizophrenia, it is thought that there is a rapid loss of unsaturated fatty acids,
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notably AA, DHA, EPA and DGLA from the sn2 position (reviewed by Horrobin,
1999). When present to a mild degree, this increased rate of loss will be compensated
by an increased role of incorporation, with no change in phospholipid composition.
But when present to a greater degree, or when associated with problems of
incorporation, there will be an actual change in membrane composition (Horrobin et
al 1995).
An increased rate of loss of the key fatty acids will lead to changes in functioning of
membrane-associated proteins and various cell signalling systems. A possible
enzymatic basis for such increased loss is the over activity of one or more of the
PLA2 group of enzymes. This could result from the presence of an abnormal enzyme
variant or from over expression of the normal enzyme. The increased rate of removal
from phospholipids would make the free acids more susceptible to oxidation
(Horrobin 1999).
For the development and function of the brain, three fatty acids are important: DHA
from the -3 series, AA from the -6 series and nervonic acid (NA) from the -9
series (Assies et al 2001). The laying down of these fatty acids is greatest during
brain growth in utero, the first months after birth and during puberty. Providing
animals with oils that have a low -linolenic content results in all brain cells and
organelles and various organs having reduced amounts of 22:6-3, which is
compensated for by an increase in 22:5-6. The speed of recovery from these
abnormalities is extremely slow for brain cells, organelles and microvessels in
contrast to other organs. Furthermore, prolonged PUFA deficiency leads to death in
animals (Bourre et al 1992). The main idea of the phospholipid hypothesis is that
normal neuronal phospholipid metabolism is essential for the normal development of
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brain architecture in utero and in childhood, for the normal modulation of the
architecture around the time of puberty, and for normal functioning of the adult
nervous system. The phospholipid hypothesis therefore proposes that “in
schizophrenia there are two major primary abnormalities in phospholipid metabolism
and that the impact of these may be modified by other lipid-related genes and by
environmental factors (such as oxidative stress). The two primary abnormalities are
an increased rate of removal of EPUFAs especially AA and DHA from membrane
phospholipids, coupled with a reduced rate of incorporation into phospholipids of
these same fatty acids” (Horrobin 1999).
1.4.1 Lipids and Fatty Acids
Biological lipids are a chemically diverse group of compounds, although they are all
insoluble in water. Furthermore, their biological functions are extremely diverse.
Fats and oils are stored mainly as energy in many organisms and phospholipids and
sterols make up about half the mass of biological membranes. Lipids have
fundamental structural and functional roles in cell membranes in general and in the
central nervous system in particular. Lipids form the matrix within which membrane
proteins such as receptors and ion channels are embedded and to which membrane
associated proteins such as those involved in second messenger systems may be
attached. Lipids are also essential constituents of synaptic vesicles; most of the
second messenger systems of the neurone depend on lipids such as free fatty acids,
diacylglycerols, prostaglandins, leukotrienes and hydroxy-fatty acids.
The formation of membrane phospholipids from simple precursors requires: a)
synthesis of the backbone molecule (glycerol or sphingosine); b) attachment of fatty
acid(s) to the backbone via ester or amide linkage; c) addition of a hydrophilic head
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group joined to the backbone through a phosphodiester linkage; and in some cases d)
alteration or exchange of the head group to produce the final phospholipid product
(Figure 1.2).
Sn1 CH2O – Fatty acid
Sn2 CHO – Fatty acid
Sn3 CH2O – P – Choline or Ethanolamine or Inositol or Serine
Figure 1.2: The general structure of a phospholipid. The three carbon atoms of the glycerol (or
sphingosine) backbone are designated Sn1, Sn2 and Sn3.
In eukaryotic cells, phospholipid synthesis usually occurs at the surface of the
smooth endoplasmic reticulum. Some stay within that membrane while others are
inserted into different cell membranes in different proportions. Because membrane
lipids are insoluble in water they cannot diffuse from their point of synthesis to their
point of insertion. Instead they are transported in membrane vesicles that bud from
the Golgi complex then move to and join to the target membrane. In addition,
cytosolic proteins bind phospholipids and sterols and carry them from one cell
membrane to another and from one face of a lipid bilayer to another. The combined
action of transport vesicles and proteins produces the characteristic lipid composition
of each organelle membrane.
Typical Western diets are made up of 10-20 fold more -6 (n-6) series fats than -3
(n-3) series. The high proportion of -6 fat is due to the large quantity of linoleic
acid (LA) in the diet which is present in high concentrations in soy, corn, safflower
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and sunflower oils and in the spreads and shortenings produced from them. In
comparison, there is a low intake of the -3 homologue of LA, -linolenic acid
(ALA) found in leafy green vegetables, flaxseed, linseed and canola oils. When
consumed, the 18-carbon fatty acids are desaturated and elongated in situ to 20-
carbon -6 fatty acids. LA is converted to AA and ALA to eicosapentaenoic acid
(EPA) and DHA, although DHA conversion is slower in humans. Compared with
LA, there is little dietary intake of AA and EPA found in meat and fish respectively.
Furthermore, unlike the 18-carbon -3 fatty acid ALA, oleic acid is consumed in
considerable amounts in the typical Western diet but is not an essential fatty acid,
and only small amounts of eicosatrienoic acid (ETA) are found in cells membranes.
Unsaturated fatty acids are not interconvertible but are metabolised by a common
series of enzymes (elongases and desaturases) (Figure 1.3). The same series of
enzymes that catalyze desaturation and elongation of 6 and  fatty acids also
catalyze desaturation and elongation of  fatty acids. The substrate preference for
these enzymes is 3 followed by 6 and finally, 9, thus competition between
the 9 fatty acids and either the 6 or 3 fatty acids is rare. However, if the
concentrations of 18:26 and 18:33 are low, 18:19 is readily desaturated and
elongated to 20:39 (eicosatrienoic acid).
An increase in dietary -3 fatty acids results in reduction of AA levels in tissue
lipids because synthesis from linoleate is inhibited. Alterations of dietary fatty acids,
therefore, can lead to changes in fatty acid composition of tissue leading to changes
in cellular responses (Hwang 2000). Because mammalian systems have lost the
ability to insert a double bond between an existing double bond and the methyl or
omega end of the fatty acyl chain, this will result in a) an omega-6 or omega-3 fatty
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acid remaining such after metabolism in situ; b) fatty acids with the requisite double
bond have to be ingested, i.e. are essential (Wahle 2000). Plant tissues and plant oils
tend to be rich sources of LA and ALA and once consumed in the diet, LA can be
converted via -linolenic and dihomo--linolenic (DGLA) acids to AA. Using the
same pathway, ALA can be converted to EPA and then DHA.
Figure 1.3. Pathways for the metabolism of ω-3, ω-6, and ω-9 polyunsaturated fatty acids. The steps
are catalyzed by either an elongase (single arrow) or a desaturase (double arrow) enzyme (Assies et al
2001).
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Marine plants such as phytoplankton carry out chain elongation and further
desaturation of ALA to yield EPA and DHA. It is because of the production of these
long -3 EPUFAs by marine algae and their transfer through the food chain that the
tissues of some marine animals and fish are a particularly rich source of these fatty
acids. Commercial products known as ‘fish oils’, a preparation of the body oils of
cold water fish, contain high quantities of EPA and DHA. These are also found in
high proportions in the oils extracted from the livers of other species of fish found in
warmer waters.
PUFA supplementation has been widely used in human schizophrenia clinical trials
since their benefits in reducing a variety of positive symptoms have been reported.
However, although a review of the current research has not conclusivley
recommended omega-3 PUFA as either a mono- or adjunctive-therapy in any mental
illness, the available evidence is strong enough to justify continued study (Ross et al
2007). Therefore, by supplementing a variety of human cells with different
concentrations of EPA and DHA, we sought to gain a better awareness of the effects
that these fatty acids might have on DNA and protein molecules. For example, we
were intestered in discovering whether levels of induced oxidative stress would be
reduced or increased in the cells following supplementation of low, medium and
high concentrations of fatty acids? Ultimately, could these changes in levels of
oxidative damage be identified by changes to the DNA and protein, ie via
biomarkers?
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1.4.2 Phospholipase Enzymes
Most cells continually degrade and replace their membrane lipids. For each of the
bonds in a glycerophospholipid, there is a specific hydrolytic enzyme.
Phospholipases of the A type (A1 and A2) remove one of the two fatty acids, by
hydrolyzing the ester bonds of the intact glycerophospholipid at C-1 and C-2
respectively of glycerol (Figure 1.4). Phospholipases C and D each split one of the
phosphodiester bonds in the head group. Phospholipases D (PLDs) cleave
phospholipids, preferably phosphatidylcholine releasing the free base (i.e. choline)
and yielding phosphatidic acid. Although many aspects of PLD enzymology have
been elucidated, the functions of mammalian PLDs remain less well understood. In
the nervous system, PLD isoforms are present in neurons as well as in glial cells
(such as astrocytes and oligodendrocytes) where they play a role in cellular
proliferation, exo- and endocytosis and neurite formation (Klein 2005). The rapid
hydrolysis of the membrane phospholipid phosphotidylinositol 4,5-bisphosphate is
catalysed by phosphoinositide-specific phospholipase C isozymes resulting in the
generation of the second messengers diacylglycerol (DAG) and inositol 1,4,5-
trisphosphate. These compounds mediate the release of Ca2+ from intracellular stores
and action of protein kinase C (reviewed by Ochocka and Pawelczyk 2003).
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Figure 1.4. Sites of phospholipid hydrolysis by PLD, PLC, PLA2 and PLA1 and acyl hydrolase
The growing family of phospholipases A2 are enzymes that specifically hydrolyze
the acyl ester bond at the sn-2 position of glycerol in membrane phospholipids and
produce free fatty acids and lysophospholipids. This provides the precursors for
many of the lipid mediators involved in normal brain function and
neuroinflammatory pathophysiological processes (Farooqui and Horrocks 2004).
AA, one such precursor, is then converted to the inflammatory mediators,
prostaglandins and leukotrienes. In theory, AA can be produced from numerous
other pathways including the DAG lipase pathway as well as phospholipase D-
generating phosphatidic acid. As well as being involved in eicosanoid synthesis,
PLA2 plays another important role in inflammation by releasing another compound
the 2-lysophospholipid, whose action on membrane phospholipids can be utilized to
form platelet-activating factor (PAF), a potential inflammatory mediator
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(Chakraborti 2003). Any oxidative modification of membrane phospholipids is a
damaging process which is best repaired by the selective cleavage of peroxidized
fatty acid residues and their replacement by native fatty acids. Because
polyunsaturated fatty acids are preferentially located in the sn-2 position of the
membrane phospholipid, this position is especially prone to lipoxygenation or lipid
peroxidation and PLA2s are best designed for such a repair function (Nigam and
Schewe 2000).
Several new PLA2s have been identified based on their nucleotide gene sequences
and have been classified mainly into three groups: a) cytosolic PLA2 (cPLA2); b)
Ca2+-dependent secretory PLA2 (sPLA2); and c) Ca2+-independent intracellular PLA2
(iPLA2) (Muralikrishna Adibhatla and Hatcher 2006). There is also a class of PLA2
called PAF acetylhydrolases which appear to act on PAF and oxidized lipids (Six
and Dennis 2000).
cPLA2 is a high molecular weight enzyme (85kDa) ubiquitous enzyme found in the
cytosol of most cell types. Because of its preference for phospholipid containing AA,
it is thought to be associated with receptor-activated signalling cascades and is
phosphorylated by kinases of the mitogen-activated protein kinases cascade.
Following an increase in intracellular Ca2+, cPLA2 translocates to membranes via a
Ca2+ lipid binding domain that is present within the protein (Gijon et al 2000).
Understanding the role that PLA2 plays in schizophrenia is an area of research that is
currently a ‘hot topic’. The effect of EPA and DHA supplementation on the levels of
PLA2 and cPLA2 in human schizophrenia patients has not been extensively explored.
However, it has been shown that in human suffers of depression, there is strong
epidemiological evidence that fish consumption reduces risk of becoming depressed
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and evidence that cell membrane levels of n-3 PUFA are reduced and two placebo-
controlled trials have shown a strong therapeutic effect of ethyl-EPA added to
existing medication (Peet 2003). Furthermore, four out of five placebo-controlled
double- blind trials of EPA in the treatment of schizophrenia have given positive
findings (Peet 2003). The mode of action of EPA is currently unknown, but research
suggests that AA, if it is of particular importance in schizophrenia, then the clinical
improvement observed in patients with schizophrenic using EPA treatment,
correlates with changes in AA (Peet 2003). Thus, if EPA and/or DHA
supplementation is to be considered a possible future adjunctive therapy for the
treatment of schizophrenia, then understanding the effect these fatty acids have on
the phospholipase enzyme is important. We undertook a study to gain better
understanding into whether different concentrations of fatty acids had any effect on
the levels of total PLA2 and cPLA2 content in human cells.
1.5 Antioxidant Defence System
Aerobic organisms have evolved many types of antioxidant defence. An antioxidant
is defined by Gutteridge and Halliwell (1994) as “any substance that delays or
inhibits oxidative damage to a target molecule” (p 40). All molecules present in
living organisms are potential targets of oxidative damage: lipids, proteins, nucleic
acids and carbohydrates. However, antioxidants are thought to protect a potential
target from attack by various mechanisms:
 scavenging oxygen-derived species, either by using enzymes or by direct
chemical reaction;
 minimizing the formation of oxygen-derived species;
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 binding metal ions needed to convert poorly reactive species (such as O2·-
and H2O2) into more damaging species (such as OH·);
 repairing damage to the target;
 destroying badly damaged target molecules and replacing them with new
ones.
The potential health promoting effects of a number of dietary antioxidants are widely
reported with epidemiological studies suggesting that naturally occurring phenols
and polyphenols have the potential to prevent oxidative damage in a variety of
pathological conditions. The first line of antioxidant defence in cells is provided by
enzymes. The antioxidant defence system (AODS) is made up of a series of
enzymatic (endogenous) and non-enzymatic (exogenous) components.
1.5.1 Endogenous Antioxidants
The human body has a complex antioxidant defence system which includes the
endogenous antioxidant enzymes superoxide dismutase (SOD), catalase (CAT) and
glutathione peroxidase (GPx). SODs contain metals essential for their catalytic
function. The metals bound to SOD catalyse the reaction of two O2·- molecules with
H+ ions to form H2O2 and O2. This reaction occurs slowly at pH 7.4 but SODs
accelerate the reaction by 10,000 times. The manganese-containing SOD (Mn-SOD)
found in human mitochondria is thought to remove O2·- produced as a result of
electron leakage on to O2 from the mitochondrial electron transport chain and by
mitochondrial oxidase enzymes. The copper- and zinc-containing SOD (Cu,Zn-
SOD) removes O2·- from cytosolic oxidases and from the cytochrome P450 enzymes
which are located in the endoplasmic reticulum of the cells. Catalase is a large
enzyme with haem-bound iron at its active site. It is located within peroxisomes and
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may be found in mitochondria of heart tissue. It is responsible for removing H2O2 by
converting it to O2. Human tissues contain glutathione peroxidases as their major
peroxide-removing enzymes. They remove H2O2 at a high rate through the process
of the oxidation of reduced glutathione (GSH) into oxidized glutathione (GSSG).
GSH also has antioxidant properties and has been shown to repair DNA damage
following attack by OH·. Failure of this first line of antioxidant defence may lead to 
initiation of lipid peroxidation. Selenium-dependent GSH protects against lipid
peroxidation through the conversion of H2O2 to H2O or by converting toxic
hydroperoxides to less toxic alcohols. Because of the importance of these enzymes,
altered activity of one of them without compensatory changes in other enzymes may
result in cell membranes being susceptible to attack.
1.5.2 Exogenous Antioxidants
1.5.2.1 Antioxidant Vitamins
A variety of intra- and extracellular antioxidants play important roles in controlling
oxidative stress. Several studies suggest that antioxidant vitamins in the diet may
partially protect the integrity of cellular DNA against ROS and so reduce the risk of
some diseases. The non-enzymatic antioxidant components that are important in the
antioxidant defence systems include those that react with activated oxygen species
and prevent the propagation of free radical chain reactions. The most common are
albumin, uric acid, bilirubin, GSH, d--tocopherol (vitamin E), ascorbic acid
(vitamin C) and -carotene. The major scavenger inside human cell membranes is d-
-tocopherol. Tocopherols inhibit lipid peroxidation by scavenging lipid peroxyl
radicals faster than these radicals can react with adjacent fatty acid side chains or
with membrane proteins:
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-tocopherol + lipid- O2· → --tocopherol· + lipid-O2H
The hydrogen atom from the hydroxyl group of the -tocopherol is donated to the
peroxyl radical converting it to a lipid peroxide, resulting in an unpaired electron on
the O· leaving behind -tocopherol radical. -tocopherol therefore is described as a
chain-breaking antioxidant since it breaks the chain reaction of lipid peroxidation but
is itself converted to a radical during the process and hence vitamin E is consumed.
Ascorbic acid is also a potent scavenger of several radicals. Found within the
aqueous phase of plasma, it also has the ability to recycle -tocopherol in
lipoproteins and delays the onset of peroxidation in human low density lipoproteins.
However, ascorbic acid can also exert pro-oxidant properties. In the presence of
H2O2, ascorbate can speed up OH· formation by the reduction of iron and copper 
resulting in Fe2+ and Cu+ which react with H2O2 to produce OH·. 
1.5.2.2 Phenolic Antioxidants
Polyphenols are the most abundant antioxidants in our diets and are widely found in
many types of foods and beverages. Consumption of fruit and vegetables, which are
rich in antioxidants, prevents cancers and may also prevent stroke, whereas wine
consumption might prevent coronary heart diseases and soy may protect against
breast cancer and osteoporosis. Food and drinks that provide a good source of
phenolic compounds, such as flavonoids (Figure 1.5) have also been associated with
decreased risk of developing several diseases (Halliwell et al 2005). Interest has also
grown in this group of compounds due to their antioxidant properties but phenolic
compounds also have several other specific biological actions that are still poorly
understood (Manach et al 2004).
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Polyphenols are reducing agents and together with other dietary reducing agents
such as vitamin C, vitamin E and carotenoids, they protect the body’s tissues against
oxidative stress. Many molecules containing a polyphenol structure (i.e. several
hydroxyl groups on aromatic rings) have been identified in higher plants and a large
number are also found in edible plants. These molecules are secondary metabolites
of plants and are generally involved in defence against ultraviolet radiation or attack
by pathogens. They are classified according to the number of phenol rings that they
contain and defined according to the nature of their carbon skeleton and comprise
phenolic acids, flavonoids, stilbenes and lignans.
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Figure 1.5. Structures of main classes of dietary flavonoids
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The chemical structure of polyphenols will affect their biological properties i.e.
bioavailability, antioxidant activity, specific interactions with cell receptors and
enzymes and other properties. The chemical structure of polyphenols also determines
their rate and extent of intestinal absorption and the nature of the metabolites
circulating in the plasma, as well as determining the conjugation reactions with
methyl, sulphate or glucuronide groups and the nature and the amounts of
metabolites formed by the gut microflora absorbed at the colon level.
Experimental data has proposed that polyphenols may provide an indirect protection
by activating endogenous defence systems. For example, resveratrol and 4-
hexylresorcinol have been shown to induce an increase in glutathione, glutathione
peroxidase and glutathione reductase (Yen et al 2003), while catechins (including
epicatechin (EC), epicatechin gallate (ECG), epigallocatechin (EGC) and
epigallocatechin gallate (EGCG) have been shown to have activity similar to or
higher than that of vitamin C in vitamin E regeneration (Mukai et al 2005). Several
reports have revealed that exogenous and endogenous antioxidants appear to act in a
co-ordinated fashion (reviewed by Masella et al 2005). The authors suggest that this
may be achieved partly via antioxidant response elements (ARE) located within the
promoter regions of the genes induced by oxidative and chemical stress and that
dietary polyphenols can stimulate antioxidant transcription and detoxification
defence systems through ARE.
A study by McCreadie (2003) which examined the lifestyle of people with
schizophrenia reported that fewer males compared with the general population,
reached acceptable levels for consumption of fruit, vegetables, milk, potatoes and
pulses. In an earlier study (McCreadie et al 1998) it was reported that as well as
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having a lower fibre consumption and a higher saturated fat intake than the control
population, more male schizophrenic patients than female patients tended to
consumed less vitamin E. In addition, high dietary intake of sugar as well as
saturated fat predicts poor outcome in schizophrenia (reviewed by Peet 2004). This
is an important consideration since the consumption of foods rich in antioxidants,
such as vitamin C, lycopene, and flavonoids has been shown to confer resistance
against lymphocyte DNA oxidation (Boyle et al 2000). Traditional Mediterranean
diets, as opposed to Northern European diets generally include a higher intake of
plant foods which have been associated with lower risk for development of coronary
heart disease and certain cancers (Visioli and Galli 2001). A major component of this
type of diet is represented by olive oil which contains antioxidants such as tyrosol
and hydroxytyrosol and recent data suggests that the components of dietary olive oil
may have a greater role in disease prevention than previously thought (Owen et al
2000). For example, the content of oleic acid, a monounsaturated long-chain fatty
acid is high in olive oil compared with the seed oils e.g. sunflower oil which is rich
in polyunsaturated linoleic acid, a fatty acid that is prone to oxidation (Owen et al
2000). The involvement of excessive free radical production and the number of
epidemiological studies linking antioxidant intake with such diseases as coronary
heart disease, suggests that dietary antioxidants may play a protective role (Visioli
and Galli 2001).
Recently, attention has focused more on the potential neuroprotective effects of the
flavonoids against the neuronal deficits associated with ageing or age-related
neurodegenerative diseases. However, to achieve high efficacy, antioxidants must
penetrate through the blood brain barrier (BBB), an endothelial barrier that contains
tight junctions, a low number of pinocytic vesicles and the expression of various
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uptake and efflux transport systems and metabolic enzymes. The tight junctions of
the BBB enable diffusion of minute quantities of water-soluble compounds while the
large surface area of the lipid membranes of the endothelium provides an effective
diffusive route for lipid-soluble agents. Essential nutrients such as glucose, purine
bases, nucleotides, choline and certain large neutral amino acids are transported into
the brain via specific membrane-transporting proteins. In addition, there also seem to
be processes that are capable of shuttling macromolecules into the brain such as
receptor-mediated and adsorptive endocytosis systems (Gilgun-Sherki et al 2001).
Although flavonoids have been shown to possess neuroprotective properties, few
studies have specifically examined entry into the central nervous system (CNS).
Evidence for CNS entry is available for epigallocatechin gallate and epicatechin (i.e.
the epicatechin conjugate and the O-methylated epicatechin conjugate) (El Mohsen
et al 2002), found in tea and wine and the citrus flavonoids naringenin (and its
glucuronide) and hesperetin (Youdim et al 2004). In their study, Youdim et al (2004)
reports novel observations on the permeability of naringenin and quercetin at the
BBB, the penetration of these flavonoids into different brain regions and the
influence of efflux transports in limiting their entry. Resveratrol, found in relatively
high quantities in grapes has been shown to protect against neuronal cell death
following experimentally induced ischemia, demonstrating that it can cross the blood
brain barrier and exert protective effects against cerebral ischemic injury over a
prolonged period of time (Wang et al 2002). Nevertheless, despite increased
awareness of the chemical forms in which antioxidants such as the flavonoids are
able to enter the circulation, studies of the non-physiologically relevant forms are
still undertaken. With this in mind Youdim et al (2004) have highlighted the
flavonoids from particular families that are able to permeate the BBB whereas the
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entry of others is limited by the actions of efflux transporters expressed at the
endothelium surface.
Numerous studies have been undertaken examining levels of antioxidant enzymes in
schizophrenic patients. The data is controversial and shows a variation for the
activities of antioxidants. Red blood cell SOD activity has been found to be
increased (Vaiva et al 1994), unchanged (Herken et al 2001) or decreased (Evans et
al 2003; Ranjekar 2003; Akyol et al 2002; Mukerjee et al 1996) and CAT and GPx
activities were found to be increased (Evans et al 2003; Herken et al 2001),
unchanged (Evans et al 2003; Akyol et al 2002; Yao et al 1998) or decreased
(Ranjekar 2003) in schizophrenic patients. Plasma bilirubin and albumin levels (Pae
et al 2004; Reddy et al 2003; Yao et al 2000) and uric acid levels (Reddy et al 2003)
have been shown to be significantly lower in schizophrenic patients compared to
controls. Here, bilirubin was significantly lower in the negative subgroup of the
patient group, suggesting antioxidant levels are associated with schizophrenia as well
as with the clinical symptomatology and the treatment implications in schizophrenia.
Antioxidant supplementation is being considered as a possible adjunctive therapy in
patients with schizophrenia, but there is limited knowledge concerning their effects
at different concentrations on DNA, proteins and lipids in schizophrenia sufferers. In
addition, when DNA, proteins and lipids are subjected to an oxidative challenge it is
not clearly understood how antioxidant supplementation helps to protect the cell
against ROS or free radical damage. However, what is known is that EGCG
biovailability in the CNS has been demonstrated (El Mohsen et al 2002) and
resveratrol has been shown to cross the BBB and protect against cerebral ischemia
(Wang et al 2002). Similarly, tyrosol, has been examined in a rat model for cerebral
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ischemia and was shown to have a neuroprotective effect which was dose-dependent
in the range of 3-30 mg/kg body weight (Bu et al 2007). By examining human cells
supplemented with a variety of antioxidants and subjected to an oxidative challenge,
we aimed to gain a clearer understanding of the effect of antioxidants on a range of
biomarkers of oxidative stress.
1.6 Biological Markers of Oxidative Stress
A ‘biomarker’ can be used to identify a molecular change in a biological molecule
(Griffiths et al 2002). When studied in tissues, organelles or fluids, biomarkers can
provide understanding concerning the nature of the denaturing radical, often along
with the location of oxidative damage. As highly sensitive markers of oxidative
damage in mammalian systems, biomarkers may provide information on three
progressive levels to disease outcome: (a) as measurable endpoints of oxidative
damage to proteins, amino acids, oxidised lipids, oxidised DNA bases; (b) as
functional markers of blood flow, platelet aggregation, or cognitive function, for
example and (c) as endpoints related to a specific disease (Griffiths et al 2002).
Although clinical symptoms are considered to be endpoints of an illness, they are
often inappropriate for early detection and disease prevention.
The peroxidation of PUFAs may be examined in a number of ways including
determination of lipid peroxides (Chamblee et al 2000), determination of
isoprostanes (Morrow et al 1990; Boyle et al 2000) determination of aldehydic end
products [e.g. malondialdehyde and 4 hydroxy nonenal] (Boyle et al 2000; Claeson
et al 2001) and by the determination of volatile hydrocarbons. Volatile hydrocarbon
analysis is increasingly being adopted as a method of assessing lipid peroxidation
both in vivo (Kivits et al 1981; Kovaleva et al 1989) and in vitro (North et al 1994).
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Volatile hydrocarbons are produced as terminal catabolites of lipid and protein
peroxides, ultimately being exhaled in breath. The volatile hydrocarbons that are
typically monitored are ethane (C2) and pentane (C5) being derived from the
oxidation of -3 and -6 fatty acids respectively. Ethane is often considered to be a
better indicator of lipid peroxidation than pentane since it is less easily metabolized
to carbon dioxide (Allerheiligen et al 1987). Furthermore, the between day
biological variation of ethane in expired air has been noted to be less than that of
pentane (24% CV vs. 38% CV) (Knutson et al 1999) with the greater variation in
pentane rates possibly being due to changes in rates of pentane metabolism.
Hydrocarbons are metabolized by hepatic monooxygenases (Frank et al 1980) and in
vitro studies have indicated that pre-treatment of subjects with a blocker of hepatic
monooxygenases decreased ethane exhalation by 70% and pentane by 1250% (Wade
and van Rij 1985) demonstrating that pentane exhalation is more significantly
influenced by hepatic metabolism and thus is a less reliable indicator of lipid
peroxidation. Butane is believed to be a catabolite of protein oxidation and arises
following the in vitro oxidation of haemoglobin (Clemens et al 1984).
Generally, oxidatively modified proteins resulting in new functional groups such as
hydroxyls and carbonyls are not repaired and must be removed by proteolytic
degradation. Amino acids capable of delocalising charge such as those containing
aromatic and thiol side chains are more prone to oxidative attack and a large number
of aliphatic residues are also subject to oxidation resulting in the generation of
protein carbonyl moieties (Griffiths et al 2002). Ultimately, therefore, a decrease in
the efficiency of proteolysis will lead to an increase in the cellular content of
oxidatively modified proteins (Stadtman and Levine 2000). Elevated markers of
protein oxidation have been associated with diseases such as Alzheimer’s disease,
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Parkinson’s disease, Duchenne muscular dystrophy, amyotrophic lateral sclerosis,
rheumatoid arthritis and progeria (Mayne, 2003). The level of modified molecules
can be quantitated by measurement of the protein carbonyl content by an enzyme-
linked immunoabsorbent (ELISA) method (Buss et al 1997) which is based on the
reaction of dinitrophenylhydrazine (DNP) with protein carbonyls.
Free radical attack generates a range of DNA lesions, including strand breaks and
modified bases. Hydroxyl radical attack on DNA leads to a large number of
pyrimidine- and purine-derived base changes. Some of these modified DNA bases
have considerable potential to damage the integrity of the genome. 8-oxo-2’-
deoxyguanosine (8-oxo-dGuo) is one of the most critical lesions. Unless repaired
prior to DNA replication, 8-oxo-dGuo residues can result in base pair transversions
(Griffiths et al 2002).
1.6.1 Membrane Phospholipid Peroxidation and Schizophrenia
Oxidative damage to lipids and proteins can result in a number of pathophysiological
processes while changes in DNA may alter gene expression or cause cell death and
lead to genetic modification and mutagenesis. Although the aetiology of
schizophrenia remains unknown, investigation of the effects of oxidative stress in
schizophrenia have largely focused on the determination of lipid oxidation products,
(Scottish Schizophrenia Research Group, 2000; Ranjekar et al 2003). So far, studies
of oxidative injury in schizophrenia have focused on membrane lipids, the rationale
behind these studies stemming from the emergence of the membrane phospholipid
theory of schizophrenia proposed by Horrobin et al (1994). In addition, reduced
membrane PUFAs have been found to be associated with psychopathology (Glen et
al 1994; Peet et al 1995; Doris et al 1998; Khan et al 2002), although in a recent
Chapter 1 Introduction 31
study by Peet et al (2004) no significant difference in red blood cell AA levels
between unmedicated patients and controls was observed.
1.6.2 DNA Oxidation and Schizophrenia
Relatively little information has so far been directed towards determining the levels
of oxidative damage to cellular proteins and DNA. Psimadas et al (2004) examined
the effects of oxidative insult on the cellular DNA of a Greek sample of male
schizophrenic patients and controls and no significant difference in DNA damage
between groups was observed. Another recent study however has reported evidence
for oxidative DNA damage and coordinated cell-cycle activation in elderly ‘poor-
outcome’ schizophrenia (Nishioka and Arnold, 2004).
Investigation of DNA damage is important because it is a possible indicator of
carcinogenic and mutagenic potential. It has been suggested in population based
studies (Cohen et al 2002; Lichtermann et al 2001) that in the absence of
confounding factors such as smoking, age, socioeconomic status and alcohol, the
risk for some types of cancer (e.g. respiratory and lung cancer) in schizophrenic
patients is reduced, although no investigation of possible gender differences has been
reported, and no clear mechanism to explain this resistance has been identified.
1.6.3 Protein Oxidation and Schizophrenia
Oxidation of catecholamines to the corresponding o-quinones and their subsequent
reduction to reactive species, which can induce redox cycling, has been postulated to
be involved in neurodegeneration in the mesolimbic and nigro-striatal systems, and
thus in the aetiology of schizophrenia and Parkinson’s disease (Baez et al 1997;
Smythies 1997). In addition, accumulation of modified protein disrupts cellular
function either by loss of catalytic and structural integrity or by interruption of
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regulatory pathways (Stadtman and Levine 2000). Tardive dyskinesia is a movement
disorder which affects 20-40% of patients treated chronically with neuroleptic drugs.
It has been suggested that neuroleptics increase striatal glutamatergic
neurotransmission by blocking presynaptic dopamine receptors, leading to neuronal
damage as a consequence of oxidative stress (Tsai et al 1998). Patients suffering
from tardive dyskinesia have been shown to have significantly higher concentrations
of N-acetylaspartate, N-acetyl-aspartylglutamate and aspartate in their cerebral
spinal fluid and higher levels of protein-oxidized products associated with tardive
dyskinesia (Tsai et al 1998).
1.7 Treatment of Schizophrena
1.7.1 Antipsychotics
At present there is no cure for schizophrenia. There are a range of drug treatments
for schizophrenia (Table 1.1), although there is no one drug that is better than
another. Each has different indications, for example, clozapine is the drug of choice
for treatment resistant schizophrenia. Each of the typical antipsychotics and the
atypicals risperidone, olanzapine, quetiapine and ziprasidone (but not clozapine) are
used as treatment for early (‘first-episode’) schizophrenia and also for other stages of
the illness. Older antipsychotics (also know as first generation, conventional, typical)
are drugs that possess antipsychotic efficacy but are also associated with
extrapyramidal side-effects (EPS). Although it is not clear how these drugs work, the
proposed mechanism of action of both typical and atypical antipsychotics is that they
block D2 receptors (reviewed by Jones and Buckley 2003). However, neuroleptics
have been shown to have both pro-oxidant and antioxidant properties (Jeding et al
1995) and the antipsychotic response of a neuroleptic may depend on its pro- or
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antioxidant property and the level of pre-existing oxidative stress in the patient
(Mahadik et al 2001).
Clinical studies have indicated that antioxidant enzyme activities are connected with
the use of neuroleptics provided during the treatment of schizophrenia (Abdalla et al
1986; Yao et al 1998), suggesting that the changes in the enzyme activity may be
due to the neuroleptic treatment (Akyol et al 2002; Evans et al 2003). The
neuroleptic Flupenthixol (Table 1.1) can accept electrons in competition with oxygen
and therefore reduce the production of superoxide and inhibit cytochrome b5
reductase activities; alternatively, neuroleptics may react directly with superoxide
(Whatley et al 1998).
Dakhale et al (2004) examined the effect of atypical antipsychotics on lipid
peroxidation, SOD and ascorbic acid. Results revealed an increase in serum SOD,
serum malondialdehyde and a decrease in plasma ascorbic acid in schizophrenic
patients as compared to controls; however, the trend altered significantly following
treatment with antipsychotics. In contrast, Taneli et al (2004) found that
antipsychotic drugs did not significantly decrease levels of serum nitric oxide in
schizophrenic patients after a 6-week treatment regimen. The authors suggest that
longer therapy periods may prove beneficial. This is in agreement with the findings
from another study (Evans et al 2003) who reported that following twelve weeks of
antipsychotic treatment antioxidant levels were not significantly different from the
low levels measured at baseline. Yet after 24 weeks, antipsychotic treatment almost
normalized the levels of SOD but further increased the levels of CAT.
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Class
Typical Example
Class
Atypical Example
Butyrophenone Haloperidol Dibenzodiazepine Clozapine
Phenothiazine
Aliphatic
Piperidine
Piperazine
Chlorpromazine
Thioridazine
Trifluoperazine
Benzisoxazole Risperidone
Thioxanthene Fluphenthixol Thienobenzodiazepine Olanzapine
Diphenylbutylpiperidine Pimozide Dibenzothiazepine Quetiapine
Substituted benzamide Sulpiride Benzisothiazolyl Ziprasidone
Phenylindol Aripiprazole
Phenylindol Sertindole
Dibenzothiepine Zotepine
Table 1.1. Classes of antipsychotic medications.
1.7.2 Fatty Acids and Antioxidants as Adjunctive Therapy for
Schizophrenia
Treatment of schizophrenia is most effectively accomplished with antipsychotics and
recent treatment with newer antipsychotics appears to have therapeutic effects
against core negative symptoms and cognitive deficits that are considered difficult to
treat (Arvindakshan et al 2003). However, response to current pharmacological
treatment of schizophrenia is variable with only 60% of patients responding
favourably (Yao et al 2004) in addition EPS, limited efficacy and cost are serious
limitations of the conventional antipsychotics. Treatment non-responders frequently
have prominent cognitive deficits and persistent negative symptoms. Adjunctive use
of EPA and DHA through dietary supplementation has shown hopeful results in
decreasing some of the clinical symptoms of schizophrenia (Yao et al 2004; Emsley
et al 2002; Peet et al 2002) and is based on altered membrane phospholipid
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composition. EPA alone has been suggested to correct the membrane EPUFA
deficits and improve the psychopathology of schizophrenia (Peet et al 2001). Yet,
the combined use of EPA and DHA may still be a preferred supplement. A large
proportion of EPA is converted to prostaglandins and may not be an adequate
substrate for DHA, a major neuronal membrane EPUFA (Arvindakshan et al 2003).
Studies in schizophrenic patients have indicated that antioxidant defence is impaired
and the content of membrane phospholipid EPUFAs is reduced and lipid
peroxidation is increased. Dietary supplementation with antioxidants has been
considered to prevent these changes and to improve some of the psychopathology
(Mahadik and Mukherjee 1996; Reddy and Yao 1996). It is known that high doses of
EPUFAs, if not balanced with dietary antioxidants can form high levels of peroxides.
As the evidence is mounting for increased oxidative stress and oxidative cellular
injury in schizophrenia, use of supplementation with a combination of -3 fatty
acids and antioxidants may be a preferred supplement and has been shown to
improve the outcome of schizophrenia (Arvindakshan et al 2003).
Mukherjee et al (1996) have reported that antioxidant enzyme defence is altered at
the onset of psychosis and might be associated with poor clinical outcome and
suggest that it might be important to use antioxidant co-treatment from the start of
the therapeutic treatment to prevent progression of pathology predating the illness as
well as its accentuation following treatment. Furthermore, persistent oxyradical-
mediated injury might contribute to progressive deterioration resulting in deficit state
in some schizophrenic patients as well as a relapsing chronic course of illness in
others irrespective of treatment. It is likely that adjunctive antioxidant treatment
Chapter 1 Introduction 36
might ameliorate the development of negative symptoms and prevent progression of
the defect state (Mahadik and Mukherjee 1996).
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1.8 Project Aims
So far, little or no research has been carried out in the area of oxidation of DNA and
protein in schizophrenia. The majority of the ongoing research of oxidative stress in
schizophrenia, to date has focused on lipid peroxidation, arising from the idea that
some neuropathological changes in schizophrenia may be the result of increased free
radical-mediated or reactive oxygen species mediated neuronal injury (Mahadik and
Mukherjee, 1996; Reddy and Yao, 1996). Numerous lipid peroxidation biomarkers
exist in the majority of human diseases and as a major component of membrane
phospholipids, PUFA are highly susceptible to free radical attack and undergo auto-
oxidation to form peroxyradicals and lipid peroxide intermediates. Altered in vivo
and in vitro phospholipid metabolism has been identified in some patients with
schizophrenia, as a result of reduced levels of membrane phospholipid PUFA injury
(Mahadik and Mukherjee, 1996; Reddy and Yao, 1996).
Limited research into the use of biomarkers of oxidative damage of DNA in
schizophrenia has been undertaken. Furthermore, establishing whether protein
carbonyls, biomarkers of protein oxidation are a characteristic of neurological
diseases such as schizophrenia is a novel aspect of this study which will be explored.
Another area to be investigated will include the investigation of the effects of
antioxidants and fatty acids within human lymphocytes and IMR-32 neuroblastoma
cells, neuronal-type cells. This novel work will be undertaken to establish whether
the response of cultured lymphocytes and a neuronal cell line to an oxidative
challenge are sufficiently similar to support the use of peripheral lymphocytes as
biomarkers/predictors of in vivo neuronal cell response. Research into the use of
neuroblastoma cells and in particular IMR-32 cells has shown that although they are
an ideal model to assess cell changes in an Alzheimer’s brain, the literature has
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identified that they are also widely used to investigate the effect of free
radical/reactive oxygen species damage in other neurological disorders, such as
schizophrenia and Parkinson’s Disease.
Breath analysis, a non-invasive technique used to assess largely lipid peroxidation
but also protein oxidation, will be applied, to assess lipid peroxidation, as part of a
collaborative project. Limited research has been undertaken on the use of this
method in relation to schizophrenia. This technique will be carried out therefore,
with the intention of investigating biomarkers of lipid and protein peroxidation in
schizophrenic patients compared with healthy controls.
The question that was sought to be answered during the course of this research was:
are levels of oxidative stress, as indicated by changes in a range of biomarkers, more
enhanced in the models of schizophrenia compared to the matched controls?
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CHAPTER 2
Examination of DNA oxidation in antioxidant and fatty acid
treated human neuroblastoma and human peripheral cells
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2.1 Introduction
2.1.1 Oxidative Stress and DNA Damage
Oxidative stress and the damage that it can cause has been implicated in an
enormous variety of natural and pathological processes including ageing, cancer,
diabetes mellitus, atherosclerosis, neurological illnesses such as Alzheimer’s disease,
schizophrenia and autoimmune diseases such as arthritis. Oxidative stress was first
recognised to cause damage to living organisms in 1952 by Conger and Fairchild
(reviewed by Shackelford et al 2000) who demonstrated that an increase in oxygen
pressure could cause chromosomal aberrations in pollen grains. Since then oxygen
and ROS have been shown to induce many types of DNA damage, including single-
and double-stranded DNA breaks, base and sugar modifications, DNA-protein
crosslinks and depurination and depyrimidination. It has been suggested that
approximately 2 x 104 DNA damaging events occur in every cell of the human body
every day (Foray et al 2003) with a large proportion of the damage occurring as a
result of ROS. Although at physiological levels ROS play a key role in regulating
signalling pathways and gene expression (Durocher and Jackson 2001), excessive
insult to the cell can be fatal.
In order to prevent attack from ROS and other free radicals, living cells use a number
of defences such as low molecular weight compounds and antioxidants (for
examples of antioxidants used in this study, see Figure 2.1) which scavenge free
radicals. These antioxidants eventually become radicals themselves although they are
much less reactive and prevent further damage to cellular biomolecules. More
complex systems such as the enzymes superoxide dismutase, catalase and
glutathione peroxidase have also evolved to limit the ROS-induced damage. In
normally functioning cells there is a tendency for ROS to avoid these defences,
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resulting in only a limited amount of damage to the cell. But if the balance between
pro- and antioxidant processes becomes damaged in favour of the pro-oxidant
systems, levels of cellular damage will initially increase. During turnover of lipids
and proteins any modification of these molecules will be removed, but damage to
DNA is required to be repaired since, unlike modified lipids and proteins, altered
DNA cannot be replaced.
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Figure 2.1. Antioxidant structures.
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The ROS that cause oxidative damage can be divided into two categories: free
oxygen radicals and non-radical ROS (Shackelford et al 2000). Common free
oxygen radicals include •OH, •NO and O2•-. Nonradical ROS include molecules such
as hydrogen peroxide (H2O2). Each of these ROS has the ability to damage most
cellular components including DNA, either via direct action on DNA or through
reaction with other cellular constituents to produce new ROS. H2O2 is produced by a
variety of intracellular reactions particularly oxidative electron transport in the
mitochondria and is normally present in cells at a concentration of roughly 1.0 x 10-
8M (reviewed by Shackelford et al 2000). H2O2 alone is relatively non-reactive
toward DNA and at concentrations at or below 20-50M has been reported as having
limited cytotoxicity to many cell types (Halliwell et al 2000). Most of the H2O2-
mediated DNA damage is due to the production of •OH via events such as the Fenton
reaction:
Fe2+ + H2O2 → intermediate complexes (ferryl?) → Fe3+ + OH• + OH-
Catalase is then responsible for the deactivation of H2O2 via the reaction:
2 H2O2 → 2H2O + O2
Hydrogen peroxide is generated in vivo by the dismutation of superoxide radical both
non-enzymatically and catalyzed by superoxide dismutase enzymes. It is also
directly produced by a collection of oxidase enzymes including glycollate and
monoamine oxidases as well as by the peroxisomal pathway for -oxidation of fatty
acids (Halliwell et al 2000). Free radicals including •OH react with organic
compounds by addition and abstraction. Hydroxyl radical adds to double bonds of
heterocyclic DNA bases and abstracts an H atom from the methyl group of thymine
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and from each of the C-H bonds of 2’-deoxyribose (Evans et al 2004). Hydroxyl
radical adds to the double bonds of pyrimidines and purines at diffusion-controlled
rates and preferentially adds to the site with the highest electron density.
The most prevalent damage to purines results in 7,8-dihydro-8-oxoguanine (also
known as 8-oxoguanine or 8-oxoG) and the most studied of oxidative DNA lesions,
8-hydroxyguanine (8-OH-Gua) (Figure 2.2). The hydroxyl radical first reacts with
guanine to form a C8-OH adduct radical followed by the loss of an electron and
proton to generate 8-oxo-G. The C8-OH adduct radical may also be reduced by
uptake of an electron and a proton forming 7-hydro-8-hydroxyguanine which is then
converted to 2,6-diamino-4-hydroxy-5-formamidopyrimidine, another major
oxidation product of guanine (Slupphaug et al 2003). Generation of oxidised
pyrimidines, such as thymine glycol also occurs from radical attacks, for example,
hydroxyl radical reacts to produce 5-hydroxy-6-peroxyl-radical. In the absence of
oxygen, the loss of an electron followed by uptake of water and then finally the loss
of a proton results in the production of thymine glycol. If oxygen is present however,
oxygen uptake at position 6 first yields a 5-hydroxy-6-peroxyl radical which is
converted to thymine glycol through loss of a proton and O2•- and reaction with
water (Slupphaug et al 2003).
N
NNH2 NH
N
O
OH
8-Hydroxyguanine (8-OH-Gua)
Figure 2.2. Structure of 8-OH-Gua
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Once formed it is essential that oxidative DNA lesions do not remain in the genome.
There are multiple repair pathways that undertake this task and are categorised into
base excision repair (BER) and nucleotide excision repair (NER) systems. The BER
pathway is initiated by non-enzymatic base loss or by a DNA glycolase. The
glycolase thought to be responsible for the removal of 8-OH-Gua in human cells is
the human 8-OH-Gua glycosylase. Prior to base removal, repair is completed by
short-patch repair (one nucleotide gap) or long-patch repair (a two to eight
nucleotide gap), the modified base is removed leaving an apurinic-apyrimidinic site
and the enzyme has specificity for 8-OH-Gua:C pairs present in double-stranded
DNA (Cooke et al 2005). The activity of the glycolase is complemented by another
enzyme which removes the 8-OH-Gua from the nascent strand in 8-OH-Gua:A or 8-
OH-Gua:G pairs.
If they are not repaired prior to DNA replication, 8-OH-Gua residues can result in
GC to TA transversions, which may ultimately lead to mutagenesis (Griffiths et al
2002). Levels of 8-OH-Gua in DNA have been assayed to determine the mechanisms
of ageing or carcinogenesis and to evaluate the risk of carcinogenesis by chemical
materials and these studies have shown 8-OH-Gua to be a useful biomarker for
elucidating the role of reactive oxygen species (Tsurudome et al 2001).
2.1.2 Detecting Biomarkers of DNA Oxidative Damage
The single cell gel electrophoresis (SCGE) or comet assay is a technique that can be
used for the measurement of oxidative DNA damage in individual cells. It is widely
used and can be applied to any cell population provided they have been isolated from
tissue without degradation (Lovell et al 1999), although at present human population
studies tend to use lymphocytes as surrogate tissues. Lymphocytes are often used as
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surrogate cells which are supposed to inform about oxidative stress, measured at a
certain level of 8-OH-Gua in other tissues (Collins et al 1998). However, factors
responsible for the formation of 8-OH-Gua and for oxidative stress may vary in
different tissues (Griffiths et al 2002). These include, for example, the activity of key
antioxidant enzymes which may affect oxidative stress in different organs
(Gutteridge and Halliwell 1994). Few studies have examined the use of lymphocytes
as surrogate markers but a direct correlation between DNA damage in human rectal
cells and lymphocytes (Pool-Zobel et al 2004) and an age-associated increase of
tissue and peripheral lymphocyte oxidative DNA damage in a rat model (Wolf et al
2004) has been identified.
The comet assay, a sensitive method for detecting DNA strand breaks can also be
used to measure oxidised bases, with the addition of a step in which DNA is
incubated with bacterial repair endonucleases, enzymes which recognise and remove
damaged bases and make nicks at the resulting abasic sites in the DNA.
Chromatographic methods such as HPLC and GC-MS are also widely applied
methods for the measurement of 8-OH-Gua in biological samples of DNA (Gedik et
al 2002).
2.1.2.1 The Comet Assay
Rydberg and Johanson (1978) were the first to attempt to quantify DNA strand
breaks using cells embedded in agarose on slides which were then lysed. Ostling and
Johanson (1984) further developed a microelectrophoretic technique, the SCGE
assay or comet assay. Following on from the earlier principle, cells were embedded
in an agarose gel on a microscope slide, lysed by detergents and high salt solution,
and following unwinding, and electrophoresis, the negatively charged DNA is pulled
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towards the anode. However, only loops of DNA which contain breaks (either overt
breaks or breaks resulting from repair enzyme digestion) are released from the
supercoiling and migrate in the gel. These loops extend from the head of the
nucleoid to form the comet tail. Further modifications to the assay were carried out
by Singh et al (1988) whereby electrophoresis was performed under alkaline
conditions (pH>13), which enabled detection of strand breaks as well as alkali-labile
sites, DNA crosslinking, and incomplete excision repair sites. This is currently the
most commonly used method (Figure 2.3) although additional modifications at
various stages of the assay have also been applied. Incubation with specific bacterial
repair endonucleases results in the recognition of the damaged bases; the enzymes
create a nick at the resulting abasic sites in the DNA and the oxidised base is
subsequently removed. Oxidised pyrimidines are detected via use of endonuclease
III, while oxidised purines including 8-oxo-Gua, are recognised by
formamidopyrimide DNA glycosylase (FPG) (Collins 2002). Furthermore,
alkylation damage and misincorporated uracil can also be measured (Collins et al
1993; Collins et al 1998; Duthie and McMillan 1997).
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Figure 2.3. Schematic of the comet assay protocol. Cell isolation, agarose embedding, lysis, enzyme
digestion, unwinding, and electrophoresis, neutralizing, staining and scoring (Adapted from Duthie
2003). Key: Fetal calf serum (FCS), Lymphocyte Separation Medium (LSM), low melting point
agarose (LMP), high melting point agarose (HMP), bovine serum albumin (BSA),
formamidopyrimidine glycosylase (FPG), 4’,6-diamidine-2-phenylindole dihydrochloride (DAPI).
Comet class:
0, 1, 2,
3, 4
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Comets are viewed by fluorescence microscopy after staining with a suitable
fluorescence DNA-binding dye. The relative intensity of fluorescence in the tail is a
function of DNA breaks and can be assessed either visually or using computer-based
image analysis. Cells with damaged DNA display increased migration of DNA
fragments from the nucleus. The length of the migration indicates the amount of
DNA breakage (Singh et al 1988), and DNA damage was often estimated based on
the percent of damaged cells or by the migration of the tail length (Fairbairn et al
1995). Tail moment, the product of the amount of DNA in the tail and the mean
distance of tail migration, is a more sensitive parameter (Olive et al 1990) and
percentage of DNA in the tail occasionally represents the most accurate evaluation
by image analyzers (McKelvey-Martin et al 1993; Olive et al 1993). It is difficult,
however, to analyze many cells by image analysis because it is time-consuming to
analyze the comets one by one. Manual scoring, on the other hand, a method that has
not been widely used, is simple, less time consuming, and does not need special
equipment (Kobayashi et al 1995).
2.1.2.2 Chromatography
High pressure liquid chromatography (HPLC) is widely used for the measurement of
8-oxo-Gua in biological samples of DNA such as animal tissue or white blood cells
although the small extent of base oxidation requires the use of electrochemical
detection (ECD) (Griffiths et al 2002). However, oxidation of guanine at any stage in
sample preparation is the most significant problem. It can be improved by including
antioxidants and by carrying out procedures in the absence of oxygen if possible,
but, as problems of oxidation of DNA are resolved, the amount of 8-oxo-Gua
detected in the DNA of normal human cells becomes even smaller and increasingly
difficult to detect even with highly sensitive coulometeric electrochemical detection
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(Griffiths et al 2002). Gas chromatography-mass spectrometry (GC-MS) is used to
analyse DNA base products but this method is also prone to oxidation artefacts
during sample preparation (Griffiths et al 2002).
For evaluation, internal standards of the analysed modifications labelled with stable
isotopes are also necessary, along with the addition of appropriate antioxidants and
the elimination of traces of oxygen (Griffiths et al 2002). A consortium of
laboratories known as European Standards Committee on Oxidative DNA Damage
(ESCODD, 2002) undertook a study highlighting the serious problem of oxidation
artefact and concluded that GC-MS is not suitable for measuring basal 8-oxo-Gua
levels in biological material. HPLC-MS has yet to yield convincing results while
HPLC-ECD can measure induced damage accurately but still suffers from
adventitious oxidation during sample preparation (Collins 2005).
Other approaches that are being employed in the detection of oxidised DNA include
enzyme-linked immunoabsorbant assay (ELISA). HPLC and ELISA methods have
been compared using placental tissue DNA. Values by both methods correlated well,
but the ELISA values were higher than those determined by HPLC. This is thought
to be due to the antibody cross reacting with compounds other than 8-oxo-Gua
(Mayne 2003).
2.1.3 DNA Oxidative Damage and Schizophrenia
Although free radical pathology in schizophrenia is widely investigated, examination
of ROS induced DNA damage is limited. However, evidence for DNA damage in the
hippocampus of schizophrenic patients, detected by the presence of the 8-oxo-Gua
biomarker, has recently been reported (Nishioka and Arnold 2004). Investigation of
DNA damage is important because it is a possible indicator of carcinogenic and
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mutagenic potential. In addition, there is accumulating evidence of altered
antioxidant capacity in schizophrenia. Membrane dysfunction can be secondary to
free radical-mediated pathology, and may contribute to specific aspects of
schizophrenic symptomatology and complications of its treatment (Yao et al 2001).
Specifically, free radical-mediated abnormalities may contribute to the development
of a number of clinically significant consequences, including prominent negative
symptoms, tardive dyskinesia, neurological 'soft' signs and parkinsonian symptoms
(Yao et al 2001).
Investigation of the effect of polyunsaturated fatty acid supplementation on oxidative
DNA damage in schizophrenia has not been undertaken to date. In cancer and ageing
studies it appears that polyunsaturated fats may have a dual role, since they may
inhibit oxidative stress and act as a protective agent, as well as provide a substrate
for peroxidation reactions (Beeharry et al 2003, Quiles 2004). The role of
antioxidants and fatty acids obtained from the diet in protection against disease is a
topic of continuing interest and some controversy. It is widely recognised however,
that people with schizophrenia make poor dietary choices and that consumption of
antioxidants is low (McCreadie 2003) and PUFA intake is also low (Kemperman et
al 2006) in this group of people.
2.1.4 Using Human Cells in Schizophrenia Studies
Whilst the importance of in vivo and ex vivo work cannot be over emphasised, in
vitro models of clinical disease have much to offer in terms of elucidating molecular
mechanisms and evaluating the efficacy of novel agents.
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2.1.4.1 U937 Cells
The U937 cell line is a well characterised human lymphoma cell line of Caucasian
origin. The use of this cell line has recently been adopted as an in vitro model of
schizophrenia since it has been reported that these cells imitate in some ways, the
lipid-related changes seen in suffers of schizophrenia (Gattaz et al 1990; Khan et al
2002) including very low levels of polyunsaturated fatty acids (Obermeier et al
1995), while a further in vitro observation obtained using the U937 monocyte
derived cell line indicated that long term supplementation with EPA increased the
stimulated release of AA from membrane phospholipids (Obajimi et al 2005).
Studies investigating phospholipase A2 have revealed that U937 cells express high
levels of PLA2 (Kramer et al 1991), and in particular, large amounts of cPLA2
(Burke et al 1999) further evidence of some of the characteristics which mimic some
of the biochemical changes reported in patients with schizophrenia. In addition,
inhibitor studies (Balsinde et al 2002) utilising U937 cells, have suggested that the
form of PLA2 responsible for release of AA is calcium-dependent cytosolic PLA2,
while differentiation of U937 cells enables the cells to activate cPLA2 to release
arachidonate upon stimulation (Burke et al 1999). The cells have been used to better
understand the biochemical features of AA incorporation into, and remodelling
within phospholipid species of U937 cells (Balsinde et al 2002), an important
process that is thought to function defectively in patients with schizophrenia.
2.1.4.2 IMR-32 Cells
The IMR-32 cell line is a human neuroblastoma cell line of Caucasian origin which
is employed as a model for assessing neuronal cell damage, typically free radical
mediated injury (Cova et al 1995). In addition, Cova et al (1995) also suggest that
cultured neuronal cells of human origin are discriminating experimental systems,
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sensitive to minor differences, of correlating in vivo and in vitro neurotoxicants. The
IMR-32 cells have several features which are considered as useful properties in
studies of oxidative stress, namely: they are of human origin; they can be grown in
large quantities for protein studies, differentiated and maintained over several weeks
and express large amounts of neurofilaments (reviewed by Cookson et al 1996).
Neurofilaments are the intermediate filaments found only in neurones and are
potential targets for free radical damage because of their abundance in motor
neurones and their long biological half-life (Cookson et al 1996). IMR-32 cells have
also been used specifically in studies of schizophrenia patients whereby antibodies to
IMR-32 proteins were detected, suggesting an autoimmune factor in the
pathogenesis of schizophrenia (Mazeh et al 1998).
2.1.4.3 Lymphoblastoid Cells
Lymphoblastoid cell lines were established by Epstein-Barr virus transformation of
peripheral blood mononuclear cells derived from a schizophrenic patient. Since these
cells were derived from a schizophrenic patient, it was anticipated that they would
provide an accurate insight into the schizophrenic biochemical processes under
investigation in our study. Furthermore, human population studies tend to use
lymphocytes as surrogate tissues. Lymphocytes are often used as surrogate cells
which are supposed to inform about oxidative stress, for example, levels of 8-OH-
Gua in other tissues can be measured in lymphocytes and compared to levels in
tissue elsewhere in the body (Collins et al 1998).
The primary focus of this research was a comparator study of these two cell lines
with a further secondary, lymphoblastoid cell line of schizophrenic origin as a means
of assessing the validity of monitoring peripheral lymphocytes as potential surrogate
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markers of DNA damage in neuronal cell types. Additionally, the reducing ability of
a range of antioxidants was assessed and in conjunction, the efficacy of a series of
polyunsaturated fatty acids along with the same antioxidants was considered in
affording protection to cellular DNA against an oxidative challenge examined.
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2.2 Materials and Methods
2.2.1 Validation and Optimisation of the Comet Assay
2.2.1.1 Materials
Lymphoprep lymphocyte separation medium (LSM) (specific gravity 1.077 ± 0.001
g/ml) was supplied by Robins Scientific (Solihull, UK). Dutch Modified RPMI 1640
medium was obtained from Sigma (Poole, UK). Heat-inactivated fetal calf serum
(FCS) was obtained from Invitrogen (Paisley, UK). Microscope slides and cover
glasses were supplied from Fisher Scientific (Loughborough, UK). Low Melting
Point (LMP) and Normal Melting Point (NMP) agarose were supplied by Gibco Life
Technologies (Paisley, UK). 4’,6-Diamidine-2-phenylindole dihydrochloride (DAPI)
was obtained from Sigma (Poole, UK). Corning centrifuge tubes were supplied by
Fisher Scientific (Loughborough, UK). Vacutainers were obtained from Aberdeen
Royal Infirmary, (Aberdeen, UK). Resveratrol, epigallocatechin gallate (EGCG), 2-
(4-hydroxyphenyl) ethanol (tyrosol), were supplied by Sigma (Poole, UK). 3,4-
dihydroxyphenyl ethanol (hydroxytyrosol) was obtained from Alexis Corp (UK) Ltd
(Nottingham, UK). 25cm2 cell culture flasks and 96-well plates were supplied by
Fisher Scientific (Loughborough, UK). Dimethyl sulfoxide (DMSO) was supplied by
Sigma (Poole, UK).
2.2.1.2 Isolation and Cryopreservation of Human Lymphocytes
Venous blood (2 x 7ml) was collected by venepuncture. The whole blood was
centrifuged at 2400xg for 15min at 4oC, the buffy coats from each vacutainer (~1ml)
were removed, combined into one centrifuge tube and diluted 1:1 with RPMI and
layered onto an equal volume of LSM before centrifuging at 700xg for 30min at
20oC. The lymphocytes were transferred to a fresh centrifuge tube, washed using
RPMI medium and spun for a further 15min under the same conditions. The
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supernatant was decanted, the cells resuspended in RPMI containing 10% heat-
inactivated FCS and counted using a Neubauer Improved Haemocytometer. Isolated
lymphocytes were either used immediately or were centrifuged and resuspended in
0.5ml aliquots at 3x106cells/ml in freezing mix (90% v/v heat-inactivated FCS and
10% v/v DMSO), frozen at -1oC/min in polystyrene and stored at -70oC.
2.2.1.3 Hydrogen Peroxide-induced DNA Strand Breakage in Fresh
Lymphocytes Measured Using the Comet Assay
Freshly isolated lymphocytes were incubated in microcentrifuge tubes with hydrogen
peroxide (H2O2) (50, 100 or 200M in phosphate-buffered saline (PBS) for 5min on
ice), washed and suspended in 140l of 1% (w/v) LMP agarose in PBS pH 7.4 at
37oC and immediately pipetted onto a glass microscope slide pre-coated with a layer
of 1% (w/v) NMP agarose prepared in distilled water. The agarose was allowed to
set for 5min at 4oC and the slides were incubated in lysis solution (2.5M NaCl,
10mM Tris, 100mM NA2EDTA, 10M NaOH to pH 10.0 and 1% v/v Triton X-100)
at 4oC for 1h to remove cellular proteins. After lysis, the slides were aligned in a
210mm wide horizontal electrophoresis tank containing buffer (1mM NA2EDTA and
0.3M NaOH, pH 13.0) for 40min before electrophoresis at 21v for 30min (at an
ambient temperature of 4oC with the temperature of the running buffer not exceeding
15oC). The slides were washed three times at 4oC for 5min each with neutralizing
buffer (0.4M Tris-HCl, pH 7.5) before staining with 20l of DAPI (1g/ml).
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2.2.1.4 Hydrogen Peroxide-induced DNA Strand Breakage in
Cryopreserved Lymphocytes
Cryopreserved lymphocytes were thawed on ice until the last trace of ice had
disappeared. The aliquots were centrifuged at 200xg for 3min to remove freezing
mix and the lymphocyte pellet resuspended gently in 0.4ml of RPMI + 10% (v/v)
heat-inactivated FCS. Lymphocytes were washed once in PBS and incubated in
microcentrifuge tubes H2O2 (10, 25, 50, 200M in PBS for 5min on ice). The cells
were resuspended immediately in LMP agarose for detection of DNA strand
breakage by Comet analysis.
2.2.1.5 Quantitation of the Comet Assay
Nucleoids were scored visually using a Leica fluorescence microscope. One hundred
comets from each gel (scored at random) were classified into one of five classes
according to the relative intensity of fluorescence in the tail and given a value of 0-4
(from undamaged, 0, to maximally damaged, 4). The total score for 100 comets can
range from 0 (all undamaged) to 400 (all maximally damaged) and is expressed in
arbitrary units. This method of visual classification has been extensively validated by
comparison with comets selected using computerized image analysis.
2.2.1.6 Statistical Analysis
The Kolmogorov-Smirnof test was used to test the normality of the data and one-
way ANOVA and the Student’s t-test was carried out as appropriate using SPSS 11.5
for Windows. For statistical analysis, a level of 0.05 was used to determine
significance.
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2.2.2 Determination of Antioxidant Activity in Poly and Monophenolic
Antioxidants
2.2.2.1 Materials
Trolox, 2,2’-azinobis(3-ethylbenzothiazoline-6-sulphonic) acid (ABTS),
diammonium salt, potassium persulphate, resveratrol, EGCG and tyrosol, were
supplied by Sigma (Poole, UK). Hydroxytyrosol was obtained from Alexis Corp
(UK) Ltd (Nottingham, UK).
2.2.2.2 ABTS Assay
The protocol used is an adaptation of Re et al (1999). 1mM Trolox was prepared in
ethanol for use as a stock standard and fresh working standards were prepared on
dilution with ethanol. Stock solutions of the antioxidants were prepared by
dissolution in ethanol and subsequently diluted in ethanol for introduction into the
assay system at a final concentration of 0.5mM. ABTS was dissolved in water to a
7mM concentration and ABTS radical cation (ABTS•+) was produced by reacting
ABTS stock solution with potassium persulfate and allowing the mixture to stand in
the dark at room temperature overnight. The ABTS•+ solution was diluted with
ethanol. Stock solutions of antioxidants were diluted such that, after introduction of a
10l aliquot of each dilution into the assay, they produced between 20%-80%
inhibition of the blank absorbance. After addition of 1ml of diluted ABTS•+ solution
(A734nm = 0.701) to 10l of antioxidant compound or Trolox standards the
absorbance reading was taken at room temperature exactly 1min after initial mixing
for up to 4min.
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2.2.2.3 Statistical Analysis
The Kolmogorov-Smirnof test was used to test the normality of the data and
Student’s t-test was carried out as appropriate using SPSS 11.5 for Windows. For
statistical analysis, a level of 0.05 was used to determine significance.
2.2.3 Investigation of Phenolic Antioxidant Mediated Cytoprotection in
Human Neuroblastoma IMR-32 and Human Peripheral (U937
and Lymphoblastoid) Cells
2.2.3.1 Materials
Dulbecco’s Minimal Essential Medium Nutrient Fixed F-12 Ham media (DMEM),
penicillin/streptomycin antibiotic, trypsin/EDTA and glucose were supplied by
Sigma (Poole, UK). Heat-inactivated FCS was obtained from Invitrogen (Paisley,
UK). RPMI 1640 media was supplied by Gibco (UK). EGCG was supplied by Sigma
(Poole, UK). Hydroxytyrosol was obtained from Alexis Corp (UK) Ltd (Nottingham,
UK). 25cm2 culture flasks supplied by Fisher Scientific, (Loughborough, UK).
DMSO was supplied by Sigma (Poole, UK). Neuroblastoma IMR-32 and
lymphoblastoid cell lines were provided frozen by European Collection of Cell
Cultures (ECACC) (Porton Down, Wiltshire). U937 cell line was provided growing
in culture by ECACC (Porton Down, Wiltshire).
2.2.3.2 Culture of Neuroblastoma Cells
Complete neuroblastoma IMR-32 media was prepared under sterile conditions.
100ml DMEM medium containing 20% (v/v) heat-inactivated FCS, 1% 100U/ml
penicillin, 100mg/ml streptomycin, 6g/L sterile filtered glucose were combined and
stored at 4oC. Neuroblastoma cells were resuscitated by incubating vials in a 37oC
water bath and agitated gently for 3-4min until completely thawed. The 1ml cell
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suspension was pipetted into a 25cm2 flask containing 8ml of complete DMEM
media and incubated at 37oC, 5% CO2 until at least 80% confluent (approximately 3
days). Cells were passaged by washing twice with 1ml sterile PBS and adding 0.5ml
trypsin/EDTA to ensure cells were dislodged from the flask. 5ml media was added to
the flask and a needle and syringe was used to homogenise the cells. A further 4ml
of media was added to the homogenised cells and 3ml of the cell suspension was
decanted into 3 x 25cm2 flasks containing 6ml of fresh media. Flasks were placed in
the incubator and the media was replaced with 9ml of fresh media after 3 days of
growth. Further passage of cells at a seeding density of 1 x 106cells/ml was
undertaken and the cells were incubated in 9ml of fresh media in 25cm2 flasks as
described above. Cells were left to grow until 80-90% confluence was obtained. Cell
viability was determined as 90-95% as ascertained by the Trypan blue dye exclusion
method of viability.
2.2.3.3 Culture of Peripheral Cells
Complete lymphocyte media was prepared under sterile conditions. RPMI medium
containing L-glutamine, 10% (v/v) heat-inactivated FCS, 1% 100U/ml penicillin,
100mg/ml streptomycin, were combined and stored at 4oC. U937 cells provided
growing in culture, were incubated at 37oC, 5% CO2 until at least 80-90% confluent
(approximately 2-3 days). Lymphoblastoid cells were resuscitated by thawing in a
37oC water bath by gentle agitation for 3-4min and then pipetted into a 25cm2 flask
containing 9ml complete RPMI media. Cells were passaged by pouring off cell
suspension into a centrifuge tube and centrifuging for 5min at 2000xg. The cell pellet
was then washed twice with sterile PBS. The cell pellet was resuspended into 1ml of
RPMI media and cells were counted using a haemocytometer and seeded at a density
of 1 x 106cells/ml. Cells were incubated in fresh media in 12 well plates until 80-
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90% confluent. Cell viability was determined as >90% as ascertained by the Trypan
blue dye exclusion method of viability.
2.2.3.4 Antioxidant Treatment of Neuroblastoma Cells
10mM stock solutions of EGCG and hydroxytyrosol were prepared freshly in DMSO
and sterile filtered. A final concentration of 10M of each antioxidant or DMSO
only was used. DMSO concentration was no more than 1% of the cell culture media.
Antioxidant was added to the flask and cells were incubated for 30min and 6h at
37oC, 5% CO2. Following incubation, supernatant was poured off and the cells were
washed 2 x with 1ml ice cold PBS. 0.5ml trypsin/EDTA was added to each flask to
dislodge cells and the cell suspension was transferred into microcentrifuge tubes and
placed on ice. Cells were washed with ice cold PBS, centrifuged at 200xg for 3min
at 4oC and stored on ice.
2.2.3.5 Antioxidant Treatment of Peripheral Cells
10mM stock solutions of EGCG and hydroxytyrosol were prepared freshly in
DMSO. A final concentration of 10M of each antioxidant or DMSO only was used.
DMSO concentration was no more than 1% of the cell culture media. Antioxidant
was added to the 12 well plates and cells were incubated for 30min and 6h at 37oC,
5% CO2. Following incubation, cell suspension was pipetted into a centrifuge tube
and the cells were centrifuged for 5min at 200xg and washed twice with PBS. The
cell pellet was resuspended in 1ml PBS and transferred into microcentrifuge tubes
and placed on ice. Cells were washed with ice cold PBS, centrifuged at 200xg for
3min at 4oC and stored on ice.
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2.2.3.6 Hydrogen Peroxide-induced DNA Strand Breakage in
Neuroblastoma Cells Measured Using the Comet Assay
Neuroblastomas were incubated in microcentrifuge tubes with 25M H2O2 as
described previously and the comet assay was carried out as described previously in
section 2.2.1.3.
2.2.3.7 Hydrogen Peroxide-induced DNA Strand Breakage in Peripheral
Cells Measured Using the Comet Assay
U937 and lymphoblastoid cells were incubated in microcentrifuge tubes with 100M
H2O2 as described previously and the comet assay was carried out as described
previously in section 2.2.1.3.
2.2.3.8 Quantitation of the Comet Assay
Nucleoids were scored visually using a Leica fluorescence microscope as described
previously in section 2.2.1.5. The slides were blinded so that treatment groups could
not be identified.
2.2.3.9 Statistical Analysis
The Kolmogorov-Smirnof test was used to test the normality of the data and two-
way ANOVA was carried out as appropriate using SPSS 11.5 for Windows. For
statistical analysis, a level of 0.05 was used to determine significance.
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2.2.4 Investigation of Fatty Acid Mediated Cytoprotection in Human
Neuroblastoma IMR-32 and Human Peripheral (U937 and
Lymphoblastoid) Cells
2.2.4.1 Materials
DMEM, penicillin/streptomycin antibiotic, trypsin/EDTA, glucose were supplied by
Sigma (Poole, UK). Heat-inactivated FCS was obtained from Invitrogen (Paisley,
UK). RPMI 1640 media was supplied by Gibco (UK). Eicosapentaenoic acid (EPA,
>95%) and docosahexaenoic acid (DHA, >90%) were supplied by Pronova,
(Norway). 25cm2 culture flasks and 12-well plates were supplied by Fisher
Scientific, (Loughborough, UK). DMSO was supplied by Sigma (Poole, UK).
2.2.4.2 Culture of Neuroblastoma Cells
IMR-32 cells were cultured, maintained at a density of 1 x 106cells/ml and harvested
as described previously in section 2.2.3.2.
2.2.4.3 Culture of Peripheral Cells
Human peripheral cells were cultured and maintained in 25cm2 flasks. Upon
reaching 80-90% confluence, cell suspension was poured into a centrifuge tube and
centrifuged at 200xg for 3min. The cells were resuspended in 1ml media and
counted. Cells were reseeded at a density of 1 x 106cells/ml in 12 well plates.
Following treatment, cells were harvested as described previously in section 2.2.3.3.
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2.2.4.4 Fatty Acid Treatment of Neuroblastoma Cells
100mM stock solutions of EPA and DHA were prepared in ethanol and stored under
nitrogen at -20oC. A final concentration of 10, 50 and 100M of EPA and DHA was
used. Fatty acid was added to the appropriate flasks and cells were incubated for
30min, 6h and 18h at 37oC, 5% CO2. Following incubation, cell media was poured
off and the cells were washed twice with 1ml ice cold PBS. 0.5ml trypsin/EDTA was
added to dislodge cells and the cell suspension was pipetted into microcentrifuge
tubes and placed on ice. Cells were washed and centrifuged at 200xg for 3min at 4oC
with ice cold PBS.
2.2.4.5 Fatty Acid Treatment of Peripheral Cells
100mM stock solutions of EPA and DHA were prepared in ethanol and stored under
nitrogen at -20oC. Final concentrations of 10, 50 and 100M of EPA and DHA were
used. Fatty acid was added to the appropriate wells and cells were incubated for
30min, 6h and 18h at 37oC, 5% CO2. Following incubation, cell suspension was
pipetted off into a centrifuge tube and the cells were washed twice with PBS and
centrifuged at 200xg for 3min. The cell pellet was resuspended in 1ml PBS and
transferred into microcentrifuge tubes and placed on ice. Cells were washed with ice
cold PBS and centrifuged at 200xg for 3min at 4oC.
2.2.4.6 Hydrogen Peroxide-induced DNA Strand Breakage in
Neuroblastoma Cells Measured Using the Comet Assay
Neuroblastomas were incubated in microcentrifuge tubes with 25M hydrogen
peroxide as described previously and the comet assay was carried out as in section
2.2.1.3.
Chapter 2 Examination of DNA Oxidation in Human Cells 64
2.2.4.7 Hydrogen Peroxide-induced DNA Strand Breakage in Peripheral
Cells Measured Using the Comet Assay
Peripheral cells were incubated in microcentrifuge tubes with 100M hydrogen
peroxide as described previously and the comet assay was carried out as in section
2.2.1.3
2.2.4.8 Quantitation of the Comet Assay
Nucleoids were scored visually using a Leica fluorescence microscope as described
previously in section 2.2.1.5. The slides were blinded so that treatment groups could
not be identified.
2.2.4.9 Statistical Analysis
The Kolmogorov-Smirnof test was used to test the normality of the data and two-
way ANOVA was carried out as appropriate using SPSS 11.5 for Windows. For
statistical analysis, a level of 0.05 was used to determine significance.
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2.3 Results
Validation of the comet assay was undertaken using freshly isolated and
cryopreserved human lymphocytes, frozen up to 12 weeks at -80oC. Lymphocytes
were treated with an increasing concentration of H2O2 for 5min on ice and the level
of endogenous and exogenous cellular DNA damage was compared (Figure 2.4).
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Figure 2.4. Comparison of endogenous and H2O2-induced DNA damage in fresh and cryopreserved
human lymphocytes, frozen at -80oC for up to 12 weeks. Levels of DNA damage measured with the
comet assay in freshly isolated and cryopreserved lymphocytes following 5min treatment of 0, 50,
100 and 200M H2O2. Data show the mean DNA damage (n=2) ± sem.
Two-way ANOVA was used to investigate the effects of H2O2 treatment and time on
the level of DNA damage. In addition, one-way ANOVA was used to make
comparisons within the time and treatment means. Statistical analysis revealed no
significant difference between the levels of DNA damage at each time point, ie.
freezing lymphocytes at -80oC up to 12 weeks had no effect on the level of DNA
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damage in either untreated or H2O2 treated cells. A treatment dose response was
observed.
A comparison of the antioxidant activity of four phenolic antioxidants was
determined by the ABTS assay and EGCG and hydroxytyrosol were shown to be the
most potent radical quenchers examined (Table 2.1). One way ANOVA revealed that
antioxidant potential in order of statistically significant (p <0.001) decreasing
effectiveness was EGCG > hydroxytyrosol > resveratrol > tyrosol. Based on these
data, EGCG and hydroxytyrosol only were used during subsequent experimentation.
Test Compound
0.5mM
Mean % Quenching
Radical Cation
SEM
EGCG 56.8 0.3
Hydroxytyrosol 35.3 0.3
Resveratrol 27.4 0.3
Tyrosol 7.2 0.1
Reference: Trolox (1mM) 24.4 0.9
Table 2.1. Comparison of phenolic antioxidant activity measured by ABTS assay. Data show the
mean percentage quenching of radical cation (ie. antioxidant activity) (n=3) ± sem. Trolox is used as a
standard reference.
The potency of the two test compounds (EGCG and hydroxytyrosol) mirrored the
protective effects observed in the in vitro cell culture systems. A time course study
(results not shown) was undertaken to determine the optimum incubation time
required in which the antioxidants used in this study would display a protective
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effect against H2O2-induced DNA damage and following 30min and 6h treatment
with EGCG and hydroxytyrosol, human IMR-32 neuroblastoma cells were incubated
with 25M H2O2 at for 5min on ice. The mean extent of H2O2-induced DNA damage
was measured and compared between H2O2 control and antioxidant+H2O2 treated
cells. Two-way ANOVA was employed to investigate effect of time and treatment
and analysis revealed a highly significant decrease in the level of DNA damage in
both the EGCG+H2O2 and hydroxytyrosol+H2O2 treated IMR-32 cells after 30min
and 6h of antioxidant incubation (Table 2.2). Furthermore, pre-treatment of U937
cells with EGCG or hydroxytyrosol for 30 minutes or 6 hours resulted in a highly
significant reduction in the level of H2O2-induced DNA damage when compared to
control cells. In contrast, pre-treatment of lymphoblastoid cells with hydroxytyrosol
but not EGCG afforded significant protection of cellular DNA against an oxidative
challenge, resulting in a 21% decrease in the level of DNA damage when compared
to the H2O2 control. Although results are not shown, for completeness all cells were
treated with antioxidants (or without ie. untreated and DMSO treated control) for
30min or 6h and without an H2O2 challenge. No difference in the level of DNA
damage was observed between the untreated and antioxidant-treated peripheral and
neuroblastoma cells and thus none of the test compounds elicited a pro-oxidant effect
at the concentrations employed.
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IMR-32 Neuroblastoma U937 Lymphoblastoid
Treatment Mean DNA
damage
comet score
(arb. units)
SEM Treatment Mean DNA
damage
comet score
(arb. units)
SEM Treatment Mean DNA
damage
comet score
(arb. units)
SEM
30
min
6
h
30
min
6
h
30
min
6
h
30
min
6
h
30
min
6
h
30
min
6
h
H2O2
control
217 228 7 7 H2O2
control
296 295 7 7 H2O2
control
302 304 11 8
DMSO+
H2O2
242 219 7 7 DMSO+
H2O2
294 298 10 11 DMSO+
H2O2
288 301 13 13
EGCG+
H2O2
142*** 117*** 8 8 EGCG+
H2O2
218*** 228*** 10 9 EGCG+
H2O2
274 293 11 5
OHTY+
H2O2
134*** 139*** 11 9 OHTY+
H2O2
173*** 173*** 8 6 OHTY+
H2O2
237*** 240*** 14 11
Table 2.2. Levels of DNA damage measured with the comet assay in human neuroblastoma and
peripheral cells following 30min and 6h treatment with 10M phenolic antioxidant and 25M H2O2
(IMR-32) and 100M H2O2 (U937 and lymphoblastoid). Data show the mean DNA damage (n=3) ±
sem. Significance is denoted by *** where p <0.001. Key: EGCG = epigallocatechin gallate, OHTY =
hydroxytyrosol.
As well as an examination of the efficacy of antioxidants in affording protection to
cellular DNA against an oxidative challenge, the protective effects of two
polyunsaturated acids were evaluated. Treatment of IMR-32 cells with 10, 50 and
100M EPA or DHA after 30min, 6 and 24h was investigated and following
incubation of cells with 25M H2O2 for 5min, the mean extent of H2O2-induced
DNA damage was measured and compared between H2O2 control and fatty acid+
H2O2 treated cells. Figure 2.5 shows significant reduction in the levels of DNA
damage in EPA-treated IMR-32 cells between the ranges of 10-100 M, after 30min
and up to 24h. A significant level (p <0.001) of cytoprotection was also observed
when IMR-32 cells were treated with the same range of DHA concentrations
between 30min and 24h (Figure 2.6). For completeness all cells were treated with
fatty acids (or without ie. DMSO control and untreated) for 30min, 6h or 24h but
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without an H2O2 challenge. No difference in the level of DNA damage was observed
between the untreated and fatty acid treated neuroblastoma cells (results not shown).
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Figure 2.5. Evaluation of EPA cytoprotection in H2O2-induced DNA damage in human IMR-32
neuroblastoma cells. Levels of DNA damage measured with the comet assay in IMR-32
neuroblastoma cells following 30min, 6 and 24h treatment with 10, 50 and 100M of EPA and 25M
H2O2. Data show the mean DNA damage (n=3) ± sem. Significance is denoted by *** where p <0.001
and ** where p <0.01.
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Figure 2.6. Evaluation of DHA cytoprotection in H2O2-induced DNA damage in human IMR-32
neuroblastoma cells. Levels of DNA damage measured with the comet assay in IMR-32
neuroblastoma cells following 30min, 6 and 24h treatment with 10, 50 and 100M of DHA and 25M
H2O2. Data show the mean DNA damage (n=3) ± sem. Significance is denoted by *** where p
<0.001.
EPA or DHA treatment without H2O2 challenge was also evaluated in peripheral
cells and the mean level of DNA damage was measured and compared between
controls and fatty acid treated cells. No difference in the level of DNA damage was
noted in the non-fatty acid treated and fatty acid treated U937 cells (results not
shown). Conversely, when lymphoblastoid cells were treated with increasing
concentrations of EPA or DHA, an increase in DNA damage was observed. This was
only statistically significant (p< 0.05) when cells were treated with 100M of DHA
for 24h (Figure 2.7).
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Figure 2.7. Evaluation of DHA cytoprotection in human lymphoblastoid cells. Levels of DNA
damage measured with the comet assay in lymphoblastoid cells following 30min, 6 and 24h treatment
with 10, 50 and 100M of DHA. Data show the mean DNA damage (n=3) ± sem. Significance is
denoted by * where p <0.05.
A significant reduction in the levels of DNA damage in the U937 and
lymphoblastoid cells treated with 10M and 50M EPA+ H2O2 (Figures 2.8 and 2.9)
was observed after 30min and up to 24h when compared to H2O2 and ethanol+ H2O2
treatments. Furthermore, DHA pre-treated U937 and lymphoblastoid cells also
offered a significant level of cellular protection against the H2O2 challenge following
30min and 24h incubations with the fatty acid (Figures 2.10 and 2.11).
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Figure 2.8. Evaluation of EPA cytoprotection in H2O2-induced DNA damage in human U937 cells.
Levels of DNA damage measured with the comet assay in U937 cells following 30min, 6 and 24h
treatment with 10, 50 and 100M of EPA and 100M H2O2. Data show the mean DNA damage (n=3)
± sem. Significance is denoted by *** where p <0.001, ** where p <0.01 and * where p <0.05.
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Figure 2.9. Evaluation of EPA cytoprotection in H2O2-induced DNA damage in human
lymphoblastoid cells. Levels of DNA damage measured with the comet assay in lymphoblastoid cells
following 30min, 6 and 24h treatment with 10, 50 and 100M of EPA and 100M H2O2. Data show
the mean DNA damage (n=3) ± sem. Significance is denoted by *** where p <0.001, ** where p
<0.01 and * where p <0.05.
Chapter 2 Examination of DNA Oxidation in Human Cells 74
0
100
200
300
400
U
nt
re
at
ed
H
2O
2
Et
oH
+H
2O
2
10
μ
M
D
H
A
+H
2O
2
50
μ
M
D
H
A
+H
2O
2
10
0
μ
M
D
H
A
+H
2O
2
U
nt
re
at
ed
H
2O
2
Et
oH
+H
2O
2
10
μ
M
D
H
A
+H
2O
2
50
μ
M
D
H
A
+H
2O
2
10
0
μ
M
D
H
A
+H
2O
2
U
nt
re
at
ed
H
2O
2
Et
oH
+H
2O
2
10
μ
M
D
H
A
+H
2O
2
50
μ
M
D
H
A
+H
2O
2
10
0
μ
M
D
H
A
+H
2O
2
30 min 6 h 24 h
D
N
A
da
m
ag
e
(a
rb
itr
ar
y
un
its
)
** *** ****** *** ****** ** *
Figure 2.10. Evaluation of DHA cytoprotection in H2O2-induced DNA damage in human U937 cells.
Levels of DNA damage measured with the comet assay in U937 cells following 30min, 6 and 24h
treatment with 10, 50 and 100M of DHA and 100M H2O2. Data show the mean DNA damage
(n=3) ± sem. Significance is denoted by *** where p <0.001, ** where p <0.01 and * where p <0.05.
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Figure 2.11. Evaluation of DHA cytoprotection in H2O2-induced DNA damage in human
lymphoblastoid cells. Levels of DNA damage measured with the comet assay in lymphoblastoid cells
following 30min, 6 and 24h treatment with 10, 50 and 100M of DHA and 100M H2O2. Data show
the mean DNA damage (n=3) ±sem. Significance is denoted by *** where p <0.001 and * where p
<0.05.
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2.4 Discussion
The main aim of this chapter was a comparator study of two human peripheral cell
lines and a neuroblastoma cell line as a means of assessing the validity of monitoring
peripheral lymphocytes as potential surrogate markers of DNA damage in neuronal
cell types. Furthermore, experimentation to test the susceptibility of each cell line to
an oxidative challenge was also undertaken along with an examination of the
potential protective effects of a series of antioxidants and fatty acids on DNA
oxidative damage.
2.4.1 Comet Assay Validation
The comet assay was undertaken to investigate single-stranded DNA breaks as a
biomarker of DNA oxidative damage. Results of the validation study reveal that
freezing lymphocytes at different time points up to 12 weeks at -80oC had no effect
on the level of endogenous or exogenous cellular DNA damage. The effects of
cryopreservation on endogenous and induced DNA damage in human peripheral
blood lymphocytes has been measured in various studies (Duthie et al 2002;
Visvardis et al 1997) where it was reported that DNA damage was the same as that
seen in freshly isolated lymphocytes. In addition, long term storage was also shown
to have no effect on endogenous and induced DNA damage.
2.4.2 ABTS Assay
In addition, the reducing ability of a range of antioxidants was assessed and in
conjunction, the efficacy of these antioxidants and a series of polyunsaturated fatty
acids were considered in affording protection to cellular DNA against an oxidative
challenge. Numerous assays have been described in which antioxidant is added to a
reaction mixture in which free radicals are generated. An example is the ABTS assay
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in which ABTS is oxidised by 2,2’azobis(2-amidopropane). Any antioxidant present
delays the appearance of the coloured product of this reaction. Two polyphenolic
(EGCG and resveratrol) and two monophenolic (tyrosol and hydroxytyrosol)
compounds were tested using the ABTS assay. EGCG and hydroxytyrosol (Table
2.1) were found to be the most potent radical quenchers examined.
Structure-activity comparisons suggest that antioxidant activity of phenolic
compounds depends on the number and orientation of hydroxyl groups relative to the
electron-withdrawing CO2H, CH2CO2H or (CH)CO2CH functional groups (Rice-
Evans et al 1996). When considering flavonoid (e.g. EGCG) antioxidant activity, the
B-ring hydroxyl configuration is the most significant determinant of scavenging of
reactive oxygen species. Hydroxyl groups on the B-ring donate hydrogen and an
electron to hydroxyl, peroxyl and peroxynitrite radicals, stabilizing them and giving
rise to a relatively stable flavonoid radical (Heim et al 2002). Functional differences
between hydroxytyrosol and tyrosol have been attributed to the presence of only a
single hydroxyl (reviewed by Quiles et al 2002) which may account for the greater
antioxidant potential of hydroxytyrosol over tyrosol. These structural differences
may explain why hydroxytyrosol and EGCG appear to have a greater antioxidant
potential than tyrosol and resveratrol (Figure 2.1) since Masella et al (1999) suggest
that the phenol chemical structure considerably influences the antioxidant activity as
a consequence of both steric factors and those related to position and type of
functional groups on the phenol ring. Furthermore, the antioxidant activity of
biphenols depends mainly on the number of hydroxyl groups in the molecule
(Masella et al 1999).
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2.4.3 Antioxidant and Fatty Acid Protection against DNA Damage
2.4.3.1 DNA Damage and Antioxidant Protection
Several studies of schizophrenia have reported abnormalities in one or more
antioxidant enzymes and/or in the levels of cerebrospinal fluid and plasma TBARs
(Mahadik and Mukherjee, 1996; Reddy and Yao, 1996). Other studies have also
reported a wide range of abnormalities in membrane phospholipids that may be a
result of oxidative damage. These changes have been considered to be a result of
altered metabolism (reduced synthesis and/or increased breakdown) of essential
polyunsaturated fatty acids (EPUFAs). EPUFAs are the -3 and -6 series of fatty
acids that must be consumed in the diet. Reduced membrane EPUFAs have been
found to be associated with psychopathology (Glen et al 1994; Peet et al 1995).
Three human cell lines were used in this research as models of schizophrenia and
cell supplementation studies were undertaken to assess potential antioxidant and
fatty acid protection against ROS-induced DNA damage. Supplementation of
neuroblastoma cells for 30min and 6 hours with EGCG and hydroxytyrosol of a
concentration within human physiological range (ie. 10M) resulted in a highly
significant decrease in the level of DNA damage in cells treated additionally with
H2O2. Furthermore, this same effect was observed in U937 cells. However, in only
those lymphoblastoid cells treated with hydroxytyrosol was a significant protection
of cellular DNA against an oxidative challenge observed.
Green tea is a widely consumed drink and has gained a reputation as a health-
promoting dietary component due to the antioxidant activity of EGCG, its main
phenolic constituent. Evidence is increasing however, that tea constituents can be
cell damaging and pro-oxidant. These effects are suggested to be due to spontaneous
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H2O2 generation by polyphenols in solution (Elbling et al 2005; Furukawa et al
2003). This pro-oxidant (or poor antioxidant) effect was perhaps more pronounced in
the lymphoblastoid EGCG-treated cells used in this study, resulting in a higher
overall ROS generation and greater level of DNA damage than seen in the U937 and
IMR-32 EGCG-treated cells (Table 2.2). In contrast, the production of H2O2 in tea
catechin-treated lymphoblastoid cells was compared by Sugisawa et al (2004) who
suggested that the structure of EGCG is less likely to result in H2O2-induced
chromosomal damage than EGC. EGC has a trihydroxyl structure with a B-ring
similar to EGCG. Another catechin, ECG which has a gallate group linked to flavan-
3-ol similar to EGCG, however, did not produce H2O2 (Sugisawa et al 2004).
Nevertheless, tea catechins and polyphenols are effective scavengers of reactive
oxygen species in vitro and may also function indirectly as antioxidants through their
effects on transcription factors and enzyme activities (Higdon and Frei 2003).
Until recently, there was little understanding of the metabolism of flavonoids and
their mode of entry into the systemic circulation after oral absorption. Although
numerous studies have reported flavonoid-mediated neuroprotection, there is little
information about the interaction of flavonoids or their circulating metabolites with
the brain endothelial cells from the blood brain barrier (Youdim et al 2004). EGCG
has been reported to enter the brain after oral administration (Suganuma et al 1998)
and has more recently been investigated as a prophylactic for Alzheimer’s disease
(Rezai-Zadeh et al 2005).
2.4.3.2 DNA Damage and Fatty Acid Protection
Epidemiological studies have shown an apparent beneficial effect of fish oil
containing high levels of -3 PUFA on mortality from heart disease and cancer
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(Kikugawa et al 2003) and there is additional evidence to suggest that -3 fatty acids
may also be important to mental health (Peet and Stokes, 2005). Conversely, a more
recent systematic review (Hooper et al 2006) found no evidence of a clear benefit of
-3 fats on health (in particular mortality, cardiovascular events, cancer or strokes).
However, the benefits of using -3 fatty acids to protect DNA against oxidative
damage, particularly in mental illness, have not been widely investigated. In this
study human peripheral and neuroblastoma cells were incubated with increasing
concentrations of EPA or DHA from 30min to 24h. Results revealed that there was
no difference in the level of DNA damage in the U937 and IMR-32 cell lines treated
with either EPA or DHA when compared to controls (i.e. non EPA or DHA treated
cells) (results not shown). Conversely, examination of lymphoblastoid cells treated
with the highest concentration of DHA after 24 hours (Figure 2.6) revealed a
significant increase in DNA damage when compared to 30 minute and 24 hour
controls.
Fatty acid treated peripheral and neuroblastoma cells were also subjected to a
peroxide challenge. Results show that in fatty acid + H2O2-treated cells the level of
DNA damage was significantly reduced in the U937 and IMR-32 cells at all time
points compared to H2O2 control cells.
Although the use of fish oil has been suggested to have many beneficial effects, lipid
peroxidation-mediated DNA damage is an undesirable consequence resulting from
intake of high concentration of fish oil. In vitro studies have shown that peroxidized
PUFA induce DNA chain breaking (Adam et al 1998) and 8-hydroxyguanosine
formation (Kaneko and Tahara 2000). Contrasting studies have shown that -3
PUFA supplementation on oxidative stress-induced DNA damage in a variety of cell
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types acts instead as a protective agent against oxidative stress rather than as a source
of mutagenic metabolites (Beeharry et al 2003, Kikugawa et al 2003). The results of
our study have also shown that EPA and DHA protect peripheral and neuroblastoma
cells against oxidative stress induced DNA damage. It is worth noting that in their
study, Kikugawa et al (2003) used fish oil supplemented with vitamin E. Since the
purported health effects of fish oil are questioned by Hooper et al (2006), the
reduction in oxidative stress-induced DNA damage reported by Kikugawa et al
(2003) may well be attributable to the antioxidant rather than the fish oil.
Nevertheless, these authors propose that although lipid peroxidation products formed
from the use of high concentrations of -3 can damage DNA, the damage caused by
these products may be significantly lower than those caused as a result of direct
oxidative stress resulting from ROS.
Within our study, pure oils without added vitamin E were used as in the study
reported by Beeharry et al (2003). In their study Beeharry et al (2003) suggest that
the DNA-protective effects seen following incubation of human cells with the -6
PUFA linoleic acid may be as a result of the fatty acid acting as a substrate for lipid
peroxidation. In addition, linoleic acid may also inhibit the induced oxidative stress
that causes lipid peroxidation by blocking an early stage in the induction of damage.
Interestingly, a preliminary study carried out by the same group has also shown
DHA to be cytoprotective (Beeharry et al 2003).
In conclusion, the efficacy of a series of antioxidants and polyunsaturated fatty acids
in affording protection against cellular DNA damage against an oxidative challenge
has been investigated. The findings have shown that the antioxidants and PUFAs
used within physiological concentrations and after a short incubation period are able
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to significantly protect human peripheral and neuroblastoma cells against oxidative
stress induced DNA damage. The validity of using peripheral cells as a potential
surrogate marker of DNA damage in a neuronal cell type was also undertaken.
Results have revealed that pre-treatment of peripheral cells with antioxidant or -3
fatty acids followed by an oxidative challenge significantly reduce the levels of DNA
damage. Results have confirmed the same effects were observed with the neuronal
cell type when provided with the same supplements under the same conditions.
Further work should perhaps include a comparison investigation of a number of
other neuronal cell types, using additional methods to detect oxidative-stress induced
DNA damage. Nevertheless, the work carried out in this research appears to be the
first to undertake such a comparator study and findings indicate that the use of
peripheral cells can potentially be used as surrogate marker for neuronal cells when
examining oxidative stress induced DNA damage.
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CHAPTER 3
Examination of biomarkers of protein oxidation in fatty
acid treated human U937 cells and detection of ROS in
antioxidant treated U937 cells
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3.1 Introduction
3.1.1 Oxidative Stress and Protein Damage
Although damage caused by oxidative stress to nucleic acids can be repaired by
proficient excision/insertion mechanisms, repairing damaged proteins appears to be
limited to the reduction of oxidised derivatives of the sulphur-containing amino acid
residues (Stadtman and Levine 2000). Damaged proteins are degraded to amino acid
elements by various endogenous proteases, while the collection of intracellular
oxidised proteins involves pro-oxidant and antioxidant activities and the
concentrations and activities of the proteases that degrade the oxidised forms of the
proteins.
Proteins can be further damaged by pro-oxidant processes that influence
environmental and dietary conditions. It is assumed that under normal conditions the
metal-catalyzed oxidation systems are the basis of oxidative damage, arising through
the interaction of ROS end-products, hydrogen peroxide and the alkylperoxides.
When transition metals Fe(II) or Cu(I) are present, these relatively unreactive
peroxides are transformed to the highly reactive hydroxyl radical (reaction 1) or the
alkoxyl radical (reaction 2) which can react with most other organic substances.
H2O2 + Fe(II)/Cu(I) → HO• + OH- + Fe(III)/Cu(I) (1)
ROOH + Fe(II)/Cu(I) → RO• + OH- + Fe(III)/Cu(I) (2)
Any of the protein amino acids can be targeted for oxidation by OH• for example, by
high concentrations of H2O2 and Fe(II) (Neuzil et al 1993). At physiological
concentrations of H2O2, however, protein damage is probably limited to the
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modification of amino acid residues at metal binding sites on the protein, which
effectively concentrate the ions (Stadtman and Levine 2000).
3.1.2 Protein Oxidation as a Biomarker of Oxidative Stress
The earliest work concerning oxidation of a biologically important protein studied
the effects of selected radicals generated by radiolysis of lysozyme (reviewed by
Griffiths et al 2002). The revelation that the thiocyanate radical (a selective modifier
of tryptophan) and the hydroxyl radical could inactivate the enzyme, suggested that
tryptophan residues are essential for biological activity. Later, protein oxidation in
respect of altered function was confirmed by oxidative modifications to histidine and
lysine in low density lipoproteins leading to altered receptor recognition
(Parthasarathy et al 1992). In addition, it was noted that the process of protein
oxidation often introduced new functional groups such as hydroxyls or carbonyls
which also play a role in altered function and turnover (Griffiths et al 2002).
ROS are capable of directly reacting with the protein or with molecules such as
sugars and lipids, creating products that then react with the protein (Levine 2002).
Either the protein peptide bond or side chain can be attacked. Following ROS
damage, the protein may be cleaved producing lower molecular weight products or it
may be cross-linked to give higher molecular weight products (Levine 2002).
Oxidative modifications can be grouped into those which are quite specific, for
example, those whose residue is oxidized and the product generated, and those which
can alter multiple residues and may give rise to several products (Levine 2002). Of
the covalent changes resulting from direct and indirect oxidative modification of
proteins, one of the most common is the introduction of carbonyl groups into the side
chains. Carbonyl groups are formed during the oxidation of the amino acid residues
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arginine, lysine and proline (Berlett and Stadtman 1997). Protein carbonyl
derivatives can also be formed via oxidative cleavage of proteins by either the -
amidation pathway or by oxidation of glutamyl side chains. This results in formation
of a peptide in which the N-terminal amino acid is blocked by an -ketoacyl
derivative (Berlett and Stadtman 1997). Carbonyl groups can also arise from a
further reaction with the primary oxidation products such as 4-hydroxy-2-nonenal
(Levine 2002). As a consequence, oxidative changes can be measured by examining
the carbonyl content of a specific protein or a tissue (Ciolino and Levine, 1997).
Carbonyls can be generated in response to a wide variety of oxidising agents such as
alkoxy and peroxy radicals illustrated in Figure 3.1.
While numerous studies of the formation of protein carbonyls have been undertaken,
they have not identified those carbonyls produced through direct protein oxidation
and those formed by the addition of previously oxidised molecules. For that reason
protein carbonyls must be considered as a broad marker of oxidation (Dalle-Donne et
al 2003). Compared with methionine sulphoxide and cysteinyl derivatives, the
production of carbonyls is relatively difficult and as a result might be indicative of a
more severe oxidative stress. In fact, elevated levels of protein carbonyls are
generally a sign not only of oxidative stress but also of disease-derived protein
dysfunction (Dalle-Donne et al 2003).
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Direct oxidation of Pro, Arg, Lys and
Thr residues.
Oxidative cleavage of the protein
backbone (-amidation pathway or
oxidation of Glu side chains.
Michael addition reactions of -
unsaturated aldehydes such as 4-
hydroxy-2-nonenal, malondialdehyde
and 2-propenal derived from lipid
peroxidation with either the amino
group of Lys, His, Cys.
PROTEIN
CARBONYL
FORMATION
Addition of reactive carbonyl
derivatives (ketoamines,
ketoaldehydes and deoxyosomes)
produced by the reaction of reducing
sugars or their oxidation products to
the amino group of Lys residues by
glycation and glycoxidation.
Figure 3.1. The production of protein carbonyls (aldehydes and ketones) (Adapted from Dalle-Donne
et al 2003)
3.1.3 Detecting Biomarkers of Protein Oxidative Damage
Using protein carbonyls as a biomarker of oxidative stress in preference to lipid
peroxidation products has the advantage that oxidised proteins are usually more
stable (Dalle-Donne et al 2003). A study by Pantke et al (1999) demonstrated that
protein carbonyls form early during coronary heart surgery (ie during the reperfusion
stage) and serum protein carbonyl content was elevated for at least four hours
indicating a much slower serum removal of oxidized protein when compared to
MDA and glutathione disulphide.
Chapter 3 Examination of Protein Oxidation in Human Cells 88
Techniques for measurement of physiological protein oxidation vary from
immunodetection by ELISA or Western blot to analytical HPLC. The most common
and reliable method of detecting protein carbonyl groups is based on the reaction of
carbonyls with 2,4-dinitrophenylhydrazine (DNPH) to form 2,4-
dinitrophenylhydrazone (DNP) (Dalle-Donne et al 2003). The method was
introduced by Levine et al (1990) and has since become one of the most widely used
measures of protein oxidation in various human diseases (Dalle-Donne et al 2003).
3.1.3.1 Enzyme-linked Immunosorbent Assay
The ELISA method of measuring protein carbonyls as an index of oxidative injury
was developed by Buss et al (1997) and the method was further amended by
Winterbourn and Buss (1999). Protein samples are reacted with DNP, adsorbed to
wells of an ELISA plate before probing with an antibody raised against protein-
conjugated dinitrophenylhydrazine. The adsorbed protein is reacted with a
biotinylated anti-DNP antibody followed by a streptavidin-biotinylated horseradish
peroxidase. The ELISA is easier to use, less labour-intensive and handles more
samples per day than the colorimetric assay (Dalle-Donne, 2003). In addition, the
ELISA only requires microgram amounts (approximately 60g) of protein, similar to
that required for the HPLC method (Levine et al 1994).
3.1.3.2 Spectrophotometric DNPH Assay
The method devised by Levine et al (1994) involves the detection of protein
carbonyl groups following their reaction with DNPH and spectrophotometric
analysis of the acid hyrazones at 370nm. It can be used to quantify carbonyl content
in a mixture of proteins in plasma, tissue homogenates, and cellular extracts or in
isolated proteins. However, the DNPH assay has been shown to be unreliable in
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samples containing high amounts of chromophore (e.g. haemoglobin, myoglobin,
retinoids). Fagan et al (1999) improved upon the technique enabling the
determination of carbonyl content to be made even in highly coloured tissue extracts
and removed residual DNPH which was also found to interfere with the assay. The
spectrophotometric detection of DNP-carbonyl derivatives after separation of the
proteins by gel-filtration HPLC (reviewed by Dalle-Donne 2003) could provide
information on the extent of oxidative damage to a particular protein in a complex
mixture such as tissue homogenates or cellular extracts. Gel-filtration by HPLC has
been shown to be a convenient and efficient technique in which DNP-carbonyl
derivatised proteins are separated by molecular weight, allowing a more specific
analysis of carbonyl content.
Other methods of detecting carbonyls include Western blot immunoassay (Shacter et
al 1994) and an immunoblot technique developed by Robinson et al (1999) which
involves a combination of DNPH derivatisation, the preparation of blanks by
treatment with sodium borohydride and immunological detection. NaBH4 reduces
carbonyl to alcohols, eliminating immunostaining due to carbonyl groups and the
difference between the staining intensities of a NaBH4-treated and untreated sample
constitutes a specific measure of the carbonyl content of the sample.
3.1.3.3 Detection of ROS
The specificity of the fluorescent probes used in flow cytometry is the most
convenient method for measuring ROS generation and the importance of these
probes was realised over 40 years ago when 2’,7’-dichlorofluorescein diacetate
(DCFH) was used to measure H2O2 in aqueous solution (reviewed by Walrand et al
2003). DCFH is a small non-polar, non-fluorescent molecule that diffuses into cells
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where it is enzymatically deacetylated by intracellular esterases to the polar non-
fluorescent compound, 2’,7’-dichlorofluorescein (DCF) in the presence of the
generated ROS (Szejda et al 1984). DCF then emits a fluorescent signal that is
measured using a flow cytometer.
Flow cytometry is a method that enables the counting, examining and sorting of cells
suspended in a stream of fluid. Simultaneous multiparametric analysis (ie the
measurement of several characteristics of each cell or particle) of single cells flowing
through an optical/electronic detection apparatus can also be carried out (BD
Biosciences 2000). A laser light of a single frequency is directed onto a
hydrodynamically focused stream of fluid and a variety of detectors are aimed at the
point where the stream passes through the light beam. One in line with the light
beam (Forward Scatter or FSC) and several perpendicular to it (Side Scatter, SSC).
FSC is proportional to cell-surface area or size while SSC is proportional to cell
granularity or internal complexity (ie shape of the nucleus, membrane roughness).
Correlated measurements of FSC and SSC can allow for differentiation of cell types
in a heterogeneous cell population (BD Biosciences 2000). Once a cell or particle
passes through the laser light, emitted SSC and fluorescence signals are diverted to
the photomultiplier tubes (PMTs) and a photodiode collects the FSC signals. PMTs
detect fluorescence signals although they are often weak. Bandpass filters enable the
optimisation of a particular fluorescent dye which allows only a narrow range of
wavelengths to reach the detector. This spectral band of light is close to the emission
peak of the fluorescent dye.
Light signals are created as the cells pass through the laser beam in a fluid stream.
The light signals are then converted to electronic signals (voltages) by
Chapter 3 Examination of Protein Oxidation in Human Cells 91
photodetectors and are then allocated a channel number on a data plot. A voltage
pulse is created when a particle enters the laser beam and starts to scatter light or
fluoresce. When the light signals or photons come into contact with one side of the
PMT they are converted into a proportional number of electrons that are multiplied
creating a larger electrical current; this in turn travels to the amplifier and is
converted to a voltage pulse. The voltage pulse is given a digital value representing
0-1,000mV channels. Cell populations can be displayed in several different formats.
A single parameter such as FSC (FL1) can be displayed as a single parameter
histogram where the horizontal axis represents the parameter’s signal value in
channel numbers and the vertical axis represents the number of events per channel
number (Figure 3.2).
Figure 3.2. Histogram representation of flow cytometric data (BD Biosciences 2000).
Each event is placed in the channel that corresponds to its signal value. Signals with
identical intensities collect in the same channel. Brighter signals are displayed in
channels to the right of the less bright signals. The histogram enables a single
parameter to be viewed against the number of events. A subclass control is used to
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determine where the markers will be placed and these are used to specify a range of
events for a single parameter (Figure 3.3). In the diagram, the first histogram M1
marker is placed around the negative peak of the subclass control while the M2
marker is placed to the right of M1 to show positive events. Statistical percentages of
the negative and positive intensity peaks are used to quantify mean fluorescence
intensities.
Figure 3.3. Histograms of subclass control (NORM001) and CD3 FITC (NORM002) with histogram
markers M1 and M2 (BD Biosciences 2000).
3.1.4 Protein Oxidative Damage and Schizophrenia
There are numerous human diseases associated with elevated levels of carbonylated
proteins. Neurological illnesses associated with this condition include Alzheimer’s
disease (AD), dementia with Lewy bodies and Parkinson’s disease. Oxidative stress
plays a major role in the development of AD typified by protein oxidation, lipid
peroxidation and ROS formation (Dalle-Donne 2003). Moreover, chemical markers
that are altered in AD have also been suggested to be abnormal in schizophrenia:
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choline acetyltransferase, catecholamines and indolamines (reviewed by Powchik et
al 1998).While schizophrenia shares many pathological similarities with AD and
other psychiatric illnesses, increased levels of PCOs as a result of protein oxidative
damage in schizophrenia has not been studied extensively before. Protein oxidation
in a treatment-related disorder, called tardive dyskinesia, has been investigated. Tsai
et al (1998) have hypothesised that neuroleptics enhance striatal glutamatergic
neurotransmission by blocking presynaptic dopamine receptors, which causes
neuronal damage as a consequence of oxidative stress. Patients suffering from
tardive dyskinesia have been shown to have significantly higher concentrations of N-
acetylaspartate, N-acetyl-aspartylglutamate and aspartate in their cerebral spinal
fluid and higher levels of protein-oxidized products associated with tardive
dyskinesia (Tsai et al 1998).
The aim of this study was to examine the effect of EPA or DHA supplementation
with a pro-oxidant challenge on the U937 cell line and evaluate the use of protein
carbonyl production as a marker of protein oxidation in a schizophrenic model.
Cellular ROS status as assessed by flow cytometry was investigated and the efficacy
of antioxidant treatment prior to a pro-oxidant challenge in U937 cells was also
determined.
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3.2 Materials and Methods
3.2.1 Examination of Biomarkers of Protein Oxidation in Fatty Acid
Treated Human Peripheral (U937) Cells
3.2.1.1 Materials
Penicillin/streptomycin antibiotic, trypsin/EDTA, glucose and bovine serum albumin
(BSA) were supplied by Sigma (Poole, UK). Heat-inactivated FCS was obtained
from Invitrogen (Paisley, UK). RPMI 1640 media was supplied by Gibco (UK).
EGCG was supplied by Sigma (Poole, UK). Hydroxytyrosol was obtained from
Alexis Corp (UK) Ltd (Nottingham, UK). Eicosapentaenoic acid (EPA, >95%) and
docosahexaenoic acid (DHA, >90%) were supplied by Pronova (Norway). Tris,
EDTA and 25cm2 culture flasks were obtained from Fisher Scientific,
(Loughborough, UK). DMSO, NaCl, EGTA, NaF, Na3VO4, Na4O7P2, protease
inhibitor cocktail, phenylmethanesulfonyl fluoride (PMSF), Triton-X-100, glycerol,
sodium dodecyl sulphate (SDS) and trichloracetic acid (TCA) were supplied by
Sigma (Poole, UK). Protein carbonyl ELISA kit components were supplied by
Zenith Technology (Dunedin, New Zealand)
3.2.1.2 Culture of U937 Cells
All experimentation work was carried out solely by me, and cells lines were cultured
and maintained by me. Human U937 cells were cultured, maintained in 25cm2 flasks
and harvested as described previously in Chapter 2.
3.2.1.3 Fatty Acid Treatment of U937 Cells
U937 cells were incubated in 10ml media containing either 50M of ethanol or
50M fatty acids prepared in ethanol and the cells were incubated for 24h under
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conditions described previously in Chapter 2. Cell viability was determined as 90-
95% as ascertained by the Trypan blue dye exclusion method of viability.
3.2.1.4 Hydrogen Peroxide Treatment of U937 Cells
Following 24h incubation, cells were washed three times with PBS and collected by
centrifugation at 2000xg for 5min. Cells were resuspended in 1ml media containing
100M H2O2 and incubated for 4h at 37oC.
3.2.1.5 Protein Extraction
Cells were washed three times with ice cold PBS and collected by centrifugation,
2000xg for 5min at 4oC. Supernatant was discarded and 0.2ml extraction buffer
(comprising 1ml protein buffer (10mM Tris pH 7.4, 100mM NaCl, 1mM EDTA,
1mM EGTA, 1mM NaF, 20mM Na4P2O7, 2mM Na3VO4, 1% Triton-X-100, 10%
Glycerol, 0.1% SDS) 10l protein inhibitor and 3.3l PMSF) was added to the pellet
and vortexed for 10min. The samples were then centrifuged at 10,000xg for 15min at
4oC. The supernatant was aliquotted into a new microcentrifuge tube and stored at -
80oC until ready for assay.
3.2.1.6 Protein Quantitation
The protein content of cell supernatants was determined by the Bradford method
(Bradford 1976) using bovine serum albumin as a reference standard.
3.2.1.7 Low Protein Procedure
Cell protein extracts were concentrated to ensure a final concentration of 35-80g/L
and the protocol was followed as per manufacturer’s instructions (Zentech PC Test,
Protein Carbonyl Enzyme Immunoassay Kit from Zenith Technology, Dunedin, New
Zealand).
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3.2.1.8 ELISA Experimental Procedure
Carbonyl groups were measured using the Zentech PC Test (Protein Carbonyl
Enzyme Immunoassay Kit) from Zenith Technology (Dunedin, New Zealand). This
kit follows the method outlined by Buss et al (1997) (as amended by Winterbourn
and Buss 1999), which uses derivatization of protein carbonyls in samples and
oxidized protein standards with dinitrophenylhydrazine, followed by ELISA with an
anti-DNP antibody. Absorbance was read at 450nm on the BIO-TEK FL600
fluorescence plate reader (BIO-TEK® Instruments Inc, Vermont, USA).
3.2.1.9 Statistical Analysis
The Kolmogorov-Smirnof test was used to test the normality of the data and
Student’s t-test and one-way ANOVA was undertaken using SPSS 11.5 for
Windows. A level of p< 0.05 was used to determine significance.
3.2.2 Detection of ROS in Antioxidant Treated Human U937 Cells
3.2.2.1 Materials
-tocopherol was supplied by Sigma (Poole, UK) and 5-(and-6)-chloromethyl-2’,7’-
dichlorodihydro-fluorescein diacetate, acetyl ester (CM-H2DCFDA) was supplied by
Invitrogen, (Paisley, UK).
3.2.2.2 Culture of U937 Cells
Human U937 cells were cultured, maintained and harvested as described previously
in Chapter 2.
3.2.2.3 Antioxidant Treatment of U937 Cells
U937 cells were incubated with 10M antioxidant (EGCG, hydroxytyrosol and -
tocopherol) for 24h under the same conditions as described previously in Chapter 2.
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Cell viability was determined as 90-95% as ascertained by the Trypan blue dye
exclusion method of viability.
3.2.2.4 CM-H2DCFDA Treatment of U937 Cells
Following 24h incubation, cells were collected by centrifugation at 2000xg for 5min
and washed three times with PBS. Intracellular ROS, via the generation of H2O2 was
estimated by resuspending cells in media containing 1mM of fluorescent probe (CM-
H2DCFDA) and incubated for 30min at 37oC. CM-H2DCFDA readily diffuses
through the cell membrane and is hydrolyzed by intracellular esterases to form non-
fluorescent 5-(and-6)-chloromethyl-2’,7’-dichlorodihydrofluorescin (CM-H2DCF)
and is efficiently retained within cells (Liu et al 2001) which in turn is rapidly
oxidised to form highly fluorescent 5-(and-6)-chloromethyl-2’,7’-dichlorofluorescine
(CM-DCF) in the presence of ROS. The fluorescence of the end product is believed
to increase with the amount of intracelluar ROS (Pérez-Pastén et al 2006).
3.2.2.5 ROS Analysis by Flow Cytometry
Cells were washed twice with PBS and collected by centrifugation (ie. 1000 –
2000xg for 10min at 4oC). The cell pellet was resuspended in 0.750ml of PBS and
then transferred to sampling tubes and vortexed thoroughly. Samples were analysed
on a EPICS XL EXPO32 flow cytometer (Beckman Coulter UK Ltd, Bucks, UK)
equipped with an argon laser (488nm emission), using EXPO32 analysis software.
Cells were recognised on the basis of forward-angle light scatter and side-angle light
scatter. The fluorescence of cells was recorded under 488nm excitation. The increase
in intracellular oxidation was measured as an increase in FL1 or fluorescence
through a 525nm band-pass filter recorded on a log scale for 10,000 events. ROS
was quantified by mean CM-DCF intensity.
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3.2.2.6 Statistical Analysis
The Kolmogorov-Smirnof test was used to test the normality of the data and one-
way ANOVA and Student’s t-test was carried out as appropriate using SPSS 11.5 for
Windows. For statistical analysis, a level of 0.05 was used to determine significance.
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3.3 Results
3.3.1 Protein Carbonyl Analysis
The ELISA method was used to detect levels of protein carbonyls from cellular
protein extracts, in particular from U937 cells incubated for 24h with or without
polyunsaturated fatty acids followed by 4h incubation with H2O2. No difference in
protein carbonyl content was found in U937 cells treated with H2O2 when compared
to control cells (Figure 3.4a). Furthermore, there was no difference in the level of
protein carbonyl content in the cells pre-treated with a PUFA but challenged with
H2O2, when compared to H2O2 only treated cells.
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Figure 3.4a. Examination of protein carbonyl content in fatty acid and H2O2-treated human U937
cells. Cells were incubated with 50M ETOH, EPA or DHA for 24h followed by 4h incubation at
37oC with 100M H2O2. Data shows change in protein carbonyl production from triplicate samples as
determined by two ELISA experiments ± sd.
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The change in protein carbonyl levels was examined between experimental days.
The data in Figure 3.4b reveals after completion of experiment 1, protein carbonyl
levels have not increased significantly in any of the treatment groups compared to
the untreated group. However, comparison of the data from experiment 2 shows a
significant decrease in protein carbonyl levels following incubation with DHA,
compared to the untreated sample. In addition, there is a significant increase in
protein carbonyl levels in the cell lysate samples pre-treated with DHA+ H2O2 when
compared to the DHA-only treated samples. Furthermore, there is significant
increase in protein carbonyl levels in all samples between experiments, except in
those samples pre-treated with DHA where protein carbonyl levels have significantly
decreased in experiment 2 compared to experiment 1.
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Figure 3.4b. Examination of protein carbonyl content in fatty acid and H2O2-treated human U937 cells
in individual experiments. Cells on both days were incubated with 50M ETOH, EPA or DHA for
24h followed by 4h incubation at 37oC with 100M H2O2. Data shows change in protein carbonyl
production from triplicate samples as determined by ELISA ± sd. Significance is denoted by * where
p <0.05.
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The results of these experiments reveal that although the H2O2 challenge was high
(100M) the cells appear to be resistant to the pro-oxidant challenge since there is no
statistically significant increase in protein carbonyl production. The lack of an effect
seen following the H2O2 treatment, however, might be as a result of large intra/inter
assay variation as shown by the error bars, rather than a high level of endogenous
cytoprotection. Finally, treatment of U937 cells with either EPA or DHA alone
induced no significant increase in protein carbonyl levels and so it would appear that
there is no evidence of a pro-oxidant stress from either of the fatty acid treatments.
3.3.2 ROS Analysis
U937 cells pre-treated with hydroxytyrosol for 24h revealed a significant decrease (p
<0.05) in intracellular ROS when compared to untreated cells, although this
reduction in ROS was not observed following EGCG treatment (Figure 3.5a).
Furthermore, pre-treatment of cells for 24h with -tocopherol revealed an increase in
intracellular ROS levels compared to those treated with DMSO only, suggesting a
pro-oxidant effect of this compound under these experimental conditions (Figure
3.5a). No difference in the level of intracellular ROS was noted following a 5min
oxidant challenge with H2O2 when compared to untreated cells. The lack of
challenge effect could be indicative of a high level of endogenous antioxidant or
enzyme scavengers of radicals. The antioxidant effect of hydroxytyrosol was again
observed when cells were pre-treated with this compound followed by an oxidant
challenge. Results reveal a significant decrease in levels of ROS in these samples
(Figure 3.5a)
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Figure 3.5a. Examination of ROS in antioxidant and H2O2-treated human U937 cells. Cells were
incubated with 10M OHTYR, EGCG or -tocopherol for 24h followed by 30min incubation with
1mM CM-H2DCFDA and 5min incubation with 100M H2O2 at 37oC. Data shows mean % change in
ROS production from triplicate samples as determined by 3 flow cytometry experiments ± %RSD.
Significance is denoted by a and b where p <0.05.
Between days variation of this assay was investigated. Although not indicated on the
graph, there is significant difference in ROS levels between days. For example, there
is significant difference between the levels of ROS on experimental day 1 and day 2
in untreated and DMSO pre-treated samples. However, there is no difference in the
levels of cellular ROS in U937 cells pre-treated with or without antioxidant and
H2O2 (Figure 3.5b).
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Figure 3.5b. Examination of ROS content in antioxidant and H2O2-treated human U937 cells in 3
individual experiments. Data shows mean ROS levels ± sd of triplicate samples.
The results of the above ROS experiments reveal significant between day variations
in those cells that were not subjected to H2O2 treatment, particularly on experimental
day 2 where ROS levels appear to be lower than on other experimental days. Despite
this, hydroxytyrosol pre-treatment does appear to be effective in reducing ROS and
H2O2-induced ROS, although the level of reduction did not reach statistical
significance. Although a reduction in ROS is noted in cells pre-treated with EGCG,
it is not significant and furthermore, although it does not appear to be an effective
antioxidant treatment following cell treatment with H2O2, neither does this
compound appear to act as a pro-oxidant.
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3.4 Discussion
3.4.1 Protein Carbonyls
The evaluation of protein carbonyls as a potential marker of protein oxidation in the
putative cell model for schizophrenia, U937 was undertaken. Treatment with H2O2
alone and following pre-treatment with EPA or DHA had no effect on the levels of
protein carbonyls detected in the cell line by ELISA. Nevertheless, although the
results were not statistically significant, DHA supplementation does appear to reduce
endogenous and H2O2-induced protein carbonylation. Further in vitro and in vivo
work would be merited since evaluation of the effect of fatty acid supplementation
on the levels of protein oxidation in schizophrenia is limited. Indeed, the potential
use of protein carbonyls as a biomarker of schizophrenia has not been widely
examined until now.
The abnormal movements seen in tardive dyskinesia occur as a result of major late-
onset chronic side effect of antipsychotic treatment. Oxidative stress and free
radicals are thought to be associated with dopaminergic malfunctions (Sadan et al
2005) and oxidative stress-induced neurotoxicity in the striatal system is implicated
in tardive dyskinesia (Shamir et al 2001). Several studies have reported that people
with schizophrenia have abnormal levels of essential fatty acids in their blood cells
and similar abnormalities have been recorded in association with the presence of
tardive dyskinesia (reviewed by Vaddadi et al 1996). In their study, Vaddadi et al
(1996) hypothesised that patients with schizophrenia would have lower levels of -3
and -6 EFAs than controls and that this abnormality would be more pronounced in
those schizophrenic patients also suffering with tardive dyskinesia.
Chapter 3 Examination of Protein Oxidation in Human Cells 105
Studies of neurological diseases such as Parkinson’s (Yang and Tiffany-Castiglioni
2005), mild cognitive impairment (Keller et al 2005) and multiple sclerosis
(Bizzozero et al 2005) have reported an increase in levels of oxidative damage,
including increased protein carbonyl levels. However, no evidence for increased
oxidative stress to lipids, proteins or DNA in Huntington’s disease was reported by
Alam et al (2000), suggesting that oxidative stress is not a major component of this
illness, or at least not to the extent that occurs in other neurodegenerative disorders.
It is suggested that in pure chemical systems, the molecules most susceptible to free
radical attack are PUFAs and in general the level of oxidation increases as the
number of double bonds increases (Liu et al 1997). In vivo, the same relative
oxidative susceptibility is thought to occur. That is, of the various biologically
relevant PUFAs, long chain -3 fatty acids such as EPA and DHA oxidise more
readily than do less saturated fatty acids such as linoleic acid (Wander and Du 2000).
It is also well established that end-products of lipid peroxidation, such as MDA and
4-hydroxy-2-nonenal cause protein damage by means of reactions with lysine amino
groups, cysteine sulphydryl groups and histidine imidazole groups (reviewed by
Refsgaard et al 2000).
Contradictory results concerning the effect of the supplementation of EPA and DHA
on oxidation have been reported both following in vivo and in vitro studies (reviewed
by Wander and Du 2000) and this may be as a result of the different assays used to
measure the extent of oxidation. Furthermore, although numerous assays are
generally considered to measure lipid peroxides, various other products such as
MDA are often measured and used as a surrogate for lipid peroxides (Wander and
Du 2000). TBARs and MDA however, are reported to be inaccurate measures of
lipid peroxidation (Esterbauer 1996; Janero 1990). The TBARs are measured via a
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spectrophotometric assay that quantifies a chromogen produced by the reaction of
thiobarbituric acid with MDA. Although easy to use, the assay is not specific in that
many substances found in human biological fluids can react with TBA (Cherubini et
al 2005). MDA can occur from degradation of endoperoxides and not from lipid
peroxidation products and so this assay can give an overestimation of free radical
damage. Even if the specificity of the measurement is improved by HPLC to separate
the MDA-TBA adduct from interfering chromogens, there is still the possibility that
part of the MDA present in the sample does not derive from oxidative damage of
fatty acids (Cherubini et al 2005).
One assay that might have particular significance in assessing the extent of oxidative
damage is the measure of protein oxidation and in particular, the protein carbonyl
assay is useful as it evaluates ‘general’ protein damage (Wander and Du 2000).
Yasuda et al (1998) reported that although mice fed on a diet rich in DHA-fish oil
had significantly higher TBARs levels in the liver compared to those fed beef tallow,
linoleic acid-rich safflower or -linolenic acid-rich perilla oil, the protein carbonyl
content in the liver was the same among the 4 dietary groups. A study by Wander
and Du (2000) where oxidative stress produced due to the consumption of -3 fatty
acids and vitamin E supplements in humans was measured, revealed although there
was a modest increase in TBARs following consumption of fish oil, it was not
modified by increased consumption of the vitamin E supplement. Furthermore, the
study reported no increase in protein carbonyls after the consumption of fish oil. The
authors concluded that if fish-oil consumption does not cause an increase in
oxidation as measured by protein carbonyls, then an increased intake of vitamin E is
not necessary. Consequently, EPA- and DHA-rich diets may not lead to increased
oxidation in vivo.
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It is also important to note the possible induction of glutathione peroxidase enzymes
by fatty acids and the protective role that these antioxidant enzyme may play in cells
and tissues against oxidative and inflammatory cytokine elicited damage (Crosby et
al 1996). In vitro enrichment of peripheral blood monocytes with low concentrations
of EPA and DHA have also been shown to induce an increase in glutathione
peroxidase (Joulain et al 1994). Indeed schizophrenia may not just be linked to
oxidative events and damage but rather to inflammatory events such as cytokine and
eicosanoid production in the brain elicited by bacterial endotoxins and infections.
For example, a recent study has reported that during critical stages of pregnancy
maternal infection may lead to sensorimotor gating deficits in schizophrenia (Fortier
et al 2007).
3.4.2 Reactive Oxygen Species
CM-H2DCFDA-sensitive reactive oxygen species of the human U937 cell line along
with the anti- or pro-oxidant effects of EGCG, hydroxytyrosol, -tocopherol and
H2O2 were evaluated by flow cytometry. Results from this study showed that the
pre-treatment with the antioxidant hydroxytyrosol significantly reduced the level of
endogenous ROS in U937 cells, while -tocopherol appears to increase endogenous
ROS levels. In addition, the beneficial effect of hydroxytyrosol was apparent
following treatment of cells with H2O2 since it was observed that only
hydroxytyrosol was effective in significantly reducing H2O2-induced cellular ROS
(Figure 3.5).
Previous studies have suggested that ROS production may play a role in the
pathogenesis of schizophrenia, and more recently, there is an emerging body of data
indicating that schizophrenia may be associated with mitochondrial dysfunction
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(Frey et al 2006). Animal studies have established that a global oxidative stress
affects predominantly the brain (Mahadik and Mukherjee 1996). Brain vulnerability
occurs because the brain is under higher oxidative stress than other organs since it
produces very high levels of ROS due to its very high aerobic metabolism and blood
perfusion (reviewed by Mahadik et al 2001). In addition, it is enriched in lipids that
are preferentially susceptible to oxidative damage and the damaged neuronal DNA in
the adult brain can not be effectively repaired since there is no DNA replication. Yet
environmental ROS also attack the brain and inflammation is a major threat to brain
function. Depending on the degree of oxidative stress and the developmental time,
oxidative neuronal injury in the brain may cause abnormal neurodevelopment,
neurodegeneration, or neuronal membrane impairment.
Gross et al (2003) report decreased production of reactive oxygen species in blood
monocytes from schizophrenic patients following treatment with the neuroleptic
clozapine. Neuroleptics have been shown to have both pro-oxidant and antioxidant
properties (Jeding et al 1995) and the antipsychotic response of a neuroleptic may
depend on its pro- or antioxidant property and the level of pre-existing oxidative
stress in the patient (Mahadik et al 2001). Clinical studies have indicated that
antioxidant enzyme activities are associated with the treatment of schizophrenic
patients with neuroleptics (Abdalla et al 1986; Yao et al 1998), suggesting that the
changes in the enzyme activity may be due in part to the neuroleptic treatment
(Akyol et al 2002; Evans et al 2003), as well as genetics and environmental stimuli.
Because of its implied involvement in the pathogenesis of various neurological
diseases, novel therapeutic approaches aimed at the inhibition of ROS-induced
neurotoxicity, support the use of ROS scavengers, transition metal chelators and
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antioxidant phenolics as part of an adjunctive therapy. The antioxidant activity of
hydroxytyrosol has been demonstrated previously (Chapter 2) where it has been
shown to lead to lower levels of hydroperoxides, DNA damage and mRNA levels of
glutathione peroxidase (Quiles et al 2002). Hydroxytyrosol has also been shown to
have greater antioxidant activity than -tocopherol or butylated hydroxytoluene
(BHT) (Trujillo et al 2006). It is also thought that hydroxytyrosol has greater
antioxidant activity than tyrosol due to the presence of a single hydroxyl (reviewed
by Quiles et al 2002) and that the phenol chemical structure considerably influences
the antioxidant activity as a consequence of both steric factors and those related to
position and type of functional groups on the phenol ring (Masella et al 1999). Other
authors have suggested that hydroxytyrosol and olive oil waste water are potent
scavengers of superoxide anions (Visioli et al 1998) while more recently Nousis et al
(2005) found that the extracted hydroxytyrosol from the olive leaves and fruits
themselves to be protective against hydrogen peroxide.
The potency of EGCG as an antioxidant is more controversial. Tea polyphenols have
been reported to be potent antioxidants and beneficial in ameliorating oxidative
stress related diseases (Higdon and Frei 2003; Frei and Higdon 2003; Lambert and
Yang 2003; Waltner-Law 2002). On the other hand, pro-oxidant effects of tea
polyphenols have been reported in cell culture systems (Johnson and Loo 2000). A
recent study (Raza and John 2005) observed increased DNA breakdown and
activation of apoptotic markers at high concentrations (>200M) of EGCG in a cell
culture system. At lower concentrations the study suggests that increased production
of ROS may be scavenged by increased GSH and GST enzymes since no increase in
peroxide formation was reported. At higher concentrations, an increase in ROS
production might lead to the disruption of free radical chemistry, decrease in the
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GSH pool and increased lipid peroxides. It has also been reported that EGCG has the
ability to produce H2O2 and alter the free radical generation in the cell culture system
which is known to induce oxidative stress (Chai et al 2003). However, flavonoid
polyphenols such as EGCG have been shown to improve age-related cognitive
decline and are neuroprotective in models of PD, AD and cerebral
ischemia/reperfusion injuries (Mandel et al 2004). In addition, studies indicate that
the radical scavenger property of green tea polyphenols is unlikely to be the sole
explanation for their neuroprotective capacity and in fact, tea flavonoids have also
been reported to have divalent metal chelating and anti-inflammatory activities, to
penetrate the brain barrier and to protect neuronal death in a wide array of cellular
and animal models of neurological diseases (reviewed by Mandel et al 2006).
Furthermore, experimental studies have also revealed that compounds such as EGCG
play a role in the regulation of molecules involved in the cell signal transduction
pathways including NF-kappa, Akt, MAPK, p53, androgen receptor, and oestrogen
receptor pathways. By modulating cell signalling pathways, these components,
among other mechanisms, activate cell death signals and induce apoptosis in
precancerous or cancer cells, resulting in the inhibition of cancer development and/or
progression (Sarkar and Li 2004).
Limited work focusing on the metabolism of flavonoids and their mode of entry into
the systemic circulation after oral absorption has been undertaken. Some studies
have reported flavonoid-mediated neuroprotection, yet the interaction of flavonoids
or their circulating metabolites with the brain endothelial cells from the blood brain
barrier (Youdim et al 2004) is not widely understood. EGCG has been reported to
enter the brain after oral administration (Suganuma et al 1998) and is more recently
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being investigated as a prophylactic for Alzheimer’s disease (Rezai-Zadeh et al
2005).
Although the possible potential beneficial effect of hydroxytyrosol in reducing the
level of ROS, and the possible potential beneficial effect of DHA in reducing protein
carbonyls in U937 cells was noted, a number of problems were encountered with
these experiments. The U937 cells were kept under the same cell culture conditions
throughout the experiment and were subjected to limited handling and exposure to
the atmosphere. However it is possible that because of the length of time that the
cells were in use, in particular, the number of passages might have lead to an
increase in basal oxidative damage. Although cell viability was checked at each
experiment only dead cells would have been highlighted and cells undergoing
damage would not be obvious.
Chapter 4 Examination of Lipid Peroxidation in Human Cells 112
CHAPTER 4
Examination of biomarkers of lipid peroxidation,
phospholipase A2 activity and cellular lipid composition in
fatty acid treated human neuroblastoma and peripheral
cells
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4.1 Introduction
4.1.1 Oxidative Stress and Lipid Damage
Lipid peroxidation (LPO) reactions are usually determined by free radical chain
reactions whereby one radical can lead to the oxidation of a relatively large number
of substrate molecules, which are represented by polyunsaturated fatty acids. Lipid
oxidation progresses in a similar way to the oxidation of many other organic
compounds and can be described in terms of initiation, propagation and termination
processes. These processes often consist of a complex series of reactions. The chain
reaction is initiated by the abstraction of a hydrogen atom from a reactive methylene
group (LH, the carbon surrounded by double-bonds in a bisallylic double-bond) of a
PUFA residue. Monounsaturated and saturated fatty acids are much less reactive and
do not normally undergo LPO. This initiation is usually performed by a radical (R•)
of sufficient reactivity:
LH + R• → L• + RH (1)
Molecular oxygen is then added to the carbon-centred radical (L•) formed in this
process resulting in a lipid peroxyl radical (LOO•):
L• + O2 → LOO• (2)
which in turn can abstract a hydrogen atom from another PUFA similarly as in
equation 1:
LH + LOO• → L• + LOOH (3)
This reaction is known as propagation suggesting that one initiation process can
result in the conversion of numerous PUFA to lipid hydroperoxides (LOOH). LOOH
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is the first relatively stable product of a lipid peroxidation reaction. In certain
conditions, lipid peroxidation is continuously initiated but a termination reaction
limits the extent of LPO resulting in non-radical products (NRP) and destroys two
radicals simultaneously:
LOO• + LOO• → NRP (4)
When transition metal ions are present, LOOH can lead to the generation of radicals
which can re-initiate LPO by redox-cycling of these metal ions:
LOOH + Men+ → LO• + Me(n-1)+ (5)
LOOH + Me(n-1)+ → LOO• + Men+ (6)
Lipid hydroperoxides are also capable of giving rise to other products such as short
and long chain aldehydes, phospholipid and cholesterol ester core aldehydes which
can be used as biomarkers of lipid peroxidation within a biological system (Abuja
and Albertini 2001).
4.1.2 Lipid Peroxidation as a Biomarker of Oxidative Stress
The products first formed as a result of lipid peroxidation are conjugated dienic
hydroperoxides. These active substances are either decomposed into various
aldehydes or into isoprostanes if the original fatty acid undergoing attack is
arachidonic acid (Figure 4.1). All of these products of degradation and
decomposition are used in determining oxidative stress (Dotan et al 2004).
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Figure 4.1. The products and pathways in the lipid peroxidation process (adapted from Dotan et al
2004). Key: MDA = malondialdehyde, HNE = hydroxynonenal.
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Following peroxidation of -3 and -6 PUFAs relatively unstable fatty acid
hydroperoxides are converted into more stable aldehydes. The major group of
aldehydes that are formed following peroxidation of -6 fatty acids are 4-
hydroxynonenal, MDA and hexanal. The peroxidation of -3 PUFAs leads to the
formation of propanol and 4-HNE. These are the most commonly detected products
found in biological tissues (reviewed by Meagher and FitzGerald 2000). Some of
these products have been shown to react with biomolecules such as proteins and
nucleic acids (Kautiainen et al 1993; Petersen and Doorn 2004). Aldehydes,
however, are relatively stable in comparison to free radicals and are able to diffuse in
or out of the cell to attack distant targets from the original site of free radical-
initiated events (reviewed by De Zwart et al 1999).
4.1.3 Detecting Biomarkers of Lipid Peroxidation
Lipid peroxidation is probably the most examined process induced by free radicals.
Because membrane phospholipids are in regular contact with radicals and are found
at sites where ROS are formed, phospholipids are easy targets for attack. The
PUFAs, in particular, are also vulnerable to attack by ROS (reviewed by De Zwart
1999). Peroxidation of fatty acids in lipids may result in a radical chain reaction
resulting in the formation of many equivalents of lipid peroxides. Further
propagation reactions in lipid membranes usually lead to the formation of a wide
variety of alkanes and carbonyl compounds and some products such as
hydroxyalkenals are toxic and may serve as second messengers for radical damage
(reviewed by De Zwart 1999). Products of lipid peroxidation are therefore useful
parameters for detecting radical damage.
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4.1.3.1 Thiobarbituric Acid-Reacting Substance Assay
A widely used index of lipid peroxidation is the measurement of MDA by the
thiobarbituric acid-reacting substance (TBARs) assay. The sample to be tested is
heated with 2-thiobarbituric acid at low pH. Absorbance of pink chromogen is
measured at 532nm or by fluorescence at 553nm. The TBARs assay is extremely
easy to use but is limited by the fact that it is not specific since many substances that
are present in human biological fluids can react with thiobarbituric acid (TBA)
(Cherubini et al 2005). In combination with HPLC, the selectivity of the MDA-assay
has been greatly improved. The use of a GC/MS assay for MDA has indicated that
the commonly used TBARs assay overestimates the actual MDA levels by more than
10-fold, possibly resulting from cross reactivity with other aldehydes and the harsh
conditions used in sample preparation such as high temperature conditions (Yeo et al
1994). More recent assays based on the measurement of MDA or HNE-lysine
adducts are thought to be more applicable to biological samples since adducts of
these reactive aldehydes are relatively stable (Moore and Roberts 1998).
4.1.3.2 Lipid Hydroperoxide Assay
Lipid hydroperoxide measurements are divided into those methods which detect
more or less all –O-O-groups and methods which separate peroxides into chemical
families of compounds (Abuja and Albertini 2001). One method to detect lipid
hydroperoxides include the utilisation of xylenol orange (a dye specific for Fe3+) and
is based on the ability of transition metals in the reduced form to catalyze the
reduction of peroxides to hydroxyl compounds while the metal is oxidised (Nourooz-
Zadeh 1999). In this LOOH assay, the amount of Fe3+ formed is proportional to the
content of total peroxides in the sample (Abuja and Albertini 2001).
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Other methods that are used to detect biomarkers of lipid peroxidation include the
measurement of volatile hydrocarbons. Hydrocarbon gases, such as ethane and
pentane are produced from the peroxidation of -3 and -6 PUFAs (Aghdassi and
Allard 2000). Measurement in the exhaled breath of these volatile alkanes not only
enables the assessment of lipid peroxidation but also the effect of disease and
antioxidant status with respect to oxidative stress (Aghdassi and Allard 2000). A
series of prostaglandin F2-like compounds (F2-isoprostanes) capable of exerting
potent biological activity is produced in vivo by free radical-induced lipid
peroxidation (Awad et al 1993) which has been shown to increase profoundly in
animal models of free radical injury and lipid peroxidation (Awad et al 1993).
Although it may be considered a disadvantage, the quantification of F2-iP requires
techniques such as GC-MS and LC-MS methods (Wang et al 1995). However,
quantification of F2-isoprostanes provides an accurate assessment of oxidative stress
both in vivo and in vitro and in a recent study F2-iPs was shown to be the most
reliable index of in vivo oxidant stress when compared to other well known
biomarkers (Milne et al 2007). In addition, using F2-iP as biomarkers has revealed
that confounding factors are reduced since these products are not present as
background in air or solvents (De Zwart et al 1999). GC/MS is considered the gold
standard method for measurement of urinary F2-isoprostanes but this method is
laborious and costly which prohibits its use in large epidemiological studies
(Il’yasova et al 2004). Immunoassays have been developed for specific F2-iP
(Patrignani et al 1996) but studies have reported mixed findings concerning the
validity of its use compared to other methods of detecting F2-iPs. One study reported
a statistically weak agreement between the GC-MS and ELISA method in human
urine (Il’yasova et al 2004); another observed that GC-MS and ELISA did not
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measure the same compounds in human urine (Bessard et al 2001) while the
application of the immunoassay method reported a linear correlation in the levels of
F2-iPs against an accepted marker of lipid peroxidation (Boyle et al 2000).
4.1.4 Phospholipase A2 and Schizophrenia
Phospholipases A2 make up a family of signal transduction enzymes which catalyse
fatty acid hydrolysis from the Sn2 position of a phospholipid resulting in the
production of lysophospholipid, a key event in the production of inflammatory lipid
mediators. Historically, PLA2s were named by activity location that is pancreatic,
cytosolic or secretory (Law et al 2006). Later naming systems also included calcium
requirement, although this was often misleading. Some calcium-dependent PLA2s
require calcium for catalytic activity, whereas others are constitutively active and
calcium promotes binding to the phospholipid membranes (Law et al 2006).
The calcium-independent PLA2 (iPLA2) is one of the PLA2 isoforms that does not
seem to mobilise fatty acids, although both cytosolic (cPLA2) and secretory (sPLA2)
are involved in total fatty acid turnover. The free fatty acid is then transformed by
various eicosanoid-synthesising enzymes to lipoxygenase products and prostanoids
(Chaitidis et al 1998). Cytosolic PLA2 is activated via extracellular agonists acting
mainly through G proteins, receptor tyrosine kinases or protein kinase C (PKC)
(reviewed by Rashba-Step et al 1997). These signals are accompanied by increases
in intracellular Ca2+ levels as part of a signalling mechanism. The signalling cascade
enables cPLA2 binding to membrane phospholipids. In addition, PKC- and
ERK1/ERK2-mediated phosphorylation of cPLA2 also modulates membrane binding
and catalytic activity (Durstin et al 1994).
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Secretory PLA2 has been widely investigated with respect to its activity toward
oxidised membranes; likewise, more and more information is being obtained
concerning the catalytic activity of cPLA2. cPLA2alpha, the most extensively studied
Group IV PLA2 is widely expressed in mammalian cells and mediates the production
of functionally diverse lipid products in response to extracellular stimuli (Ghosh et al
2006). For example, cPLA2 requires submicromolar concentrations of calcium to
enable its translocation from the cytosol to the membrane where its substrate is
located and the translocation is mediated by its calcium-dependent phospholipid
binding domain (Nafelski et al 1998) and phosphorylation has been shown to occur
via various pathways (reviewed by van Rossum et al 2004). Moreover, cPLA2 is
maximally activated when it is first phosphorylated followed by Ca2+-dependent
translocation to membranes (Schalkwijk et al 1996). In their study van Rossum et al
(2004) showed that in Her14 fibroblasts cPLA2 is activated in a concentration-
dependent manner by H2O2 which also induced a transient activation of cPLA2 and
cPLA2 translocated to the membrane under calcium-free conditions with a
concomitant increase in cPLA2 activity.
cPLA2alpha has also been shown to have PLA2 and lysophospholipase activities and is
the only PLA2 that has specificity for phospholipid substrates containing arachidonic
acid. Furthermore, due to its role in initiating agonist-induced release of AA for the
production of eicosanoids, cPLA2alpha activation is important in regulating normal
and pathological processes in a variety of tissues (Ghosh et al 2006).
PLA2 catalytic activity is thought to be enhanced following changes forced upon the
membrane structure (Sweetman et al 1995). When there is an increased rate of loss
of crucial fatty acids, changes in the functioning of membrane-associated proteins
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and various cell signalling systems will occur. It is suggested that an enzymatic basis
for such increased loss could be due to either the over activity of one or more of the
PLA2 enzymes as a result of the presence of an abnormal enzyme variant or from
over expression of the normal enzyme, or because of sequential action of a
phospholipase C and of a DAG lipase (Horrobin 1999). Either way, the increased
rate of removal from phospholipids would make the free acids more susceptible to
oxidation (Horrobin 1999). The hypothesis of the involvement of increased PLA2
activity in schizophrenia initially received support from Gattaz et al (1990) and was
later confirmed by a study conducted by Noponen et al (1993), although a study
carried out in the same year found PLA2 activity to be normal in schizophrenic
patients (Albers et al 1993). Most studies measuring PLA2 activity in psychotic
disorders have used either a radiometric or a fluorometric method (reviewed by Law
et al 2006), for example, a study by Macdonald et al (2004) using ELISA reported
on a direct measure of the cPLA2 protein and found increased levels of cPLA2 in
schizophrenia. An earlier report has suggested that the enzyme activity elevated in
blood of schizophrenic patients points to the calcium-independent form (Ross et al
1997), while increased calcium-independent PLA2 activity has also been reported
more recently in first but not in multi-episode chronic schizophrenia (Smesny et al
2005), suggesting increased lipid turnover in the acute early phases of schizophrenia
that is less obvious in chronic stages.
An absent response to the niacin skin test has been reported to occur in
approximately 80% of schizophrenic patients as compared to 20% of healthy
individuals (Tavares et al 2003). Niacin provokes redness in skin caused by a
capillary vasodilation mediated by prostaglandins. The metabolism of prostaglandins
is regulated by PLA2 and several studies have reported increased PLA2 activity in
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schizophrenia. Tavares’ study (2003) also supported the finding that absent response
to niacin is more frequent in schizophrenic than in healthy individuals, although the
magnitude of the difference was smaller than in the reported literature. Interest in the
membrane phospholipid hypothesis has fuelled genetic association studies between
PLA2 genes and schizophrenia. The association between schizophrenia and the
cPLA2 variants in populations of different ethnicity and alternative statistical models
have shown promising results, although many studies have not replicated these
associations (Law et al 2006).
4.1.5 Lipid Peroxidation and Schizophrenia
Although observations of lipid peroxidation are limited in schizophrenic patients,
reports have been consistent. Increased blood levels of MDA (Gama et al 2006;
Zhang et al 2006; Dietrich-Muszalska et al 2005; Arvindakashan et al 2003; Khan
et al 2002; reviewed by Yao et al 2001) and a similar increase in levels of lipid
peroxides in cerebrospinal fluid (CSF) have been reported (Skinner et al 2005;
reviewed by Yao et al 2001). Mahadik et al (1999) have also reported increased
plasma lipid peroxide levels at the onset of psychosis in never-medicated, first-
episode patients, suggesting the presence of oxidative stress early in the course of
illness and independent of treatment. In addition, higher levels of pentane in the
breath of schizophrenic patients compared to controls have also been reported
(Phillips et al 1993; Kovaleva et al 1989).
Substantial evidence is available to indicate that membrane phospholipids and
esterified EPUFAs are altered in schizophrenia (Muskiet and Kemperman 2006;
Kemperman et al 2005; Reddy et al 2003; reviewed by Peet and Stokes 2005). The
membrane phospholipid hypothesis suggests that disturbed phospholipid metabolism
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is the fundamental cause of schizophrenia. It is thought that in people who develop
schizophrenia, there is an increased rate of loss of unsaturated fatty acids,
particularly AA, DHA, EPA and linolenic acid from the Sn2 position of
phospholipids (Peet 1995; Horrobin et al 1994). When present to a mild degree the
increased rate of loss will be balanced by an increased role of incorporation and no
change in phospholipid composition. But if present to a greater degree or when
associated with problems of incorporation, there will be a change in membrane
composition (Horrobin et al 1995).
Unlike plasma membranes of non-neuronal cells, neuronal plasma membranes are
approximately 70% lipids which constitute over 50% of the dry weight of human
brain, and are enriched in phosphatidylcholine, phosphatidylethanolamine,
phosphatidylserine and phosphatidylinositol. These phospholipids, particularly in the
cortex, hippocampus and basal ganglia are enriched in EPUFAs, primarily AA and
DHA (Carlson 2001) that are selectively susceptible to lipid peroxidation due to the
lowered bond dissociation energy of their allylic hydrogens. Hydrogen abstraction
from their methylenic carbons has also been shown to occur in the presence of ROS
(Gutteridge 1982).
The aim of this study was to examine any effect of H2O2-induced lipid peroxidation
in pre-treated fatty acid human cells, used as models of schizophrenia. Because of its
suggested involvement in schizophrenia, cytosolic PLA2 content in neuroblastoma
cells was investigated while total and cPLA2 activity was also examined following
fatty acid pre-treatment and a pro-oxidant challenge on the same human cell lines.
Finally, the validity of using the fatty acid profiles of fatty acid-treated U937,
lymphoblastoid and IMR-32 cells as models of schizophrenia, was investigated.
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4.2 Materials and Methods
4.2.1 Examination of Biomarkers of Lipid Peroxidation, Phospholipase
A2 Activity and Fatty Acid Composition
4.2.1.1 Materials
DMEM, penicillin/streptomycin antibiotic, trypsin/EDTA, glucose were supplied by
Sigma (Poole, UK). Heat-inactivated FCS was obtained from Invitrogen (Paisley,
UK). RPMI 1640 media were purchased from Gibco (UK). EPA and DHA were
supplied by Pronova (Norway). DMSO, thiobarbituric acid (TBA), trichloroacetic
acid (TCA), tetramethoxypropane and acetic acid were supplied by Sigma (Poole,
UK).
4.2.1.2 Evaluation of Lipid Peroxides (MDA) in Human Secondary Cells
4.2.1.2.1 Culture of Neuroblastoma Cells
IMR-32 cells were cultured, maintained and harvested as described previously in
Chapter 2. Cell viability was determined as 90-95% as ascertained by the Trypan
blue dye exclusion method of viability.
4.2.1.2.2 Culture of Peripheral Cells
Human peripheral cells were cultured, maintained and harvested as described
previously in Chapter 2. Cell viability was determined as 90-95% as ascertained by
the Trypan blue dye exclusion method of viability.
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4.2.1.2.3 H2O2 Treatment of Neuroblastoma and Peripheral Cells
Fresh media mixed with 100M H2O2 in PBS or PBS alone was added to the flasks
and cells were incubated at 37oC for 30min or 4h.
4.2.1.2.4 Sample Preparation – Cell Lysate
Cells were washed twice with PBS and collected by centrifugation (ie. 1000 –
2000xg for 10min at 4oC). IMR-32 cells were harvested using a rubber policeman.
The cell pellet was resuspended in 1ml of ice cold PBS and sonicated using a sonic
probe for 5 cycles of 15sec at 50% power. Cells were stored on ice for assay.
4.2.1.2.5 TBARs Assay
1ml of cell sample was added to 1ml 0.05M H2SO4 in a screw-topped glass test tube
and mixed. 0.5ml of 20% TCA was added and mixed and incubated at room
temperature for 5min. Following centrifugation for 10min at 4000xg at 4oC, 0.5ml of
TBA was added to the tubes and incubated in a 100oC water bath for 1h. The
samples were left to cool.
4.2.1.2.6 TBARs Quantitation
For quantitation, calibration curves were constructed using 1,1,3,3
tetramethoxypropane as a standard, ranging from 0 to 3nmol. All measurements
were performed in duplicate. Absorbance measurements of solutions were measured
in 1ml plastic cuvettes in a Hewlett Packard spectrophotometer at 532nm.
4.2.1.2.7 Statistical Analysis
The Kolmogorov-Smirnof test was used to test the normality of the data and one-
way ANOVA was carried out as appropriate using SPSS 11.5 for Windows. For
statistical analysis, a level of 0.05 was used to determine significance.
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4.2.1.3 Evaluation of Lipid Peroxide (LOOH) Activity in Human
Secondary Cells
4.2.1.3.1 Materials
Lipid Peroxidation Assay Kit II was supplied by Calbiochem, San Diego, CA, USA.
4.2.1.3.2 Culture of Peripheral Cells
Human peripheral cells were cultured, maintained and harvested as described
previously in Chapter 2. Cell viability was determined as 90-95% as ascertained by
the Trypan blue dye exclusion method of viability.
4.2.1.3.3 Fatty Acid Treatment of Peripheral Cells
Peripheral cells were incubated with 50M of fatty acids for 24h under the same
conditions as described previously in Chapter 2. Cell viability was determined as 90-
95% as ascertained by the Trypan blue dye exclusion method of viability.
4.2.1.3.4 H2O2 Treatment of Peripheral Cells
Following 24h incubation, cells were washed three times with PBS and collected by
centrifugation at 2000xg for 5min. Cells were resuspended in media containing
100M H2O2 and incubated for 4h at 37oC.
4.2.1.3.5 Sample Preparation – Cell Lysate
Cells were washed twice with PBS and collected by centrifugation (ie. 1000 –
2000xg for 10min at 4oC). The cell pellet was resuspended in 1ml of ice cold PBS
and sonicated using a sonic probe for 5 cycles of 15sec at 50% power. Cell lysate
was frozen at -80oC until ready to assay.
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4.2.1.3.6 Determination of LOOH in Human Peripheral Cells
Cell lysate was thawed at room temperature. 10l of catalase enzyme was added to
each microcentrifuge tube and 90l of sample was then added. Samples were mixed
gently and incubated at room temperature for 2min. Blanks were prepared by adding
10l of Reducing Agent and Test was prepared by adding 10l of deionised water
into a microcentrifuge tube. Samples were then covered and mixed by vortexing and
incubated at room temperature for 30min. 900l of Working Reagent (1 volume of
Color Developer with 100 volumes of Chromogen) was added to each tube, covered
and vortexed for 30sec and incubated at room temperature for 60min. Samples were
then centrifuged at 10,000–12,000xg for 10min to remove all flocculated materials.
Supernatants were transferred to spectrophotometric cuvettes and absorbance was
measured at 560nm.
4.2.1.3.7 Statistical Analysis
The Kolmogorov-Smirnof test was used to test the normality of the data and one-
way ANOVA was carried out as appropriate using SPSS 11.5 for Windows. For
statistical analysis, a level of 0.05 was used to determine significance.
4.2.1.4 Investigation of Total PLA2 Activity and cPLA2 Activity in
Human Neuroblastoma and Peripheral Cells
4.2.1.4.1 Materials
cPLA2 assay kit components were supplied by Cayman Chemical Company
(Michigan, USA).
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4.2.1.4.2 Culture of Neuroblastoma Cells
IMR-32 cells were cultured, maintained and harvested as described previously in
Chapter 2.
4.2.1.4.3 Culture of Peripheral Cells
Human peripheral cells were cultured, maintained and harvested as described
previously in Chapter 2.
4.2.1.4.4 Fatty Acid Treatment of Neuroblastoma and Peripheral Cells
U937 cells were incubated with 50M of fatty acids for 24h under the same
conditions as described previously in Chapter 2. Cell viability was determined as 90-
95% as ascertained by the Trypan blue dye exclusion method of viability.
4.2.1.4.5 H2O2 Treatment of Neuroblastoma and Peripheral Cells
Following 24h incubation, cells were washed three times with PBS and collected by
centrifugation at 2000xg for 5min. Cells were resuspended in media containing
100M H2O2 and incubated for 4h at 37oC.
4.2.1.4.6 Total PLA2 Sample Preparation – Cell Lysate
Cells were washed twice with PBS and collected by centrifugation (ie. 1000 –
2000xg for 10min at 4oC). IMR-32 cells were harvested using a rubber policeman.
The cell pellet was resuspended in 1ml of ice cold PBS containing 1mM EDTA and
sonicated using a sonic probe for 5 cycles of 15sec at 50% power. Cells were then
stored on ice until ready to assay.
4.2.1.4.7 cPLA2 Sample Preparation – Cell Lysate
Cells were washed twice with PBS and collected by centrifugation (ie. 1000 –
2000xg for 10min at 4oC). IMR-32 cells were harvested using a rubber policeman.
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The cell pellet was resuspended in 1ml of ice cold PBS containing 1mM EDTA and
sonicated using a sonic probe for 5 cycles of 15sec at 50% power. Samples were then
concentrated using a Millipore Centriprep®. Samples were centrifuged for 5min at
10,000xg and lysate containing molecules of >30,000 nominal molecular weight was
decanted. The retained pellet was centrifuged again as above and lysate poured off
once again. During this process, any residual sPLA2 within the sample is also
removed. To avoid any measurement of iPLA2 activity in the remaining sample, 1ml
samples were incubated with 5l of 1 mM bromoenol lactone for 15min at 25oC.
Cells were then stored on ice until ready to assay.
4.2.1.4.8 PLA2 Assay
Buffers and reagents were prepared as per protocol instructions. 15l of assay buffer
was added to the blank wells in triplicate as non-enzymatic controls. 10l of PLA2
and 5l of assay buffer were added to the positive control wells in triplicate. 10l of
sample and 5l of assay buffer were added to the sample wells in triplicate.
Reactions were initiated by adding 200l of substrate solution to all of the wells. The
plate was shaken gently for 30sec to mix and covered and incubated for 60min at
room temperature. Following incubation, the plate cover was removed and 10l of
reagent was added to each well to stop enzyme activity and to develop the reaction.
The plate was gently shaken for 30sec to mix and incubated for 5min at room
temperature. The plate was placed into a BIO-TEK FL600 fluorescence plate reader
and absorbance of the wells was read at 405nm.
4.2.1.4.9 Statistical Analysis
The Kolmogorov-Smirnof test was used to test the normality of the data and one-
way ANOVA and Student’s t-test were carried out as appropriate using SPSS 11.5
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for Windows. For statistical analysis, a level of 0.05 was used to determine
significance.
4.2.1.5 Examination of Fatty Acid Composition in Human
Neuroblastoma and Peripheral Cells
4.2.1.5.1 Cell Culture
Human neuroblastoma and peripheral cells were grown and maintained in 25cm2
flasks at a seeding density of 1x106cells/ml, as previously described in Chapter 2.
4.2.1.5.2 Fatty Acid Treatment of Neuroblastoma and Peripheral Cells
Cells were incubated with 50M of fatty acids for 24h under the same conditions as
described previously in Chapter 2. Cell viability was determined as 90-95% as
ascertained by the Trypan blue dye exclusion method of viability. Following
treatment cells were washed 3 times with PBS and the cell pellet was resuspended in
50l PBS. The cell suspension was added to 2ml chloroform:methanol (2:1v/v) in
glass vials and was purged for a few seconds with nitrogen gas. Samples were sealed
and posted to Institute of Aquaculture, University of Stirling for fatty acid content
analysis by GC. In brief, cell pellets were extracted by a variation of the Bligh and
Dyer’s (1959) method and the polar lipid fraction isolated by thin layer
chromatography. Fatty acid methyl esters (FAMEs) were prepared by acid-catalysed
trans-esterification of total lipids according to the method of Christie (1982). FAMEs
were separated and quantified by GLC with flame ionisation detection using a 60m x
0.32mm i.d. capillary column (Phenomenex ZB Wax, Macclesfield, UK) and on-
column injection. Hydrogen was used as carrier gas (flow rate 2ml/min) and
temperature programming 50oC to 150oC at 40oC/min and then to 225oC at 2oC/min
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employed. Individual methyl esters were identified and quantified by comparison to
known standards (Cyhlarova et al 2007).
4.2.1.5.3 Acknowledgement
I gratefully acknowledge the support offered by Dr J G Bell and his group at the
Institute of Aquaculture, University of Stirling, in undertaking the cellular fatty acid
determinations.
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4.3 Results
4.3.1 Cellular Lipid Composition
Evaluation of the fatty acid content of the three human cells lines was undertaken
using GC. Table 4.1 details in particular AA, EPA and DHA percentage values in
untreated or EPA or DHA pre-treated cells. Analysis has revealed that in untreated
cells, of the three PUFAs under investigation, all cell lines contain a higher
percentage of AA than DHA or EPA. Following 24h incubation with EPA, levels of
AA and DHA decrease when compared to the untreated cells. However, EPA content
has increased by approximately 20% in EPA-treated U937 cells, 13% in
lymphoblastoid cells and 9% in IMR-32 cells. Even more considerable is the
percentage increase in the levels of DHA following cell treatment for 24h with DHA.
In the U937 cell line, DHA content has increased by 46%, by 24% in lymphoblastoid
cells and 13% in IMR-32 cells compared to DHA content in untreated cells. When
compared to fatty acid content in untreated cells, AA levels in DHA-treated cells had
decreased, while EPA content had increased marginally.
Total % saturated fatty acid has decreased in all cells lines pre-treated with DHA, but
total percent saturated fatty acid level has increased marginally in IMR-32 cells pre-
treated with EPA, while total percent monounsaturated fatty acid has decreased in
the three cell lines pre-treated with either EPA or DHA. Total % -6 PUFA levels
have also fallen following pre-treatment of cells with the chosen fatty acids while
total -3 % PUFA levels have increased in the pre-treated fatty acid cells.
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U937 Lymphoblastoid IMR-32
Untreated
Cells
EPA
Treated
Cells
DHA
Treated
Cells
Untreated
Cells
EPA
Treated
Cells
DHA
Treated
Cells
Untreated
Cells
EPA
Treated
Cells
DHA
Treated
Cells
% AA 5.00 3.06 2.50 5.56 3.30 3.50 4.39 2.33 3.28
% EPA 0.21 20.58 0.90 0.39 13.71 1.00 0.29 9.13 1.16
% DHA 1.75 1.34 47.77 2.44 1.58 26.55 2.84 1.40 16.20
Total %
Saturated
FA
35.16 22.68 23.97 42.89 33.42 35.20 42.30 44.69 38.79
Total %
Mono-
unsaturated
FA
45.15 19.05 16.14 36.57 20.62 23.85 39.17 25.77 29.94
Total %
-6 PUFA 11.19 6.83 5.45 12.19 7.39 7.86 9.15 5.54 7.22
Total %
-3 PUFA 3.71 49.32 52.59 4.40 36.01 30.14 5.15 21.66 20.43
-3/-6
Ratio
0.33 7.22 9.65 0.36 4.87 3.83 0.56 3.91 2.83
Table 4.1. Fatty acid profiles in untreated and 24h EPA and DHA 50M treated human peripheral and
neuroblastoma cell lines. Data show fatty acid composition (%) in 1x106cells/ml following analysis
by GC.
4.3.2 MDA Analysis
Cellular membrane components are highly susceptible to oxidation, thus the
formation of lipid peroxides were investigated, whereby levels of MDA in particular
were measured by using the TBARs assay. A validation study was undertaken to
determine the specificity of the assay and involved the incubation of peripheral and
neuroblastoma cells lines with an oxidant for 30 minutes or 4 hours. Linearity was
demonstrated over a range of 0 -5 nm MDA of triplicate samples.
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Figure 4.2 reports the effect of the treatment of 100M H2O2 over both time points
on MDA production in the three cell lines. Treatment with H2O2 at 30min or at 4h
had no significant effect (p <0.05) on the production of MDA in any of the three cell
lines. In fact, a reduction in the level of MDA in the H2O2-treated cells at 30min and
4h was observed when compared to the untreated cells both in the U937 and IMR-32
cell lines. An increase in MDA production was only observed in the 30min H2O2-
treated lymphoblastoid cells.
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Figure 4.2. Investigation of MDA production in H2O2 treated human peripheral and neuroblastoma
cells. Peripheral cells (U937 and lymphoblastoid) and IMR-32 neuroblastoma were treated for 30min
or 4h with 100M H2O2 and compared with MDA production in H2O2 untreated (control) samples
measured by TBARs. Values are expressed as mean ± sem of three independent experiments.
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4.3.3 LOOH Analysis
U937 cells pre-treated with 50M fatty acid for 24h were incubated with or without
100M H2O2 for 4h (Figure 4.3) and cell viability was determined as 90-95% as
ascertained by the Trypan blue dye exclusion method of viability. The frozen cell
lysate was used in the Calbiochem LOOH assay and absorbance of the samples was
read at 560nm. ANOVA analysis revealed no significant difference in the levels of
LOOH in either the fatty acid pre-treated H2O2 incubated cells or the fatty acid
treated cells without H2O2 challenge.
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Figure 4.3. Evaluation LOOH in fatty acid treated and untreated U937 cell lysate, with and without
H2O2 treatment. U937 cells were treated for 24h with fatty acid followed by 100M H2O2 treatment
for 4h. Values are expressed as mean ± sem of two independent experiments.
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Analysis of this experiment suggests that although a high H2O2 challenge was used,
the cells appear to be resistant to the pro-oxidant challenge since there is no
statistically significant increase in lipid peroxides. Furthermore, treatment of U937
cells with either EPA or DHA alone induced no significant increase in LOOH levels
and so it would appear that there is no evidence of a pro-oxidant stress from either of
the fatty acid treatments. Untreated cells appear to have a high level of oxidative
stress although all cells were subjected to the same culture conditions.
4.3.4 Total PLA2 Activity Analysis
The cytosolic PLA2 enzyme catalyses the hydrolysis of fatty acids at the Sn2
position of glycerophospholipids and its activity can be determined in cell cultures.
The Cayman cPLA2 assay kit was used to determine total and cytosolic PLA2
enzyme activity in human peripheral and neuroblastoma cell lines.
In the first experiment the effect of H2O2 treatment over time was investigated
(Figure 4.4). The three cell lines were incubated with or without 100M H2O2 for a
period of 30min or 4h and thawed cell lysates were used in the assay. One-way
ANOVA was used to determine any effect of the H2O2 treatment over time. A highly
significant increase in PLA2 activity was observed at 4h within the U937 H2O2
treated samples (Figure 4.4). In addition, significant increase in PLA2 activity was
also observed after 4h in the H2O2 treated IMR-32 cells compared to the 4h untreated
IMR-32 cells. No difference in enzyme activity was noted between the 30min or 4h
untreated and H2O2-treated lymphoblastoid samples.
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Figure 4.4. Determination of PLA2 activity in human peripheral and neuroblastoma cells. Peripheral
cells (U937 and lymphoblastoid) and IMR-32 neuroblastoma were treated for 30min or 4h with
100M H2O2 and activity was compared to H2O2 untreated (control) samples. Values are expressed as
mean ± sem. of two independent experiments (n=2). Significance is denoted by *** where p <0.001
and ** where p <0.01. If not shown, the error bars are too small to be visible.
Total PLA2 activity was further examined in all three cell lines. Cells were pre-
treated with fatty acids for 24h followed by H2O2 treatment for 4h and fresh cell
lysate was used in the assay. In this experiment, a high variance was observed within
the untreated cells which lead to the adoption of the ethanol-treated cells as the
control set. In addition, the large error bars recorded in this experiment in particular
may be due to the possible lack of intra-assay precision.
As observed in Figure 4.5, pre-treatment of U937 and IMR-32 cells with DHA for
24h appeared to increase mean total PLA2 activity when compared to the ETOH-
treated cells, but there is no comparable difference in the level of total PLA2 activity
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in the lymphoblastoid DHA-treated cells. U937 and lymphoblastoid cells pre-
incubated with EPA report a decrease in total PLA2 activity when compared to
ETOH-treated cells, except in IMR-32 cells pre-incubated with EPA where an
increase in total PLA2 activity is observed. A decrease in mean total PLA2 activity
can be seen in all cell lines challenged with H2O2 compared to ETOH-treated cells,
although U937 and IMR-32 cells pre-treated with ETOH followed by the H2O2
treatment reveal no difference in mean total PLA2 levels and only an increase in
PLA2 activity is noted in the lymphoblastoid cells. H2O2 treatment of fatty acid pre-
treated U937 cells reveal no marked change in mean total PLA2 activity levels when
compared to H2O2 and ETOH/H2O2 treated cells, although the hydrogen peroxide
treatment does appear to increase PLA2 activity in EPA pre-treated cells when
compared to those EPA pre-treated cells not subjected to the H2O2 treatment.
Conversely, the H2O2 challenge of pre-treated DHA cells appears to decrease mean
total PLA2 activity when compared to pre-treated DHA only U937 cells.
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Figure 4.5. Examination of mean total PLA2 activity in fatty acid and H2O2-treated peripheral and
neuroblastoma cells. Cells were pre-treated for 24h with 50M fatty acid and for 4h with or without
100M H2O2. Values are expressed as mean ± sem of triplicate samples of one experiment ± sem.
Mean total PLA2 activity is increased in lymphoblastoid cells pre-treated with ETOH
followed by H2O2 in comparison to ETOH-only treated cells but following the H2O2
treatment of the pre-treated fatty acid lymphoblastoid cells, a decrease in PLA2
activity is observed. Moreover, mean total PLA2 activity appears to be further
decreased in lymphoblastoid cells pre-treated with fatty acid followed by H2O2
stimulation when compared to the lymphoblastoid cells pre-treated with fatty acids
only. PLA2 activity in H2O2 treated IMR-32 cells is slightly reduced in contrast to
ETOH pre-treated cells, however, there is no apparent difference in levels when
comparing ETOH/H2O2 treated cells to ETOH pre-treated cells. In addition there is a
marginal decrease in mean total PLA2 activity in IMR-32 cells pre-treated with fatty
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acid followed by the H2O2 challenge and without the H2O2 treatment in comparison
to the pre-treated ETOH/H2O2 cells.
Results from Figure 4.5 suggest that pre-treatment of U937 and lymphoblastoid cells
with EPA appeared to decrease PLA2 activity while pre-treatment of U937 cells with
DHA and IMR-32 with EPA and DHA appeared to increase total PLA2 activity.
However, not only is mean total PLA2 activity decreased when cells are subjected to
a high oxidative stress, pre-treatment of cells with EPA or DHA followed by an
oxidative challenge decreased PLA2 activity levels or had no effect on the mean total
PLA2 activity in these cell lines.
Figure 4.6 shows mean cPLA2 activity in peripheral and neuroblastoma cells. Again,
due to experimental error, ethanol-treated cells were used as controls. All
experiments would have been repeated had time permitted. U937 cells pre-treated
with ethanol appear to have the highest level of cPLA2 activity. Yet, pre-treatment of
these cells with fatty acid reduced cPLA2 activity substantially and as can be seen,
this reduction is more evident following pre-treatment of cells with EPA followed by
a H2O2 treatment. However, U937 DHA pre-treated cells challenged with H2O2
reveal a slight increase in cPLA2 activity in comparison to DHA pre-treated cells not
challenged with H2O2. Evaluation of cPLA2 activity in the lymphoblastoid cell line
reveals a decrease in activity levels in cells pre-treated with fatty acids when
compared to ETOH pre-treated cells. However, treatment of lymphoblastoid cells
with H2O2 and pre-treatment with ETOH followed by H2O2 challenge reveals no
change in cPLA2 activity levels in comparison to ETOH pre-treated cells while the
fatty acid pre-treated cells subjected to the oxidative stress show a decrease in mean
cPLA2 activity in contrast to the H2O2 and ETOH/H2O2 treated lymphoblastoid cells.
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Figure 4.6. Examination of cPLA2 activity in fatty acid and H2O2-treated peripheral and
neuroblastoma cells. Cells were pre-treated for 24h with 50M fatty acid and for 4h with or without
100M H2O2. Values are expressed as mean of triplicate samples of one experiment ± sem.
DHA pre-treatment in IMR-32 cells appears to have no effect on cPLA2 activity
while EPA pre-treatment appears to have reduced cPLA2 activity. The oxidative
stress challenge on the pre-treated ETOH cells has increased cPLA2 activity
marginally in comparison to the ETOH unchallenged IMR-32 cells, however the
fatty acid pre-treatment in combination with the H2O2 stress appears to have further
decreased cPLA2 activity levels.
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Analysis of the data suggests that pre-treatment of cells with fatty acid seems to
reduce cPLA2 activity and this activity may be reduced further with the additional
treatment of H2O2. Cytosolic PLA2 activity in these cell lines therefore, does not
appear to be enhanced by fatty acid supplementation nor by the treatment of the ROS
generating H2O2.
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4.4 Discussion
The aim of this chapter was to evaluate the effect of modifying cellular membrane
fatty acid profiles by fatty acid supplementation trials and ROS-induced oxidative
stress in putative cell models of schizophrenia, and in particular on biomarkers of
lipid oxidation. Finally, total PLA2 and cPLA2 activity levels were assessed
following EPA or DHA and H2O2 treatment in human neuroblastoma and peripheral
cells in order to determine the extent to which EPA and DHA altered cell fatty acid
composition.
4.4.1 Cellular Lipid Composition
Examination of the cellular lipid composition of the U937, lymphoblastoid and IMR-
32 cells revealed the basal level of -3 fatty acids in the U937 cell line to be lower in
comparison to the lymphoblastoid or IMR-32 cell lines. This observation strengthens
the validity of the U937 cell line as a suitable system in vitro for examining cellular
mechanism in schizophrenia. The similarity of the values and the lower -3/-6
ratio between the U937 and lymphoblastoid cell lines can be clearly seen compared
to that observed in the IMR-32 cell line. The 3 fatty acid content expressed as a
percentage of total fatty acids increased markedly in each cell line following
treatment with either EPA or DHA but in both instances the U937 cells showed the
greatest increase. Similarly, following treatment with DHA the % -3 fatty acid
content was 52.59%, 30.14% and 20.43% respectively for the U937, lymphoblastoid
and IMR-32 cells. As a result, all 3 cell lines were responsive to supplementation
with DHA and EPA but the U937 cell line significantly more so.
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Enrichment of -3 PUFA content was even more marked following DHA
supplementation. Following 24 hour treatment, the DHA content in the U937 cell
line had increased by 46%, by 24% in lymphoblastoid cells and by 13% in IMR-32
cells compared to DHA content in untreated cells. Astrocytes grown in medium
supplemented with DHA and/or AA plus -tocopherol have been shown to
incorporate large amounts of long chain PUFA so that the -6/-3 PUFA
compositions of the phosphatidylethanolamine and phosphatidylcholine, the two
main classes of membrane phospholipids, were greatly altered (Champeil-Potokar et
al 2004). Furthermore, the astrocytes cultured in medium plus DHA had a more
physiological -3 status, grew better and retained their astrocyte phenotype
(Champeil-Potokar et al 2004).
The profile of essential fatty acids in neuronal membranes has been suggested to
affect normal physiological events in the brain. For example -6 and -3 PUFA
imbalance early in life leads to irreversible changes in hypothalamic composition (Li
et al 2006). DHA, the main -3 polyunsaturated fatty acid in membranes is
particularly abundant in brain cells and decreased cerebral concentrations of DHA
are associated with impaired cognitive function (Champeil-Potokar et al 2004).
Moreover the fatty acid composition of neuronal cell membrane phospholipids
reflects their intake in the diet (Li 2006; Haag 2003). Dietary fatty acids, therefore,
may induce changes in neurophysiological and psychopathological parameters (Haag
2003; Evans et al 2003) while animal studies have shown that diet-induced lack of
DHA in the brain leads to alterations in cognitive processes (Vancassel et al 2007).
A diverse range of biological actions of DHA, a major component of brain
membrane phospholipids, is involved in neuronal function, gene regulation and
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maintenance of the structural integrity of neurones. DHA is also thought to have a
protective role in a cell culture model of apoptosis (Salem et al 2001) and may play
an important role in the regulation of cell signalling and in cell proliferation (Salem
et al 2001). Similarly, EPA plays a role in many biological activities and a variety of
actions have been reported. These include inhibition of phospholipase A2 (El Azher
et al 2000), inhibition of the apoptotic pathway (Englebrecht et al 2005; Martin et al
2002), the induction of apoptotic cell death (Schley 2005; Heimli 2002), the indirect
neuroprotective effects of metabolites such as D series resolvins that have potent
anti-inflammatory actions (Das 2006), and the ability to exert a number of positive
actions against atherosclerosis and its complications (von Schacky 2006).
4.4.2 Lipid Peroxidation
Lipid peroxides are compounds that are unstable and have the ability to rapidly
degrade into numerous products such as short chain alkanes and aldehydes.
Examples of lipid peroxide end products that are used to investigate clinical disease
include TBARs, exhalation of the alkanes pentane and ethane and cytotoxic
aldehydes (Meagher and FitzGerald 2000). In this study MDA analysis was
undertaken using the TBARs assay while lipid hydroperoxide analysis was
completed using a commercial kit. Treatment of the three cell lines with a high
concentration of H2O2 for 30min or 4 hours did not induce a significant increase in
MDA. The human cell line U937 was then supplemented for 24 hours with fatty
acids followed by a 4 hour oxidative stress. Both EPA and DHA treatment appeared
to reduce LOOH levels in the U937 cells but not significantly. Furthermore, pre-
treatment of the cells with the fatty acids followed by the H2O2 treatment did not
further induce an increase in LOOH levels. The results suggest that not only is there
no pro-oxidant stress arising from the supplementation of the chosen fatty acids but
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the cells also appear to be resistant to the high ROS challenge in the presence of the
PUFA. It is also possible that enhanced antioxidant enzyme activity induced by -3
fatty acid supplementation of the U937 cells caused a decrease in LOOH production.
Crosby et al (1996) reported an induction of glutathione peroxidase activity in
HUVEC treated with EPA and DHA for 24h, and consequently a reduction in the
production of conjugated dienes, a marker of lipid peroxidation.
Further review of the literature revealed that there is limited data examining the
supplementation of U937 cells with EPA and DHA and their effects on LOOH
levels. However, a study examining retinal fatty acid binding protein also noted that
lipid hydroperoxides stimulated by long-chain fatty acids were reduced on rod outer
segments (Guarjado et al 2002). In contrast, Udilova et al (2003) reported that
peroxidation of biomembranes can be initiated by LOOH from heated dietary oils
and more recently the same group reported the production of LOOH from
unsaturated oils as a key factor in colon carcinogenesis (Jurek et al 2005).
One of the most commonly used methods in free radical research is the
determination of the TBA adduct and MDA in plasma. MDA has been found to be
elevated in patients with schizophrenia when compared with normal controls (Zhang
et al 2006; Dakhale et al 2005; Kuloglu et al 2002; Ravikumar et al 2000), as well as
in animal models (Ozyurt et al 2007), although a recent human study (Zhang et al
2007) found significantly lower MDA plasma levels from male schizophrenic
subjects who smoked compared to the non-smokers. While reports of increased
levels of lipid peroxides in patients with schizophrenia have been observed (Li et al
2006, Evans et al 2003), and increased LOOH levels in patients with psychiatric
disease have been reported (Balkan et al 2005; Karelson et al 2001), studies of lipid
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hydroperoxides in particular, in patients with schizophrenia is limited. In our recent
study, however, (Young et al 2007) we reported no significant differences in the
levels of LOOH in either the schizophrenic or control group.
4.4.3 Phospholipase A2
Phospholipases A2 are important enzymes involved in the process of AA metabolism
and are activated during monoaminergic neurotransmission (Berger et al 2006).
Reduced membrane AA levels and an altered activity of PLA2 have been found in
peripheral membranes of drug-naïve patients with schizophrenia with some
conflicting results in more chronic patient populations (reviewed by Berger et al
2006). Analysis of post-mortem brain tissue has further reported a decrease in
calcium-dependent PLA2 activity rather than an increase (Ross et al 1999).
Furthermore, it has been suggested that genes expressing cytosolic PLA2 may be
involved in contributing to the aetiology of schizophrenia (Tao et al 2005).
Initial studies revealed significantly increased total PLA2 levels in the U937 and
IMR-32 cells following 4 hour treatment with H2O2 alone. An increase in total PLA2
activity was also seen in lymphoblastoid cells although this did not reach
significance. However, further experimentation with or without pre-treatment of
cells with -3 fatty acids revealed total PLA2 levels to be similar in all the cell lines
and no change in activity levels was observed following challenge with H2O2. These
findings are in contrast to the reports that H2O2 activates cytosolic phospholipase A2
(van Rossum et al 2004) and it is difficult to provide an explanation for this
discrepancy at present.
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In an additional exploratory study, the cPLA2 activity in the three human cell lines
was examined and the basal level of cPLA2 activity was found to be comparable in
the lymphoblastoid and IMR-32 cells but lower than that measured in the U937 cells.
However, because only one study was carried out, the results cannot be deemed
significant since no statistical analysis was undertaken. In this experiment, a high
variance was observed within the untreated cells which lead to the adoption of the
ethanol-treated cells as the control set. In addition, the large error bars recorded in
this experiment in particular may be due to the possible lack of intra-assay precision.
An enhanced level of cPLA2 activity in the U937 cell line has been previously
reported by Obajimi et al (2005) and is a feature which has led to the suggestion that
this cell line is a suitable in vitro model for studying cellular mechanisms of
schizophrenia. Supplementation of the U937 cell line with EPA appeared to reduce
cPLA2 activity relative to the vehicle treated control, an outcome which again
appears to mimic some of the biochemical changes reported following EPA
supplementation of Asperger’s syndrome sufferers (Bell et al 2004). Neither EPA
nor DHA supplementation appeared to have any significant effect on either total
PLA2 or cPLA2 activity in IMR-32 or lymphoblastoid cell lines. However, it is also
reported that -3 PUFAs modulate T-cell functions such as T-cell proliferation and
cytokine secretion (Calder 2001). This is important since inflammatory cytokines
such as IL-1, TNF and IFN, play a role in the activation of cPLA2 (Xu et al
2003). A more recent study also reported that IL-2 increased cPLA2 activity in the
shell of the nucleus accumbens but IL-1-induced changes were significantly
attenuated by EPA treatment (Song et al 2007).
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In conclusion, although this study has attempted to evaluate the use of LOOH and
PLA2 as markers of oxidative stress in models of schizophrenia, the results are quite
inconclusive. It is possible that the number of passages and general maintenance of
the cells lead to the ‘poor’ results although this was not as a result of cell loss. The
viability of the cells was checked before and after each treatment of every
experiment and the cell viability was not changed so it seems unlikely that the
inconclusiveness of the results was because of the treatments. Had resources and
time permitted it would have been ideal to have carried out the experiments again,
perhaps with minimal passages and minimal interference to the cells.
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CHAPTER 5
Evaluation of biomarkers of lipid peroxidation in
schizophrenic and control subjects. Human trial part 1.
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5.1 Introduction
Lipid peroxidation in biological tissues can be measured by numerous peroxidation
products including lipid hydroperoxides, conjugated dienes and malondialdehyde.
Lipid peroxidation also produces hydrocarbon gases, such as ethane and pentane
which are produced from the peroxidation of -3 and -6 PUFAs. Measurement in
the exhaled breath of these volatile alkanes is another way of assessing lipid
peroxidation and the effect of disease and antioxidant status with respect to oxidative
stress (Aghdassi and Allard 2000).
5.1.1 Volatile Breath Hydrocarbons as a Biomarker of Lipid
Peroxidation
Analysis of exhaled air products enables the observation of biochemical processes in
the body via a non-invasive procedure. Gas chromatographic analysis of exhaled air
was first investigated over 4 decades ago by Aulik (1966) and further by Pauling et
al (1971) who determined more than 200 components in human breath. Evidence
that volatile hydrocarbons are generated after peroxidation of unsaturated fats was
provided by in vitro studies where it was shown that hydrocarbon gases evolved
during the decomposition of fatty acid hydroperoxides by -scission (Dumelin and
Tappel 1977) leading to the formation of an alkyl radical and an aldehyde. In many
studies the formation of alkanes in the C2-C5 range is analysed (Griffiths et al
2002), but as a result of the physiological ratio of -3 to -6 fatty acids, four times
more pentane than ethane is generated through lipid peroxidation (Miekisch et al
2004) and so these gases are more often measured.
Lipid peroxidation is a chain reaction which is initiated by the removal of an allylic
hydrogen atom through ROS. The radical generated in this way is conjugated,
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peroxidized by oxygen and undergoes further reactions. Eventually saturated
hydrocarbons such as ethane and pentane are produced in this way from -3 and -6
fatty acids respectively, as well as MDA from the same pathway. Animal and
clinical studies have demonstrated a close correlation between clinical conditions
whereby dietary antioxidants and lipid sources significantly influenced ethane and
pentane output, supporting the idea that breath alkane output is a useful index of
lipid peroxidation (Dillard et al 1977). In addition, levels of exhaled pentane and
ethane have also been shown to correlate well with other lipid peroxidation markers
such as lipid peroxides and F2-isoprostanes (Aghdassi et al 2003).
Although originally difficult to quantify, the non-invasive measure of breath alkane
output was finally standardised and validated as a measure of lipid peroxidation in
humans (Dumelin and Tappel 1977; Filser et al 1983; Lemoyne et al 1987).
Hydrocarbons as stable end products of lipid peroxidation show only low solubility
in blood and are excreted into breath within minutes of their formation in tissues
(Miekisch et al 2004). Therefore, exhaled concentrations of ethane and pentane can
be used to monitor the degree of oxidative damage in the body (Risby and Sehnert
1999).
5.1.2 Breath Collection and Analysis
Because real-time monitors for breath biomarkers are unavailable at the present time,
exhaled breath must be collected and transported to the laboratory for analysis. Most
published studies have collected total exhaled breath in inert gas sampling bags and
analysis is performed as soon as possible after collection. The requirements for gas
sampling bags are that the bags must be inert and not adsorb analyte molecules
(Risby and Sehnert 1999). Furthermore, the bags should have a volume that
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corresponds to at least twice the amount of breath collected, minimizing any back
pressure from the collected gas that could restrict the exhalation of the study subject.
In addition, the inlet to the gas sampling bag should have sufficient dimensions to
restrict any pressure drop across the inlet to the gas sampling bag (Risby and Sehnert
1999). More recently, thermal desorption tubes packed with adsorbents have been
used to collect expiratory gases. These devices collect known volumes of the exhaled
breath at controlled flow rates which results in no resistance to breathing and
enabling the collected breath sample to be transported from sample site to laboratory
(Risby and Sehnert 1999).
Separation of volatile compounds has been carried out using gas-liquid
chromatography and gas-solid chromatography. Hydrocarbons in the nmol/l-pmol/l
range such as ethane, pentane or isoprene usually are determined using gas
chromatography coupled to flame ionisation or mass selective detection (reviewed
by Miekisch et al 2004). Currently, the analytical method that is most frequently
used is a capillary GC method with an adsorption/desorption sample-handling
method which enables the preconcentration of small volumes of exhaled breath. For
further analysis, volatile substances have to be released from the adsorption material.
This can be achieved by heating the trap (thermal desorption or by means of
microwave energy (Miekisch et al 2004) and can be carried out automatically or by
commercially available devices. Breath volatiles can also be preconcentrated by
means of solid phase microextraction (Grote and Pawliszyn 1997). The method
involves extraction and preconcentration with a fused silica fibre, coated with a
polymeric stationary phase. Desorption of the volatile compounds from these coated
fibres is carried out by direct heating at very high temperatures and assayed by GC-
MS.
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The choice of the separation column is fundamental. Chromatographic separation of
pentane and isoprene in human breath has proved difficult with the sum of isoprene
and pentane being determined as pentane (Springfield and Levitt 1994). In addition,
care is required in the measurement of breath pentane so that pentane and its isomer,
isopentane are not co-eluted (Mitsui et al 2000). Although there are other potential
sources of hydrocarbons in the body such as protein oxidation and colonic bacterial
metabolism, these appear to be of limited importance and do not interfere with the
interpretation of hydrocarbon breath test for ethane and pentane (Kneepkens et al
1994). Propane and butane are mainly derived from protein oxidation and faecal
flora and their role as markers of lipid peroxidation is uncertain (Miekisch et al
2004)
5.1.3 Volatile Hydrocarbons and Schizophrenia
Clinical studies have shown that the presence of abnormal volatiles can aid diagnosis
of certain diseases. For example, breath isoprene levels have been reported to be
altered in a number of clinical conditions; although the physiological meaning of
these changes has not yet been established (Salerno-Kennedy and Cashman 2005).
Various lines of evidence suggest that isoprene is related to cholesterol biosynthesis.
Therefore, breath isoprene measurements could potentially be used for screening of
lipid disorders (Salerno-Kennedy and Cashman 2005).
It is thought that hydrocarbons found in breath may result from increased lipid
peroxidation caused by oxidative stress (Ward 2000). Since it is suggested that
oxidative stress may be a contributory factor in neurodevelopmental disorders (Ross
2000) the non-invasive breath test may have a role as a diagnostic tool in oxidative
stress-related diseases.
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The aim of this study was to utilise the non-invasive technique of breath
hydrocarbon analysis. The results of the hydrocarbon analysis will be compared with
another lipid biomarker in a population of schizophrenic patients compared to a
population of apparently healthy aged-matched control subjects. In addition, a
correlation of the lipid peroxidation products will be undertaken against the findings
of the psychiatric rating scales.
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5.2 Materials and Methods
5.2.1 Investigation of Biomarkers of Lipid Peroxidation in Breath
Exhalant from Schizophrenia Patients and Control Subjects
5.2.1.1 Ethical Approval and Recruitment of Participants
Ethical approval was obtained from the NHS Highland Ethics Committee and all
procedures were carried out in accordance with the Helsinki Declaration (1975) and
the Data Protection Act (1998). Schizophrenic patients and apparently healthy
controls were recruited from in- and out- patients and staff at the New Craigs
Hospital, Inverness and written informed consent obtained after a full explanation of
the study was given. All participants with schizophrenia were diagnosed according to
DSM-IV criteria (American Psychiatric Association, 1994). Patients with
schizophrenia were assessed using the Brief Psychiatric Rating Scale (BPRS)
(Overall and Gorham 1962) and the Positive and Negative Symptom Scale (PANSS)
(Kay et al 1987) (Table 5.3). The age of participants with schizophrenia did not
differ significantly from apparently healthy control subjects. Mean age ± sem were
36.6 ± 1.9 and 37.4 ± 3.2 in the healthy control and schizophrenic groups
respectively.
In each study (human trial part 1 and part 2) the volunteer sample size was small (ie.
the number of volunteers in the control and patient group was 17 or less). However,
the population recruited to our breath alkane study was comparable to those
employed in a previous study by our collaborators who reported a significant
elevation of breath ethane levels in their schizophrenic patient population (Glen et al
2003). Furthermore, our studies were exploratory since to date, there has been no
published data examining the investigation of various biomarkers of oxidative stress
in schizophrenia. Thus, at this stage, the results were not confirming any earlier or
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previously published work. Additional factors that had to be considered were cost
and resources. Funding was limited and had to be stretched over a 3-year research
period which meant as a consequence resources and time was also limited.
Subsequently, the smaller the sample size, the more manageable the tasks were.
Furthermore, although additional help was provided throughout the human studies,
large parts of the experimental work were completed solely by me. This meant that
in order to carry out the experiments within in a reasonable time and to ensure that
frozen samples were not held over a long time-frame to invalidate any result, it was
important that the sample size was manageable. Finally, it has been noted that
exploratory human trials have been undertaken and successfully published using
small sample sizes (Puri et al 2007). As a result, we felt that the sample size chosen
here was practical and acceptable.
5.2.1.2 Collection of Exhalants
All smokers were required to abstain from cigarette inhalation for at least 45 minutes
prior to collection of the exhalant sample. Exhalant samples were obtained from
seated subjects using a syringe system of volume 130ml equipped with a disposable
mouthpiece. The subject was instructed to exhale one long breath into the OSI
PanBag (Figure 5.1) until they could no longer breathe to collect the alveolar (end
expired) air from the lungs. Once sample collection was complete, the OSI PanBag
was sealed by means of a goggle clamp. Samples of ambient hydrocarbons were also
collected and analysed thus enabling a correction for high atmospheric backgrounds
to be introduced where appropriate.
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5.2.1.3 Storage of Exhalant Samples
Samples were stored for a maximum of 48 hours at ambient temperature prior to GC-
MS analysis.
5.2.1.4 Transfer of Breath Sample from OSI PanBag to ATD Tube
The OSI PanBag and contents were cooled rapidly to ensure that any moisture
present in the breath sample was effectively trapped in the OSI PanBag, reducing the
potential for interferents in the ATD tube. The OSI PanBag was immersed in dry ice
with the exit tube remaining above the ice level (Figure 5.2). A glass syringe fitted
with a stopcock was attached to the exit pipe of the PanBag via a PTFE connector.
Both the goggle clamp on the PanBag and the exit valve on the syringe were opened
and 100 ml sample was drawn from the PanBag into the syringe. The syringe was
then closed and inserted into the ribbed end of the ATD tube. The stopcock of the
syringe was opened and 100ml sample injected into the tube.
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Figure 5.1: Illustration of OSI PanBag
Figure 5.1. Illustration of OSI PanBag
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Procedure
 PanBag is covered in dry ice, for approximately 20 minutes, with exit tube remaining above ice
level.
 Syringe is attached to exit pipe of PanBag with PTFE connector.
 Ensure that stopcock at end of syringe is closed.
 A goggle clamp on PanBag is opened along with turn valve on syringe.
 100ml volume of sample is removed and the turn valve on the syringe is closed.
 A goggle clamp is now closed and the syringe can now be detached from the PanBag.
 Syringe is inserted to ribbed end of ATD tube.
 Stopcock of syringe is opened and 100ml sample injected into tube.
Figure 5.2: Process of breath transfer from OSI PanBag to glass syringe
5.2.1.5 Determination of Exhalants by GC-MS/ATD Analysis
The measured volume of expelled air was injected into a Perkin-Elmer (UK)
automatic thermal desorption (ATD) tube packed with carbotrap 300 (Perkin-Elmer,
UK) via a sodium sulphate drying cartridge (International Sorbent Technology Ltd.,
UK). Gas samples were analysed using a Perkin-Elmer autosystem XL equipped
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with a Turbo Mass spectrometer and ATD 400 automatic thermal desorption. ATD
tubes were desorbed onto the cold trap at 320oC, the cold trap being held at 5oC. The
trap was then rapidly heated to 350oC and the liberated volatiles injected onto a 30m
x 0.32mm PLOT GQ column (Perkin-Elmer, UK) with helium at 2ml/min. The
oven was set at 45oC for 3min and ramped at 14oC per minute to 200oC where it was
held for 8min, yielding an analysis time of 22.07min.
5.2.1.6 Mass Spectrometer Conditions
The mass spectrometer was operated in EI mode with data collection enabled from
0.02 seconds to 18 minutes. Selected ion response (SIR) was included in the method
to enable detection and identification of the analytes of interest. The timed windows
for ion monitoring were as follows:
Time period SIR/mass (Da)
0.02sec – 5min 30.00 for ethane
6.30min – 13.00min 67.00 for isoprene
6.30min – 13.00min 57.00 for pentane
5.2.1.7 Quantification
Quantification was by reference to calibration curves (0-60pmol) constructed using
an authentic C1-C6 alkane standard mix (Supelco, UK).
5.2.1.8 Statistical Analysis
Statistical Analysis was carried out using Minitab. As anticipated there was
significant inter-individual variation in the profile and level of ethane and pentane
noted in the exhalant samples of trial participants. Both datasets are not normally
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distributed, failing the Anderson Darling tests. Lack of normality implied that non-
parametric tests, comparing median levels for patient and control groups, were
appropriate and statistical significance was therefore tested by Mann-Whitney tests.
5.2.1.9 Determination of Total Plasma Malondialdehyde
The method is a modification of Grotto et al (2007) which has been validated
internally and enables the determination of total plasma MDA with quantification by
both mass spectrometric and diode array detection. Free malondialdehyde was
prepared fresh by the acid hydrolysis of 1,1,3,3 tetramethoxypropane and a series of
10 calibrants over the range of 3 to 30µM employed in the calibration line. Plasma
MDA determinations were performed in replicate (n=5) using 0.1ml aliquots of
sample. Alkaline hydrolysis and protein precipitation enabled the determination of
total MDA measured as a conjugate of thiobarbituric acid (Grotto et al 2007).
5.2.1.10 Determination of MDA by HPLC with Diode Array and MS
Detection
An Agilent Technologies 6130 Quadrupole LC-MS was employed which had an
auto-sampler and on-line diode array detection. Separation was achieved on a
Phenomenex Hyperclone BDS C18 column (150 x 2mm, 3µm) with a 15%
acetonitrile: 85% formic acid (0.1 % v/v) mobile phase at a flow rate of 0.25ml/min.
The column oven was held at 35oC and an injection volume of 50µl used.
The diode array detector was set at 532nm (λmax for TBA-MDA conjugate) and
spectra were measured over a range of 500 to 580nm. The MS detector was set to
measure in the negative mode and used a scan over the mass range of 300 – 350amu.
Single ion monitoring was set at 323amu (characteristic of TBA-MDA conjugate).
Analysis of an MDA calibration standard produced a single peak by LC-UV with a
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typical retention time of 2.31 minutes. Linearity was established over the range of 3
– 30mM MDA and fresh calibration lines were prepared and analyzed daily.
5.2.1.11 Statistical Analysis
The Kolmogorov-Smirnof test was used to test the normality of the data and the
Mann-Whitney test was carried out as appropriate using SPSS 11.5 for Windows.
For statistical analysis, a level of 0.05 was used to determine significance.
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5.3 Results
5.3.1 Validation of GC-MS Assay
5.3.1.1 Analyte Resolution and Identification
Method development and validation included an optimization of chromatographic
conditions to ensure the resolution of key analytes and an assessment of assay
linearity, sensitivity and specificity.
Figure 5.3 depicts typical chromatograms illustrating the resolution of the volatile
hydrocarbons when analysed in a standard mix. Peak assignation resulted from a
consideration of the fragmentation patterns under each chromatographic peak.
Ethane eluted at 1.49min and was identified at m/z 30 (Figure 5.3), butane eluted at
7.3min and was identified at m/z 43 (Figure 5.3) whilst pentane eluted at 9.7min and
was identified at m/z 43 (Figure 5.3). The resolution of isoprene (Rt = 9.77min), m/z
67 (Figure 5.3) from pentane (Rt = 9.70min) is not achieved in this method but by
using selection ion monitoring it is possible to accurately quantify pentane in the
presence of isoprene. The associated mass fragmentation patterns for ethane, butane,
pentane and isoprene are depicted in Figures 5.4a-5.4d respectively. By employing
on-line mass spectrometric analysis the specificity of the assay for each of the
analytes of interest is ensured.
5.3.1.2 Linearity of Alkane Determination
Quantification was by reference to calibration curves (0-60pmol) constructed using
an authentic C1-C6 alkane standard mix (Supelco, UK). Typical calibration lines for
ethane, butane, pentane and isoprene are depicted in Figures 5.5-5.8 respectively and
a summary of the regression equations and correlation coefficients is presented in
Table 5.1.
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A high measure of linearity was noted in all calibration analyses with a mean
correlation coefficient of the order of 0.9974 (n=18) and a mean precision of 0.33%
(%CV, n=18) being obtained (Table 5.1). There was significant inter-day variation in
the assay response for each of the analytes with % coefficients of variation ranging
(% CV) from 25.9 % for ethane (n=6) to 126.9% for butane (n=6). Such between
day variations in detector response is corrected for by the inclusion of a range of
calibration standards in each chromatographic run.
Figure 5.3: Chromatograms illustrating the gas chromatographic separation of ethane, propane butane,
pentane and isoprene following analysis of a standard mix.
Butane Rt = 7.30 min
Pentane Rt = 9.70
Isoprene Rt = 9.77
Total ion
chr matogram
Ethane Rt = 1.49 min
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Linearity of Alkane Determination
Quantification was by reference to calibration curves (0-60 pmol) constructed using
an authentic C1-C6 alkane standard mix (Supelco, UK).
Typical calibration lines for ethane, butane, pentane and isoprene are depicted in
Figures 4-7 respectively and a summary of the regression equations and correlation
coefficients is presented in Table 1. A high measure of linearity was noted in all
calibration analyses with a mean correlation coefficient of the order of 0.9974 (n=18)
and a mean precision of 0.33% (%CV, n=18) being obtained (Table 1). There was
significant inter-day variation in the assay response for each of the analytes with %
coefficients of variation ranging (% CV) from 25.6 % for ethane (n=6) to 126.9% for
butane (n=6). Such between day variations in detector response is corrected for by
the inclusion of a range of calibration standards in each chromatographic run.
Figure 5.4a: Typical mass fragmentation pattern for ethane. Ethane (C2H6, Mr=30) was the
predominant chromatographic peak in the range of 1.00-2.00 minutes and was identified by the
presence of m/z = 30.
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Figure 5.4b. Typical mass fragmentation pattern for butane. Butane (C4H10, Mr=58) was the
predominant chromatographic peak in the range of 7.0-8.2 minutes and was identified by the presence
of m/z=58.
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Figure 5.4c. Typical mass fragmentation pattern for pentane. Pentane (C5H12, Mr = 72) was the
predominant chromatographic peak in the range of 9.00 – 11.00 minutes and was identified by the
presence of m/z = 72.
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Figure 5.4d. Typical mass fragmentation pattern isoprene. Isoprene (C5H8, Mr = 68) was the
predominant chromatographic peak in the range of 9.0 – 11.0 minutes and was identified by the
presence of m/z = 67.
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Figure 5.5. Typical calibration line for the determination of ethane by GC-MS. The linearity of assay
response to ethane was determined by GC-MS analysis of a series of ethane calibrants (n=3).
Calibration lines were included in the analysis of every batch of trial samples.
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Figure 5.6. Typical calibration line for the determination of butane by GC-MS. The linearity of assay
response to butane was determined by GC-MS analysis of a series of butane calibrants (n=3).
Calibration lines were included in the analysis of every batch of trial samples.
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Figure 5.7. Typical calibration line for the determination of pentane by GC-MS. The linearity of assay
response to pentane was determined by GC-MS analysis of a series of pentane calibrants (n= 4).
Calibration lines were included in the analysis of every batch of trial samples.
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Figure 5.8. Typical calibration line for the determination of isoprene by GC-MS. The linearity of
assay response to isoprene was determined by GC-MS analysis of a series of isoprene calibrants
(n=4). Calibration lines were included in the analysis of every batch of trial samples.
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Analyte Regression Equation Correlation Coefficient
ETHANE y = 75.21x 0.9998
y = 41.946x 0.9996
y = 70.374x 0.9972
y = 56.181x 0.9941
y = 56.513x 0.9942
y = 38.653x 0.9933
Mean gradient 56.48 0.9964
%RSD (n=6) 25.9% 0.29%
BUTANE y = 565.54x 0.9996
y = 297.96x 0.9991
y = 539.95x 0.9992
y = 3229.6x 0.9984
y = 486.08x 0.9995
y = 298.3x 0.9966
Mean gradient 902.88 0.9987
%RSD (n=6) 126.9% 0.11%
PENTANE y = 469.13x 0.9879
y = 209.28x 0.9994
y = 405.98x 0.9985
y = 322.33x 0.9977
y = 373.74x 0.9990
y = 212.19x 0.9998
Mean gradient 332.11 0.9970
%RSD (n=6) 31.7% 0.48%
Table 5.1. Statistical summary of precision of assay response and assay linearity following GC-MS
analysis of a series of ethane, butane and pentane calibrations standards. Summary of typical between
day variation in the regression equation and correlation coefficients obtained following the GC-MS
analysis of a series of ethane, butane and pentane calibration standards.
5.3.1.3 Assay Sensitivity
The limits of detection for ethane, butane and pentane were determined to be
0.02ppb. In the adult population, the 95% reference range for breath ethane levels
using this technique is from 0.05 to 2.1 parts per billion (n=70 subjects) (Glen et al
2003).
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5.3.2 Clinical Rating Scales (PANSS, BPRS)
Clinical rating scales, as assessed by a psychiatric nurse, using PANSS and BPRS
questionnaires were carried out with the consent of all participating volunteer
schizophrenia patients resident at New Craig’s Hospital. The findings are detailed in
Table 5.2. (Note: there are more BPRS results than patient breath samples as some
breath samples were not able to be analysed post collection).
Volunteer Positive Symptoms Negative
Symptoms
General
Psychopathology
BPRS
1 9 13 24 8
2 NA NA NA NA
3 25 14 43 32
4 15 19 32 19
5 18 24 38 25
6 26 28 47 32
7 27 15 23 32
8 27 17 40 32
10 26 23 45 25
12 21 24 46 32
13 28 29 50 37
14 19 21 56 34
15 25 19 43 26
16 26 20 56 36
17-21 NA NA NA NA
22 22 17 41 23
23-29 NA NA NA NA
30 25 33 48 35
31-33 NA NA NA NA
34 30 27 24 39
37-38 NA NA NA NA
38 27 27 56 38
39 34 38 24 48
41 30 27 53 40
43-44 NA NA NA NA
46 29 15 49 45
47-48 NA NA NA NA
49 15 16 41 33
50 30 35 67 52
51-52 NA NA NA NA
53 24 28 64 44
55 NA NA NA NA
56 24 22 47 35
57 22 12 35 22
Total 604 563 1092 824
Mean 24.16 22.52 43.68 32.96
Standard Dev 6.51 7.05 12.03 9.61
Table 5.2: Clinical rating scales (PANSS, general psychopathology and BPRS) of all volunteer
subjects. NA = not applicable.
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Statistical analysis of PANSS and BPRS clinical ratings with breath and blood
biochemical variables, ie ethane, pentane and total plasma MDA was undertaken
(Table 5.3) and Pearson’s correlation coefficient was determined. Using this test, r
gives a measure of the strength of the relationship of the variables under examination
(r =1 for a perfect straight line with upward slope, r = -1 for a perfect straight line
with a downward slope). The results show that there is no correlation between the
psychiatric clinic rating scales with the biochemical variables (Figure 5.9).
Correlations
1 .537** .214 .771** .197 -.221 .299
.006 .305 .000 .482 .490 .278
25 25 25 25 15 12 15
.537** 1 .319 .637** -.026 .005 .402
.006 .120 .001 .928 .987 .137
25 25 25 25 15 12 15
.214 .319 1 .493* .022 .080 .139
.305 .120 .012 .938 .806 .622
25 25 25 25 15 12 15
.771** .637** .493* 1 .092 -.241 .491
.000 .001 .012 .744 .450 .063
25 25 25 25 15 12 15
.197 -.026 .022 .092 1 -.012 .096
.482 .928 .938 .744 .956 .634
15 15 15 15 27 23 27
-.221 .005 .080 -.241 -.012 1 -.371
.490 .987 .806 .450 .956 .082
12 12 12 12 23 23 23
.299 .402 .139 .491 .096 -.371 1
.278 .137 .622 .063 .634 .082
15 15 15 15 27 23 27
Pearson Correlation
Sig. (2-tailed)
N
Pearson Correlation
Sig. (2-tailed)
N
Pearson Correlation
Sig. (2-tailed)
N
Pearson Correlation
Sig. (2-tailed)
N
Pearson Correlation
Sig. (2-tailed)
N
Pearson Correlation
Sig. (2-tailed)
N
Pearson Correlation
Sig. (2-tailed)
N
Positive Symptoms
Negative Symptoms
General Psychopathology
BPRS
Ethane
Pentane
Mean Total Plasma MDA
(mM)
Positive
Symptoms
Negative
Symptoms
General
Psychopa
thology BPRS Ethane Pentane
Mean Total
Plasma
MDA (mM)
Correlation is significant at the 0.01 level (2-tailed).**.
Correlation is significant at the 0.05 level (2-tailed).*.
Table 5.3. Statistical analysis using Pearson’s correlation coefficient r, to determine correlation with
the findings of the clinical rating scales and the biochemical variables.
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Figure 5.9. Scatter diagram detailing the random, non-linear relationship (correlation = 0.197,
significance = 0.482) between the biochemical variable (ethane) with the findings from the rating
scales (positive symptoms) of the patients with schizophrenia as determined by assessment using the
PANSS questionnaire.
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5.3.3 Determination of Breath Volatiles in Patient and Control Samples
This validated method was used to determine the level of exhalants in samples from
trial participants. Tentative identification was made on comparison of Retention
times (Rts) between calibration standards and participant samples, with definitive
peak identity being assigned upon consideration of the fragmentation pattern and
presence of the characteristic m/z of the characteristic ion.
5.3.3.1 Breath Exhalants
Figures 5.10/11 shows dotplots for the ethane groups and pentane groups, revealing
the existence of some extreme levels in the patient groups.
Data
3.53.02.52.01.51.00.50.0
Ethane_Patient
Ethane_Control
Dotplot of Ethane_Patient, Ethane_Control
Median data:
Ethane_Patient (n=15) 0.250
Ethane_Control (n=14) 0.120
Figure 5.10. The dotplot shows mostly similar levels of ethane in both patient and controls groups
with the exception of 3 patients who have ethane levels in excess of 1.5 and one patient reaching a
level of 3.64.
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Data
1.261.080.900.720.540.360.180.00
Pentane_Patient
Pentane_Control
Dotplot of Pentane_Patient, Pentane_Control
Median
Pentane_Patient (n=12) 0.0480
Pentane_Control (n=13) 0.080
Figure 5.11. The dotplot reveals similar levels of pentane between the patient and control groups with
the exception of 5 patients who show pentane levels in excess of 0.16. One patient has a pentane level
of 0.54 and another at 1.28.
In conclusion, there was marginal evidence (P = 0.0840) that patients have a higher
median level of ethane than the control group. There is no evidence of any difference
in medians for pentane levels (P = 0.4458). However, for both ethane and pentane
there are incidences of much higher levels for certain individuals in the patient
groups.
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5.3.4 Determination of Total Plasma Malondialdehyde in Patient and
Control Samples
Patient and control total plasma MDA levels were measured utilising the TBARs
assay and HPLC and the results are illustrated in Figure 5.12. Results of the Mann-
Whitney test reveal that the level of MDA is similar between the patients and
controls and therefore no statistical significant difference in the MDA levels can be
seen between the two groups.
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Figure 5.12. Investigation of total plasma MDA production in human schizophrenic patients (n=15)
and control (n=14) samples as measured by TBARs and HPLC. Values are expressed as mean ±
standard deviation of 5 assay replicates.
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5.3.5 Comparison of Ethane, Pentane and Total Plasma
Malondialdehyde in Male and Female Patient Samples
Levels of ethane, pentane and total plasma MDA were compared in the male and
female patient samples (Figure 5.13). Although not statistically significant, on
average, a higher level of ethane and MDA was detected in the male group than the
female patient group. However, a comparison of the pentane levels in the two groups
revealed that the female patient group had a higher average pentane level than the
male patient group but again the results were not statistically significant.
Figure 5.13. Evaluation of ethane and pentane levels measured by GC-MS and MDA levels measured
by TBARs and HPLC in the patient male (n=12) and female (n=3) groups. Values are expressed as
mean ± sem of 5 replicates.
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5.4 Discussion
5.4.1 Breath Analysis
Breath analysis is a non-invasive and easy to use method to assess lipid peroxidation.
In the first part of the human trial undertaken during this project, the level of breath
hydrocarbons measured by gas chromatography-mass spectrometry (GC-MS) was
compared in schizophrenic and control subjects. Although there were incidences of
higher levels of both ethane and pentane in the patient group, suggesting that these
individuals may be subjected to greater oxidative stress and hence greater levels of
lipid peroxidation than individuals in the control group, no significant difference was
found between the levels of ethane and pentane in the breath from the schizophrenic
patients and control samples on the whole. In addition, plasma MDA levels were
evaluated in the schizophrenic patients and controls but again there was no
significant difference in the levels of plasma MDA between the two groups. Further
analysis of the breath and MDA data from the schizophrenic group alone was
undertaken to determine any gender differences and although ethane levels and
MDA levels were higher in the male schizophrenic samples the data was not
statistically significant. Only the pentane levels were higher in the female
schizophrenic samples when compared to the male samples but these were not
significantly greater. The lack of significance may be as a result of the small sample
sizes, although it is possible that there is just no definite difference in the levels of
oxidative stress between the two groups. However, any future work that may be
carried out would probably benefit from larger sample sizes.
During the lipid peroxidation chain reaction process, saturated hydrocarbons such as
ethane and pentane are eventually formed from the -3 and -6 fatty acids along
with aldehydes such as MDA and in vitro studies have shown that ethane and
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pentane are generated when cell cultures are exposed to ROS (reviewed by Miekisch
et al 2004). As stable end products of lipid peroxidation, hydrocarbons show low
solubility in blood and are excreted into the breath minutes following their formation
in tissues and exhaled concentrations of ethane and pentane therefore can be used to
monitor the degree of oxidative stress within the body (Risby and Sehnert 1999).
Animal and clinical studies have also reported close correlation between clinical
conditions where high levels of lipid peroxidation or inflammation occur and the
exhalation of ethane and pentane generated through ROS attack on lipid membrane
structures (Aghdassi et al 2000) while the same authors have also shown that levels
of exhaled pentane and ethane correlate well with other markers of lipid peroxidation
including MDA and TBARs (Aghdassi et al 2003). Although the comparison was
made, we were unable to demonstrate a correlation between the two different
methods of determining lipid peroxidation or plasma MDA levels, or any correlation
between these variables and the clinical rating scales. Furthermore, we did not
observe any differences in the mean population levels of breath hydrocarbons or
MDA between the patient and control group.
As mentioned earlier incidences of higher levels of ethane and pentane were noted in
the patient group, however, only one patient had an ethane level falling outside the
95% reference range for breath ethane levels as determined by Glen et al 2003. Why
this patient appears to produce higher levels of breath ethane is unknown. Volatile
organic compounds (VOCs) such as ethane and pentane may be produced
endogenously ie in the body or they may be exogenously generated ie absorbed as
contaminants from the environment. Furthermore, the composition of VOCs in
breath varies hugely between individuals both qualitatively and quantitatively (Cao
and Duan 2006). Increased levels of oxidative stress might be a cause and perhaps
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the type of medication that the patient is receiving may also be a factor. Gama et al
(2006) recently reported serum TBARs to be significantly higher in patients
receiving clozapine than those under haloperidol treatment although it is possible
that the increase in TBARs levels may be as a result of the course of the disease
rather than the medication, as may be the case with our patient.
Markers of oxidative stress have been reported in the breath of patients with
schizophrenia by Phillips et al (1993), and Glen et al (2003). Breath analysis is also
being used more commonly to determine oxidative stress and inflammation in a
variety of diseases such as asthma (Paredi et al 2000), lung diseases (Kanoh et al
2005) and Crohn’s disease (Aghdassi et al 2003) where increased levels of both
ethane and pentane have been reported and the method is receiving support as a non-
invasive method of determining lipid peroxidation. But if the technique is such an
easy one to use, why is it not even more commonplace in clinical practice? It would
seem that there are some obstacles, mainly technical problems. Yet, there appears to
be some improvement of these problems since development and technical progress is
being made which will enable improved and simplified analytical techniques being
utilised for routine use in the future (Miekisch et al 2004). There are however, a
number of advantages of using breath analysis over the existing serum and urine
analytical techniques such as i) breath samples closely reflect the arterial
concentrations of biological substances and may help to prevent the more difficult
collection of arterial blood samples; ii) breath is a less complicated mixture than
serum or urine and a complete analysis of all its compounds is possible; iii) breath
analysis provides direct information on respiratory function that is not obtainable by
other means and iv) it is easy to use and non-invasive (reviewed by Cao and Duan
2006).
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5.4.2 Thiobarbituric Acid Reactive Substances
The measurement of MDA by the TBARs method is widely debated but although it
has its pitfalls, it is still one of the most commonly reported indices of oxidative
damage. Plasma MDA levels have been found to be elevated in patients with
schizophrenia when compared to normal controls (Zhang et al 2007; Medina-
Hernandez et al 2007; Gama et al 2006; Zhang et al 2006; Khan et al 2002; Kuloglu
et al 2002), while only one recent study (Skinner et al 2005) reported lower levels of
MDA measured by TBARs in CSF from schizophrenic patients compared to
controls. These are in contrast to our study which has shown no difference in the
level of plasma MDA from schizophrenic patients compared to controls, although
the MDA levels in our volunteers appear to be much higher than the reported normal
ranges of <1.0 micromol/litre as reported by Kropp et al 2005. Nevertheless, these
results are similar to our earlier findings (Young et al 2007) where we reported no
significant difference in the levels of MDA and hydroxyalkenals in cryopreserved
plasma samples from control and schizophrenic samples. Furthermore, between sex
comparisons of the level of plasma MDA and hydroxynonenal from control and
schizophrenic patients also revealed no statistically significant difference (Young et
al 2007).
Whilst a few studies have reported evidence of elevated TBARs in drug naïve
patients (Skinner et al 2005; Arvindakshan et al 2003) most studies reporting an
increase in TBARs have focused on schizophrenic patients treated with typical
neuroleptic (eg haloperidol) regimes (Gama et al 2006; Kropp et al 2005). In our
study, patients were treated with a range of psychotropic agents, both typical and
atypical neuroleptics. Parikh et al (2003) reported an increase in lipid peroxidation in
the brains of rats chronically treated with haloperidol but not in animals chronically
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treated with risperidone, olanzapine or clozapine, while Kropp et al (2005) observed
MDA levels in schizophrenic patients receiving clozapine, quetiapine, amisulpride
and risperidone were significantly lower than those group of patients treated with
first generation (typical) antipsychotics. In contrast, Gama et al (2006) found that
serum TBARs was significantly higher (p = 0.008) in schizophrenic patients treated
with clozapine than those treated with haloperidol. Thus the effects of neuroleptic
treatment are unclear, effects of species and tissue further confound the field and
essentially further investigations are required, the design of which should be
sufficiently large as to enable a detailed examination of treatment effects on a profile
of oxidative indices.
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6.1 Introduction
Oxidative stress occurs when there is disequilibrium between pro-oxidant processes
and the antioxidant defence system in favour of the former. Oxidative stress often
occurs as a result of increased production of free radicals, or even when the
antioxidant defence system is ineffective or a combination of both events and will
lead to a free radical attack of protein, DNA and lipids. Direct measurement of
reactive species and free radicals is impractical because they are short-lived, due to
their highly reactive nature. Thus, biomarkers have been used to reflect the degree of
oxidative damage in light of a particular clinical or research interest ie. disease or
disorder state (Peoples and Karnes 2005).
6.1.1 Biomarkers
A biomarker enables the identification of a modified biological molecule and
provides understanding of the nature of the denaturing radical along with the location
of oxidative damage. As highly sensitive markers of oxidative damage in
mammalian systems, biomarkers may provide information on three progressive
levels to disease outcome: a) as measurable endpoints of oxidative damage to
proteins, amino acids, oxidised lipids, oxidised DNA bases; b) as functional markers
of blood flow, platelet aggregation, or cognitive function, for example and c) as
endpoints related to a specific disease (Griffiths et al 2002). Although clinical
symptoms are considered to be endpoints of an illness, they are often inappropriate
for early detection and disease prevention. Increasing evidence supports the view
that a number of neuropathological changes seen in schizophrenia may be the result
of increased free radical-mediate or ROS mediated neuronal injury (Mahadik and
Mukherjee 1996).
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6.1.2 Lipid Biomarkers
The process of lipid peroxidation includes oxidative chain reactions of fatty acids
where several measurable products may be produced and numerous lipid
peroxidation biomarkers exist in the majority of human diseases. The peroxidation of
PUFAs may be monitored in a number of ways including determination of lipid
peroxides (Chamblee et al 2000), determination of aldehydic end products such as
MDA and 4-HNE (Boyle et al 2000; Claeson et al 2001), determination of volatile
hydrocarbons and by determination of isoprostanes (Morrow et al 1990; Boyle et al
2000). The prostaglandin-like isoprostanes are thought to be specific markers of lipid
peroxidation since their production is non-enzymatic. F2-isoprostanes formed from
the peroxidation of arachidonic acid, have represented the bulk of isoprostane
research. Recently there has been a greater focus on F4-neuroprostanes which
originate from peroxidation of docosahexaenoic acid, the major fatty acid in the
brain (Reich et al 2000). F4-neuroprostanes may therefore reflect oxidative injury to
nervous system tissue (reviewed by Peoples and Karnes 2005).
6.1.3 Protein Biomarkers
The measurement of protein markers as indicators of oxidative stress may involve
several products due to the fact that there are 20 amino acids available for oxidative
attack. Oxidatively modified proteins that result in new functional groups such as
hydroxyls and carbonyls are not repaired and must be removed by proteolytic
degradation. Amino acids capable of delocalising charge such as those containing
aromatic and thiol side chains are more open to oxidative attack and numerous
aliphatic residues are also the focus of oxidation resulting in the generation of
protein carbonyl moieties (Griffiths et al 2002). Ultimately therefore, a decrease in
the efficiency of proteolysis will lead to an increase in the cellular content of
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oxidatively modified proteins (Stadtman and Levine 2000). The level of modified
molecules can be quantitated in a variety of ways, for example by the measurement
of the protein carbonyl content of an ELISA (Buss et al 1997). Elevated markers of
protein oxidation have been associated with diseases such as Alzheimer’s disease,
Parkinson’s disease, Duchenne muscular dystrophy, amoytrophic lateral sclerosis,
rheumatoid arthritis and progeria (Mayne 2003).
6.1.4 DNA Biomarkers
Oxygen and ROS have been shown to induce many types of DNA damage. ROS (ie.
hydroxyl radical) can alter the deoxyribose-phosphate backbone, cause DNA-protein
cross-links and modify both purine and pyrimidine bases. It has been suggested that
approximately 2 x 104 DNA damaging events occur in every cell of the human body
every day (Foray et al 2003) with a significant proportion of the damage occurring as
a result of ROS. Although at physiological levels ROS play a key role in regulating
signalling pathways and gene expression (Durocher and Jackson 2001), excessive
insult to the cell can be fatal. Repair of oxidized DNA in vivo is accomplished by
glycosylases (bases) and endonucleases (deoxynucleotides) (Figure 6.1).
Nevertheless, some of these modified DNA bases have considerable potential to
damage the integrity of the genome. Guanine most readily undergoes oxidative
attack, possessing the lowest oxidation potential of the four bases (Peoples and
Karnes 2005). Consequently, the nucleoside 8-oxo-2’deoxyguanosine (8-OHdG) is
one of the most critical lesions and most studied biomarker of oxidative damage (Wu
et al 2004).
Evidence has indicated that urinary 8-OHdG not only is a biomarker of generalized,
cellular oxidative stress but might also be a risk factor for illnesses such as cancer,
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atherosclerosis and diabetes. For example, elevated level of urinary 8-OHdG has
been detected in patients with various cancers (Kuo et al 2007; Wada et al 2006).
Elevated urinary 8-OHdG and leukocyte DNA have also been detected in diabetic
patients with hyperglycaemia, with the level of urinary 8-OHdG in diabetes
correlating with the severity of diabetic nephropathy and retinopathy (Wu et al
2004). Upon DNA repair, 8-OHdG is excreted in the urine; however, unless repaired
prior to DNA replication, 8-oxo-2’deoxyguanosine residues can result in base pair
transversions (Griffiths et al 2002) (Figure 6.1). Rydberg and Johanson (1978) were
the first to attempt to quantify DNA strand breaks while Ostling and Johanson
(1984) further developed a microelectrophorectic technique, the SCGE assay or
comet assay.
Figure 6.1. Pathway of commonly measured biomarkers of oxidative stress (adapted from Peoples and
Karnes 2005).
Free radicals/ROS
DNA
Oxidised guanineRepair
No repair
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6.1.5 Oxidative Stress in Schizophrenia
Although the aetiology of schizophrenia remains unknown, investigation of the
effects of oxidative stress in schizophrenia has largely focused on the determination
of lipid oxidation products (Scottish Schizophrenia Research Group 2000; Khan et al
2002). So far, studies of oxidative injury in schizophrenia have focused on
membrane lipids with relatively little information available on oxidative damage to
cellular proteins and DNA. To date, only one study has examined the effects of
oxidative insult on the cellular DNA of a Greek sample of male schizophrenic
patients and controls (Psimadas et al 2004). The authors did not observe any
difference in basal levels of DNA damage between schizophrenic and normal
populations in cryopreserved cells. However, the research reported here is the first to
investigate the effects of oxidative stress, on the level of DNA damage in peripheral
blood lymphocytes, in a British population. Previous work has noted a disparity in
erythrocyte PUFA stability when stored at -20oC (Fox et al 2003). Consequently, the
research reported here determined the level of DNA damage in both fresh and
cryopreserved lymphocyte samples.
The main aim of this study therefore, was to try to ascertain whether schizophrenic
subjects exhibit enhanced levels of oxidative stress as indicated by changes in a
profile of biomarkers compared to healthy matched controls. Equally importantly,
the effects of diet on schizophrenia outcome has recently been addressed (Peet 2004)
and since there are clear differences between the habitual diet of a Greek and British
population, the research sought to examine the effects of disease state on the levels
of endogenous and H2O2-induced DNA damage and plasma vitamin C levels in an
indigenous British population.
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6.2 Materials and Methods
6.2.1 Examination of Biomarkers of DNA Oxidation in Peripheral
Blood Lymphocytes from Schizophrenia Patients and Control
Subjects
6.2.1.1 Materials
Lymphoprep lymphocyte separation medium (LSM) (specific gravity 1.077 ±
0.001g/ml) was supplied by Robins Scientific (Solihull, UK). Dutch Modified RPMI
1640 medium was obtained from Sigma (Poole, UK). Heat-inactivated FCS was
obtained from Invitrogen (Paisley, UK). Microscope slides and cover glasses were
supplied from Fisher Scientific (Loughborough, UK). LMP and NMP agarose were
supplied by Gibco Life Technologies (Paisley, UK). DAPI was obtained from Sigma
(Poole, UK). Corning centrifuge tubes were supplied by Fisher Scientific
(Loughborough, UK). Vacutainers were obtained from Aberdeen Royal Infirmary,
(Aberdeen, UK).
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6.2.1.2 Study Design – Lymphocyte Collection, Storage and Analysis
Figure 6.2. Human study, study 1 and 2. Experimental design for lymphocyte collection, storage and
analysis of DNA damage.
6.2.1.3 Ethical Approval and Consent
Ethical approval was obtained from the LREC and all procedures were carried out in
accordance with the Helsinki Declaration (1975) and the Data Protection Act (1998).
Schizophrenic patients and apparently healthy controls were recruited and informed
consent obtained from ward patients and staff at the New Craigs Hospital, Inverness.
The trial protocol was reviewed by ward consultants at the hospital and participants
matched for age, gender and smoking status.
9 ml of venous blood
Isolate buffy coat by centrifugation
Isolate lymphocytes by centrifugation
Use freshly isolated
lymphocytes immediately
Count and freeze remaining
lymphocytes at -70oC
Study 2Study 1
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6.2.1.4 Subjects
Of the 32 volunteers (27 smokers and 5 non-smokers), the schizophrenic group
comprised 11 male and 4 female patients (average age 37.9 ± 11.0 years) and 12
male and 5 female healthy controls (average age 38.9 ± 9.2 years). Smoking habit
was assessed by a self-reported lifestyle questionnaire. There was a range of smokers
and non-smokers in the male and female populations with the maximum smoking
habit in each population being 30 cigarettes per day. This equated to an average
(self-reported) daily intake of cigarettes of 12 and 14 in the female and male
populations, respectively. No significant difference in the smoking habit of the
patient/control groups was noted and similarly there was no significant difference in
the smoking habit of male and female schizophrenic patients.
6.2.1.5 Drug Therapy
The schizophrenic group comprising 12 male and 4 female patients were on a range
of drug therapies which for the male patients included antipsychotics (n=3,
Zuclopenthioxol Decanoate; n=1 Haloperidol; n=1 Chlorpromazine), atypical
antipsychotics (n = 3 Clozapine; n = 4 Risperidone; n = 1 Olanzapine), SSRIs (n = 2
Fluoxetine), antianxiety/antipsychotic (n=1 Trifluoperazine), H2-receptor
antagonists (n=1 Cimetidine), b blockers (n=1 Lorazepam and Diazepam; n=1
Diazepam; n=1 Lorazepam) and antidepressant therapy (Venlafaxine XL). Whilst
the female patients were being treated with a range of drug therapies including
antipsychotics (n=2 Zuclopenthixol Decanoate), atypical antipsychotics (n=2
Quietapine), SSRIs (n=2 Fluoxetine), antianxiety/antipsychotic (n=2
Trifluoperazine), anxiolytics (n=1 Diazepam) and antimuscarinic therapy (n=1
Procyclidine).
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6.2.1.6 Isolation and Cryopreservation of Human Lymphocytes
Venous blood (1 x 9ml) was collected by venepuncture at the New Craigs Hospital.
The whole blood was centrifuged at 2400xg for 15min at 4oC, the buffy coat (~2ml)
removed and diluted 1:1 with RPMI. Samples were retained on ice until
transportation to the laboratory enabled the remainder of the separation procedure to
be completed. The buffy coat was layered onto an equal volume of LSM before
centrifuging at 700xg for 30min at 20oC. The lymphocytes were transferred to a
fresh centrifuge tube, washed using RPMI medium and spun for a further 15min
under the same conditions. The supernatant was decanted, the cells resuspended in
RPMI containing 10% heat-inactivated FCS and counted using a Neubauer
Improved Haemocytometer. Isolated lymphocytes were either used (or treated)
immediately (freshly isolated lymphocytes), (study 1, Figure 6.2) as described
previously or were centrifuged and resuspended in 0.5ml aliquots at 3x106 cells/ml
in freezing mix (90% v/v heat-inactivated FCS and 10% v/v DMSO), frozen at -
1oC/min in polystyrene and stored at -70oC (study 2, Figure 6.2).
6.2.1.7 Hydrogen Peroxide-induced DNA Strand Breakage in Fresh
Lymphocytes Measured Using the Comet Assay (Study 1)
Freshly isolated lymphocytes were incubated in microcentrifuge tubes with hydrogen
peroxide (H2O2) (50, 100 or 200M in phosphate-buffered saline (PBS) for 5min on
ice), washed and suspended in 140l of 1% (w/v) LMP agarose in PBS pH 7.4 at
37oC and immediately pipetted onto a glass microscope slide pre-coated with a layer
of 1% (w/v) NMP agarose prepared in distilled water. The agarose was allowed to
set for 5min at 4oC and the slides were incubated in lysis solution (2.5M NaCl,
10mM Tris, 100mM NA2EDTA, 10M NaOH to pH 10.0 and 1% v/v Triton X-100)
at 4oC for 1h to remove cellular proteins. After lysis, the slides were aligned in a
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210mm wide horizontal electrophoresis tank containing buffer (1mM NA2EDTA and
0.3M NaOH, pH 13.0) for 40min before electrophoresis at 21v for 30min (at an
ambient temperature of 4oC with the temperature of the running buffer not exceeding
15oC). The slides were washed three times at 4oC for 5min each with neutralizing
buffer (0.4M Tris-HCl, pH 7.5) before staining with 20l of DAPI (1g/ml).
6.2.1.8 Hydrogen Peroxide-induced DNA Strand Breakage in
Cryopreserved Lymphocytes (Study 2)
Lymphocytes cryopreserved for 5 and 12 weeks were thawed on ice until the last
trace of ice had disappeared. The aliquots were centrifuged at 200xg for 3min to
remove freezing mix and the lymphocyte pellet resuspended gently in 0.4ml of
RPMI + 10% (v/v) heat-inactivated FCS. 5 week cryopreserved lymphocytes were
washed once in PBS and incubated in microcentrifuge tubes H2O2 (10, 25, 50,
200M in PBS for 5min on ice). A change in the study design meant that 12 week
cryopreserved lymphocytes were washed once in PBS and incubated in
microcentrifuge tubes H2O2 (10, 25, 50M concentrations only, in PBS for 5min on
ice). The cells were resuspended immediately in LMP agarose for detection of DNA
strand breakage by Comet analysis.
6.2.1.9 Quantitation of the Comet Assay
Nucleoids were scored visually using a Leica fluorescence microscope. One hundred
comets from each gel (scored at random) were classified into one of five classes
according to the relative intensity of fluorescence in the tail and given a value of 0-4
(from undamaged, 0, to maximally damaged, 4). The total score for 100 comets can
range from 0 (all undamaged) to 400 (all maximally damaged) and is expressed in
arbitrary units. This method of visual classification has been extensively validated by
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comparison with comets selected using computerized image analysis. The slides
from Study 1 and Study 2 were blinded so that treatment groups could not be
identified.
6.2.1.10 Statistical Analysis
The Kolmogorov-Smirnof test, Student’s t-test and one-way ANOVA were carried
out as appropriate using SPSS 11.5 for Windows. For statistical analysis, a level of
0.05 was used to determine significance.
6.2.2 Investigation of Biomarkers of Protein Oxidation in Plasma from
Schizophrenia Patients and Control Subjects
6.2.2.1 Materials
Protein carbonyl ELISA kit components were supplied by Zenith Technology
(Dunedin, New Zealand) and contained: ELISA 96-well plate and sealing tape, EIA
buffer powder, blocking reagent, dinitrophenylhydrazine (DNP), guanidine
hydrochloride diluent, anti-DNP-biotin-antibody, streptavidin-horseradish-
peroxidase, chromatin reagent, stopping reagent, standards (5) and carbonyl control
samples (low, medium and high).
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6.2.2.2 Study Design – Plasma Collection, Storage and Analysis
Figure 6.3. Human study. Experimental design for plasma collection, storage and analysis of vitamin
C, protein carbonyls and lipid peroxides.
6.2.2.3 Collection and Storage of Human Plasma
Venous blood (1 x 9ml) was collected by venepuncture at the New Craigs Hospital.
The whole blood was centrifuged at 2400xg for 15min at 4oC and the plasma
(~1.5ml) was aliquotted into a microcentrifuge tube. From this aliquot, 50l of
plasma per tube was transferred into 3 microcentrifuge tubes and kept on dry ice
until samples were transported back to the lab and placed in storage at -80oC.
6.2.2.4 Pre-assay Preparation
Buffers and reagents were prepared as per protocol instructions. Plasma samples
were allowed to thaw at room temperature and centrifuged before use.
9 ml of venous blood
Isolate plasma by centrifugation
Vitamin C
Freeze at -80oC
1 x 600l plasma
+ 10% MPA
15 schizophrenic patients/17
matched controls
Protein Carbonyl
Freeze at -80oC
3 x 50l plasma
Lipid Peroxides
Freeze at -80oC
2 x 600l plasma
HPLC ELISA
LOOH Assay Kit MDA/HNE Assay Kit
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6.2.2.5 Sample Derivatisation with DNP
1.5ml microcentrifuge tubes were labelled as appropriate and 200l of diluted DNP-
solution was added to each tube. 5l of each sample, standard or control was added
to the appropriate tube and contents were mixed and incubated for 45min. A
complimentary set of 1.5ml microcentrifuge tubes for samples, standards and
controls were prepared and 1ml of EIA buffer was added to each tube. 5l of each
DNP-treated sample was added to the appropriate tube and mixed thoroughly.
6.2.2.6 ELISA Procedure
200l of each sample in EIA-buffer (plasma from schizophrenic or control subjects,
blinded to the examiner) was added into each of the assigned ELISA-plate wells,
covered with sealing tape and incubated for 2h at 37oC. Following incubation, the
plate was washed with EIA buffer (5 x approximately 300l per well). 250l of
diluted blocking solution was added per well and incubated for 30min at room
temperature. The plate was washed with EIA buffer as before. 200l of diluted anti-
DNP-biotin-antibody was added to each well and incubated for 1h at 37oC.
Following plate washing as before, 200l of diluted streptavidin-HRP was added to
each well and incubated for 1h at room temperature. The plate was washed for a final
time as before.
6.2.2.7 Colour Development and Measurement
Chromatin reagent (200l) was added to each well and the colour was left to develop
for 4-7min. The reaction was stopped by adding 100l of stopping reagent to each
well to ensure that all wells were exposed to the chromatin reagent for the same
amount of time. The plate was shaken gently to mix reagents and absorbance at
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450nm was read directly after the addition of the stopping reagent. All measurements
were performed in triplicate.
6.2.2.8 Statistical Analysis
The Kolmogorov-Smirnof test was used to examine the normality of the data and
non-parametric tests, ie. the Mann-Whitney and Kruskal-Wallis tests were carried
out as appropriate using SPSS 11.5 for Windows. For statistical analysis, a level of
0.05 was used to determine significance.
6.2.3 Investigation of Biomarkers of Lipid Peroxidation in Plasma
from Human Schizophrenic and Control Subjects
6.2.3.1 Materials
Lipid Peroxidation Assay Kit was supplied by EMD Biosciences Inc, La Jolla, CA,
USA and Lipid Peroxidation Assay Kit II was supplied by Calbiochem, San Diego,
CA, USA.
6.2.3.2 Collection and Preparation of Human Plasma
From the 1.5ml of collected plasma (section 6.2.2.1.3), 600l of plasma per tube was
aliquotted into 2 microcentrifuge tubes and kept on dry ice until samples were
transported back to the lab and placed in storage at -80oC.
6.2.3.3 Determination of Lipid Peroxidation in Cryopreserved Human
Plasma
MDA and HAE are end products derived from peroxidation of PUFA and related
esters. Measurement of such aldehydes provides a convenient index of lipid
peroxidation. The Calbiochem Lipid Peroxidation Assay Kit employs a chromogenic
reagent which reacts with MDA and HAE at 45oC. Condensation of one molecule of
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either MDA or HAE with 2 molecules of chromogenic reagent yields a stable
chromophore with maximal absorbance at 586nm. Lipid hydroperoxides were
measured using the Lipid Peroxidation Assay Kit II which utilises a simple direct
colorimetric measurement of lipid hydroperoxides measured by UV detection at
560nm.
6.2.3.4 Statistical Analysis
The Kolmogorov-Smirnof test was used to test the normality of the data. Student’s t-
test and one-way ANOVA was carried out as appropriate using SPSS 11.5 for
Windows. For statistical analysis, a level of 0.05 was used to determine significance.
6.2.4 Investigation of Vitamin C Content in Plasma from
Schizophrenic and Control Subjects
6.2.4.1 Collection and Preparation of Human Plasma
From the 1.5ml of collected plasma, 600l of plasma per tube was aliquotted into a
microcentrifuge tube and mixed with 10% w/v metaphosphoric acid (MPA).
Samples tubes were kept on dry ice until samples were transported back to the lab
and placed in storage at -80oC.
6.2.4.2 HPLC Analysis
Cryopreserved human schizophrenic and control subject plasma samples treated in
MPA were transported to Dr Garry Duthie, Molecular Nutrition Group, Rowett
Research Institute, Aberdeen, on ice. On arrival samples were transferred to -80oC
freezer for storage. Plasma samples were analysed by reverse-phase HPLC with UV
detection at 263nm (Boyle et al 2000).
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6.2.4.3 Statistical Analysis
The Kolmogorov-Smirnof test was used to test the normality of the data and
Student’s t-test was carried out as appropriate using SPSS 11.5 for Windows. For
statistical analysis, a level of 0.05 was used to determine significance.
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6.3 Results
6.3.1 Examination of Biomarkers of DNA Oxidation in Peripheral
Blood Lymphocytes from Schizophrenia Patients and Control
Subjects
Following 5 minutes treatment with H2O2 at concentrations of 0, 50 and 200M, the
mean extent of endogenous and H2O2-induced DNA damage in freshly isolated
lymphocytes was measured and compared in control and schizophrenic subjects.
There is a small difference in the extent of DNA damage between schizophrenics
and the control group (Figure 6.4), although not statistically significant.
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Figure 6.4 Study 1. Comparison of endogenous and H2O2-induced DNA damage in freshly isolated
lymphocytes from control subjects and schizophrenic patients. Levels of DNA damage measured with
the comet assay in freshly isolated control and schizophrenic lymphocytes following treatment with 0,
50 and 200M of H2O2. Data show the mean ± sem DNA damage of control (n=17) and
schizophrenic samples (n=15).
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Examination of endogenous and H2O2-induced DNA damage in the freshly isolated
lymphocytes of male and female schizophrenic patients, however, revealed
significantly greater (p <0.05) DNA damage in male than female patients in the
levels of both basal and H2O2-induced DNA damage (Figure 6.5).
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Figure 6.5 Study 1. Comparison of endogenous and H2O2-induced DNA damage in freshly isolated
lymphocytes of male and female schizophrenia patients. Levels of DNA damage measured with the
comet assay in freshly isolated male and female schizophrenic lymphocytes following treatment with
0, 50 and 200M of H2O2. Data show the mean ± sem DNA damage of male (n=11) and female (n=4)
schizophrenic samples. Significance is denoted by * where p <0.05.
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6.3.2 H2O2-induced DNA Strand Breakage in Cryopreserved
Lymphocytes from Control Subjects and Schizophrenia Patients
(Study 2)
Thawed cells were treated for 5 minutes with H2O2 at concentrations of 0, 10, 25, 50
and 200M. Endogenous and H2O2-induced DNA damage in cryopreserved
lymphocytes was measured and compared in the control and schizophrenic samples.
No significant difference was found between the levels of endogenous DNA damage
in the control and schizophrenic groups as illustrated in Figure 6.6. Similarly there
was no difference in the susceptibility of DNA damage from control or
schizophrenic subjects at each of the H2O2 concentrations examined (Figure 6.6).
Following statistical analysis using ANOVA, no significant differences were found
in levels of endogenous and H2O2-induced DNA damage in the male and female
schizophrenic patients’ cryopreserved lymphocytes (Figure 6.7). However, a
student’s t-test did reveal that after 5 weeks cryopreservation, the level of DNA
damage in 50m H2O2-induced cells was statistically significantly greater in males
than females (Figure 6.7).
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Figure 6.6 Study 2. Comparison of endogenous and H2O2-induced DNA damage in cryopreserved
lymphocytes from control subjects and schizophrenia patients. Levels of DNA damage measured with
the comet assay in cryopreserved lymphocytes from control subjects and schizophrenia patients
following treatment with 0, 10, 25, 50 and 200M of H2O2. Data show the mean ± sem DNA damage
of 16 control and 15 schizophrenic samples. Key: C 5wk = control lymphocytes cryopreserved for 5
weeks, S 5wk = schizophrenic lymphocytes cryopreserved for 5 weeks, C 12wk = control
lymphocytes cryopreserved for 12 weeks, S 12wk = schizophrenic lymphocytes cryopreserved for 12
weeks.
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Figure 6.7 Study 2. Comparison of endogenous and H2O2-induced DNA damage in cryopreserved
lymphocytes from male and female schizophrenia patients. Levels of DNA damage measured with the
comet assay in cryopreserved lymphocytes from male and female schizophrenia patients following
treatment with 0, 10, 25, 50 and 200M of H2O2. Data show the mean DNA damage of 11 male and 4
female samples ± sem. Key: M 5wk = male lymphocytes cryopreserved for 5 weeks, F 5wk = female
lymphocytes cryopreserved for 5 weeks, M 12wk = male lymphocytes cryopreserved for 12 weeks, F
12wk = female lymphocytes cryopreserved for 12 weeks. Significance is denoted by * where p <0.05.
6.3.3 Determination of Protein Carbonyl Levels in Plasma from
Control Subjects and Schizophrenia Patients
The ELISA method was used to detect levels of protein carbonyls in plasma from
control and patient subjects. A comparison of the level of protein oxidation in plasma
from the control and schizophrenic group revealed a slight increase in protein
carbonyl levels in the schizophrenic group. However, Mann-Whitney analysis
revealed that this increase in carbonyl levels in the schizophrenic group was not
statistically significant (Figure 6.8).
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Figure 6.8. Determination of protein oxidation in plasma from control subjects and schizophrenia
patients. Levels of protein carbonyls detected in human cryopreserved plasma from control (n=17)
and schizophrenic (n=12) subjects. Data shows mean ± sem. of protein carbonyl production from
triplicate samples as determined by ELISA.
Further analysis of the two test groups, specifically investigating any gender effect
reported an increase in carbonyl levels in both male groups when compared to the
female groups with a noticeable increase in plasma protein carbonyl levels from the
male schizophrenic group. Using the Kruskal-Wallis test, analysis of the samples
revealed that the observed increased levels of protein carbonyls in the male
schizophrenic group in particular, were not statistically significantly higher than any
other group (Figure 6.9).
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Figure 6.9. Determination of protein oxidation in plasma from control and schizophrenic male and
female subjects. Levels of protein carbonyls detected in human cryopreserved plasma from control
male (n=12), control female (n=5) and male schizophrenic (n=10) and female schizophrenic (n=2)
subjects. Data shows mean ± sem of protein carbonyl production from triplicate samples as
determined by ELISA.
6.3.4 Determination of Lipid Peroxidation in Plasma from Control
Subjects and Schizophrenia Patients
Cryopreserved human plasma samples were used to measure levels of lipid
hydroperoxides and a comparison in the levels of LOOH in duplicate samples were
investigated in the control and schizophrenic samples (Figure 6.10). Student’s t-test
revealed no statistically significant difference in the levels of LOOH between the
two groups under investigation. Comparison of the levels of plasma LOOH from
control and schizophrenic male and female subjects also revealed no statistically
significant difference (Figure 6.11).
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Figure 6.10. Comparison of lipid hydroperoxide levels in cryopreserved plasma from control subjects
and schizophrenia patients. Levels of plasma LOOH detected in human cryopreserved plasma from
control (n=17) and schizophrenic (n=16) subjects. Data shows mean ± sem of LOOH production from
duplicate samples as determined by LOOH assay.
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Figure 6.11. Comparison of lipid hydroperoxide levels in cryopreserved plasma from control and
schizophrenic male and female subjects. Levels of LOOH detected in human cryopreserved plasma
from control male (n=12), control female (n=5) and schizophrenic male (n=12) and schizophrenic
female (n=4) subjects. Data shows mean ± sem of LOOH production from duplicate samples as
determined by LOOH assay.
Levels of MDA and HNE were examined in cryopreserved plasma samples from the
control and schizophrenic samples (Figure 6.12). Student’s t-test revealed no
statistically significant difference in lipid peroxide levels between the control and
schizophrenic groups. Comparison of the levels of plasma MDA+HNE from control
and schizophrenic male and female subjects also revealed no statistically significant
difference (Figure 6.13).
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Figure 6.12. Comparison of MDA+HNE levels in cryopreserved plasma from control and
schizophrenic subjects. Levels of lipid peroxides detected in human cryopreserved plasma from
control (n=17) and schizophrenic subjects (n=16) Data shows mean ± sem of duplicate samples.
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Figure 6.13. Comparison of MDA+HNE levels in cryopreserved plasma from control and
schizophrenic male and female subjects. Levels of lipid peroxides detected in human cryopreserved
plasma from control male (n=12), control female (n=5) and schizophrenic male (n=12) and
schizophrenic female (n=4) subjects. Data shows mean ± sem of duplicate samples.
6.3.5 Determination of Vitamin C in Plasma from Control Subjects and
Schizophrenia Patients
A comparison of the level of vitamin C in plasma from the control and schizophrenic
groups was analysed by HPLC. Results show an increase in vitamin C levels in the
control group when compared to the schizophrenic group (Figure 6.14) although this
increase did not reach statistical significance.
Examination of the vitamin C levels from male and female plasma samples within
the two test groups reported a highly significant (p <0.01) increase in the level of
vitamin C in the control female group when compared to the male groups (Figure
6.15).
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Figure 6.14. Evaluation of vitamin C levels from plasma of control subjects and schizophrenia
patients. Levels of vitamin C detected in human cryopreserved plasma from control (n=17) and
schizophrenic (n=16) subjects. Data shows mean ± sem of vitamin C production from duplicate
samples as determined by HPLC.
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Figure 6.15. Evaluation of vitamin C levels from plasma of male and female control subjects and
schizophrenia patients. Levels of vitamin C detected in human cryopreserved plasma from control
male (n=12), control female (n=5) and schizophrenic male (n=12) and schizophrenic female (n=4)
subjects. Data shows mean ± s.d. of vitamin C production from duplicate samples as determined by
HPLC. Significance is denoted by ** where p <0.01.
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6.4 Discussion
Although free radical pathology in schizophrenia is widely investigated, examination
of ROS induced DNA and protein damage is limited. The aim of this research was to
investigate all biomarkers of oxidative stress in schizophrenic and control subjects
including not only biomarkers of lipid peroxidation but also biomarkers of DNA and
protein oxidation.
6.4.1 Biomarkers of DNA Oxidation in Schizophrenia
Differences in endogenous and H2O2-induced DNA damage in freshly isolated and
cryopreserved peripheral blood lymphocytes from male and female control and
schizophrenic subjects was first examined using the comet assay. The results of this
study reveal no significant difference in the level of DNA damage, neither
endogenous nor H2O2-induced in normal and schizophrenic subjects when assessed
in freshly isolated lymphocytes. Furthermore, no significant difference in either
endogenous or H2O2-induced DNA damage was noted in lymphocytes from control
and schizophrenic subjects that were cryopreserved for up to 12 weeks. These results
are identical to findings observed by Psimadas et al (2004) in their study using
cryopreserved lymphocytes.
Our study sample differed, however, in that the control and patient group consisted
of both male and female schizophrenics. We observed that in the freshly isolated
lymphocytes, the level of DNA damage in male schizophrenic subjects was
significantly greater than in female schizophrenic subjects (p <0.05). Furthermore, a
trend emerged whereby endogenous and H2O2-induced DNA damage in
cryopreserved lymphocytes was greater in male than in female schizophrenic
subjects. In addition, after 5 weeks of cryopreservation, the level of induced DNA
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damage at a concentration of 50 M H2O2 in the male schizophrenic group was also
statistically significantly (p <0.05) greater than in the female schizophrenic group.
6.4.4.1 Effect of Cryopreservation
The effects of cryopreservation on endogenous and induced DNA damage in human
peripheral blood lymphocytes has been measured in various studies (Duthie et al
2002; Visvardis et al 1997) where it was reported that DNA damage was the same as
that in freshly isolated lymphocytes. In addition, long term storage was also shown
to have no effect on endogenous and induced DNA damage. In our investigation,
cryopreservation did not appear to have an effect on the level of DNA damage in
lymphocytes from either group up to 5 weeks storage at -80oC. However, statistical
differences at the level of DNA damage were observed following 12 weeks of
cryopreservation, suggesting that possible changes in lymphocyte environment may
occur following storage for this length of time.
6.4.4.2 Gender Differences
The risk of schizophrenia was originally thought to be the same in men and women.
However, more recent studies have reported the risk to be higher in men (reviewed
by Leung and Chue 2000). Furthermore, the existence of gender differences in
schizophrenics has received wide empirical support with respect to age at onset,
premorbid functioning, course of illness and outcome, familial transmission and
neurobiological factors. Uncertainties concerning the gender differences remain
although a number of theories to explain the sex differences in schizophrenia have
been proposed. These include the effects of oestrogen, differential vulnerability to
sub-types of schizophrenia, neurodevelopment and lateralization differences (Leung
and Chue 2000).
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6.4.5 Biomarkers of Lipid Peroxidation in Schizophrenia
One of the most commonly used methods in free radical research is the
determination of the TBA and MDA adduct in plasma since MDA has been found to
be elevated in patients with schizophrenia when compared with normal controls
(Zhang et al 2006; Dakhale et al 2005; Kuloglu et al 2002; Ravikumar et al 2000).
This is in contrast to the findings here whereby plasma MDA levels in our
schizophrenic group, measured using a lipid peroxidation assay was determined as
not being significantly different from those recorded in the control group. Ravikumar
et al 2000 also reported in their study elevated levels of lipid hydroperoxides in
plasma from schizophrenic subjects. Our findings reveal no significant differences in
the levels of plasma LOOH in either the schizophrenic and control group.
6.4.6 Biomarkers of Protein Oxidation in Schizophrenia
This study is the first to investigate the use of protein carbonyls as a marker of
oxidative stress in human schizophrenic patients. Observations have revealed no
significant difference in the levels of production of plasma protein carbonyls
between the schizophrenic and control group. Moreover, although a marked increase
of protein carbonyl levels was noted in the male schizophrenic group when
compared to other male and female groups, the increase was not statistically
significant.
Accumulation of modified protein disrupts cellular function either by loss of
catalytic and structural integrity or by interruption of regulatory pathways (Stadtman
and Levine 2000). Oxidation of catecholamines to the corresponding o-quinones and
their subsequent reduction to reactive species, which can induce redox cycling, has
been postulated as being involved in neurodegeneration in the mesolimbic and nigro-
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striatal systems and thus in the aetiology of schizophrenia and Parkinson’s disease
(Baez et al 1997; Smythies et al 1997). Tardive dyskinesia is a movement disorder
which affects 20-40% of patients treated chronically with neuroleptic drugs and it
has been hypothesised that neuroleptics enhance striatal glutamatergic
neurotransmission by blocking presynaptic dopamine receptors which causes
neuronal damage as a consequence of oxidative stress (Tsai et al 1998).
6.4.6.1 Neuroleptics
Neuroleptics have also been shown to have both pro-oxidant and antioxidant
properties (Jeding et al 1995) and the antipsychotic response of a neuroleptic may
depend on its pro- or antioxidant property and the level of pre-existing oxidative
stress in the patient (Mahadik et al 2001). Clinical studies have indicated that
antioxidant enzyme activities are associated with the treatment of schizophrenic
patient with neuroleptics (Abdalla et al 1986; Yao et al 1998), suggesting that the
changes in the enzyme activity may be due to the neuroleptic treatment (Akyol et al
2002; Evans et al 2003). The neuroleptic Flupenthixol can accept electrons in
competition with oxygen and therefore reduce the production of superoxide and
inhibit cytochrome b5 reductase activities; alternatively, neuroleptics may react
directly with superoxide (Whatley et al 1998). A recent study (Dakhale et al 2004)
examined the effect of atypical antipsychotics on lipid peroxidation, SOD and
ascorbic acid. Results revealed an increase in serum SOD, serum MDA and a
decrease in plasma ascorbic acid in schizophrenic patients as compared to controls,
however, the trend altered significantly following treatment with antipsychotics and
results of the Brief Psychiatry Rating Scale for schizophrenia also improved.
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6.4.7 Levels of Plasma Vitamin C in Schizophrenia
The study of plasma vitamin C levels was reported in mentally ill and schizophrenic
patients over two decades ago (Morgan and Hullin 1982; Schorah et al 1983;
Suboticanec et al 1986; Suboticanec et al 1990) where lower levels of vitamin C
were noted in patients compared to control subjects. More recent studies have also
recorded similar findings (Dakhale et al 2004; Dakhale et al 2005) and these and
other supplementation studies have reported reduction in oxidative stress (Dakhale et
al 2005) and improved outcome in schizophrenia (Arvindakshan 2003; Dakhale et al
2005). Our results recorded a decrease in the level of plasma vitamin C in the
schizophrenic group in comparison to the control group but this was not statistically
significant. Further examination of plasma vitamin C between the sexes, revealed a
significantly higher concentration of vitamin C in the female control group than in
the male groups. This pattern was also observed in the schizophrenic group but
statistical analysis revealed no significant difference between the schizophrenic male
and female vitamin C levels.
Vitamin C is the first line of defence against oxygen radicals in the water-soluble
compartment (Nordberg and Arner 2001). This vitamin reacts directly with
superoxide, hydroxyl radical and singlet oxygen and serves to prevent lipid
hydroperoxide formation in plasma lipoproteins by reducing -tocopherol radicals
formed upon reaction with lipid peroxyl radicals. Under conditions of protective
plasma vitamin C concentrations (>50mol/l) significantly lower values of DNA,
protein and lipid oxidative damage have been found in comparison with a vitamin C-
deficient group (<50mol/l) (Krajčovičová-Kudláčková et al 2006). Our results
revealed a parallel between the levels of vitamin C and levels of cellular DNA
damage. DNA damage in lymphocytes from schizophrenic male subjects was higher
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than in lymphocytes from schizophrenic females. However, mean plasma vitamin C
levels were found to be higher in the female schizophrenic patients (~70mol/l) than
in male schizophrenic patients (~38mol/l).
6.4.7.1 Dietary Factors
Nutrition may also play an important role in the outcome of schizophrenia. A dietary
intake profile of patients with schizophrenia (Henderson et al 2006) reports
differences in diet compared to controls. The schizophrenia group were found to
consume significantly fewer calories, carbohydrate, protein total fat, saturated fat,
monounsaturated fatty acids, PUFA, fibre, folate, sodium and alcohol but
significantly more caffeine than the control group. A study by McCreadie (2003)
which examined the lifestyle of people with schizophrenia reported that fewer males
compared with the general population, reached acceptable levels for consumption of
fruit, vegetables, milk, potatoes and pulses. In an earlier study (McCreadie et al
1998), the authors reported that as well as consuming less fibre and consuming more
saturated fat than the control population, more male schizophrenic patients than
female patients consumed less vitamin E.
In conclusion, this human study has examined biomarkers of lipid peroxidation,
DNA and protein oxidation to assess oxidative stress status in schizophrenia
compared to controls. The findings have revealed no significant differences in the
levels of biomarkers of lipid, DNA and protein oxidation between the patient and
control groups. However, a trend was seen whereby the level of oxidatively damaged
DNA and proteins was greater in male schizophrenic patients compared to the
female patients. In addition, it was also noted that the sub-population with the lowest
level of DNA damage ie. female controls also had the highest level of plasma
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vitamin C suggesting that an intrinsic protection may have arisen from an increased
dietary intake of this essential dietary vitamin. Ultimately, it is important to
investigate a range of biomarkers to gain vital information concerning free radical
damage and antioxidant status and to be able to better understand the disease of
interest.
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This research looked at investigating whether levels of oxidative stress, indicated by
a variety of biomarkers was increased in the models of schizophrenia compared to
controls. The study was mostly inconclusive in its findings regarding lipid
peroxidation and protein oxidation biomarkers; however, our observations were
more easily interpreted following evaluation of DNA damage.
7.1 Evaluation of DNA Damage in Models of Schizophrenia
7.1.1 DNA Damage in Human Cell Cultures
A comparator study of two human peripheral cells lines and a neuroblastoma cell
line as a means of assessing the validity of monitoring peripheral lymphocytes as
potential surrogate markers of DNA damage in neuronal cell types was undertaken.
Furthermore, experimentation to test the susceptibility of each cell line to an
oxidative challenge was also undertaken along with an examination of the potential
protective effects of a series of antioxidants and fatty acids on DNA oxidative
damage. During the investigation of both models of schizophrenia ie the cell culture
models and the human peripheral lymphocytes extracted from volunteer blood
samples, it appeared that freezing of the lymphocytes at -80oC had no effect on the
basal level of DNA damage as assessed by the comet assay, a method used to detect
DNA strand breaks. Furthermore, although no significant difference in the level of
cellular DNA damage was noted in the lymphocytes from either the schizophrenic or
control groups, and a possible confounding factor may present due to differences in
antioxidant status, either endogenous or dietary derived, an apparent difference
between sexes in terms of DNA damage within the schizophrenic group was noted
which reached a level of significance.
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7.1.2 DNA Damage and Antioxidant Protection in Human Cell
Cultures
Several studies of schizophrenia have reported abnormalities in one or more
antioxidant enzymes and/or in the levels of cerebrospinal fluid and plasma TBARs
(Mahadik and Mukherjee, 1996; Reddy and Yao, 1996). Other studies have also
reported a wide range of abnormalities in membrane phospholipids that may be a
result of oxidative damage. These changes have been considered to be a result of
altered metabolism (reduced synthesis and/or increased breakdown) of essential
polyunsaturated fatty acids (EPUFAs). EPUFAs are the -3 and -6 series of fatty
acids that must be consumed in the diet. Reduced membrane EPUFAs have been
found to be associated with psychopathology (Glen et al 1994; Peet et al 1995).
Three human cell lines were used in this research as models of schizophrenia and
cell supplementation studies were undertaken to assess potential antioxidant and
fatty acid protection against ROS-induced DNA damage. Supplementation of
neuroblastoma cells for 30min and 6 hours with EGCG and hydroxytyrosol of a
concentration within human physiological range (ie. 10M) resulted in a highly
significant decrease in the level of DNA damage in cells treated additionally with
H2O2. Furthermore, this same effect was observed in U937 cells. However, in only
those lymphoblastoid cells treated with hydroxytyrosol was a significant protection
of cellular DNA against an oxidative challenge observed.
The effect of hydroxytyrosol observed in this study is interesting. It is known that
3,4-dihydroxyphenylethanol, also known as hydroxytyrosol, is an endogenous
metabolite of dopamine (Hashimoto et al 2004) and has been shown to protect cells
against H2O2 induced damage (Grasso 2007; Hashimoto et al 2004) as well as being
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protective against the peroxynitrite-dependent nitration of tyrosine and DNA damage
by peroxynitrite in vitro (Deiana et al 1999). More recently, hydroxytyrosol has been
shown to protect brain cells in vitro and ex vivo against Fe2+ and nitric oxide-induced
cytotoxicity (Schaffer et al 2007) and the study by Schaffer et al provides the first
evidence of the neuroprotective effects of oral hydroxytyrosol intake. With this in
mind when thinking of future work, it might be beneficial to use the antioxidant
hydroxytyrosol as a supplement alone or in conjunction with EPA and/or DHA in
human schizophrenic patient studies and in further cell culture studies. However,
because increased dopamine activity is thought to lead to the psychotic symptoms
associated with schizophrenia, it is worth considering the role, if any, that the
dopamine metabolite 3,4-dihydroxyphenylethanol might play in the psychotic
symptoms, regardless of its antioxidant properties.
Green tea is a widely consumed drink and has gained a reputation as a health-
promoting dietary component due to the antioxidant activity of EGCG, its main
phenolic constituent. Evidence is increasing however, that tea constituents can be
cell damaging and pro-oxidant. These effects are suggested to be due to spontaneous
H2O2 generation by polyphenols in solution (Elbling et al 2005; Furukawa et al
2003). This pro-oxidant effect was perhaps more pronounced in the lymphoblastoid
EGCG-treated cells used in this study, resulting in a higher overall ROS generation
and greater level of DNA damage than seen in the U937 and IMR-32 EGCG-treated
cells (Table 2.2). In contrast, the production of H2O2 in tea catechin-treated
lymphoblastoid cells was compared by Sugisawa et al (2004) who suggested that the
structure of EGCG is less likely to result in H2O2-induced chromosomal damage
than EGC. EGC has a trihydroxyl structure with a B-ring similar to EGCG. Another
catechin, ECG which has a gallate group linked to flavan-3-ol similar to EGCG,
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however, did not produce H2O2 (Sugisawa et al 2004). Nevertheless, tea catechins
and polyphenols are effective scavengers of reactive oxygen species in vitro and may
also function indirectly as antioxidants through their effects on transcription factors
and enzyme activities (Higdon and Frei 2003).
Until recently, there was little understanding of the metabolism of flavonoids and
their mode of entry into the systemic circulation after oral absorption. Although
numerous studies have reported flavonoid-mediated neuroprotection, there is little
information about the interaction of flavonoids or their circulating metabolites with
the brain endothelial cells from the blood brain barrier (Youdim et al 2004). EGCG
has been reported to enter the brain after oral administration (Suganuma et al 1998)
and is more recently being investigated as a prophylactic for Alzheimer’s disease
(Rezai-Zadeh et al 2005).
7.1.3 DNA Damage and Fatty Acid Protection in Human Cell Cultures
Epidemiological studies have shown an apparent beneficial effect of fish oil
containing high levels of -3 PUFA on mortality from heart disease and cancer
(Kikugawa et al 2003) and there is additional evidence to suggest that -3 fatty acids
may also be important to mental health (Peet and Stokes, 2005). Conversely, a more
recent systematic review (Hooper et al 2006) found no evidence of a clear benefit of
-3 fats on health (in particular mortality, cardiovascular events, cancer or strokes).
However, the benefits of using -3 fatty acids to protect DNA against oxidative
damage, particularly in mental illness, have not been widely investigated. In this
study human peripheral and neuroblastoma cells were incubated with increasing
concentrations of EPA or DHA from 30min to 24h. Results revealed that there was
no difference in the level of DNA damage in the U937 and IMR-32 cell lines treated
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with either EPA or DHA when compared to controls (i.e. non EPA or DHA treated
cells) (results not shown). Conversely, examination of lymphoblastoid cells treated
with the highest concentration of DHA after 24 hours (Figure 2.6) revealed a
significant increase in DNA damage when compared to 30 minute and 24 hour
controls.
Fatty acid treated peripheral and neuroblastoma cells were also subjected to a
peroxide challenge. Results show that in fatty acid + H2O2-treated cells the level of
DNA damage was significantly reduced in the U937 and IMR-32 cells at all time
points compared to H2O2 control cells.
Although the use of fish oil has been suggested to have many beneficial effects, lipid
peroxidation-mediated DNA damage is an undesirable consequence resulting from
intake of high concentration of fish oil. In vitro studies have shown that peroxidized
PUFA induce DNA chain breaking (Adam et al 1998) and 8-hydroxyguanosine
formation (Kaneko and Tahara 2000). Contrasting studies have shown that -3
PUFA supplementation on oxidative stress-induced DNA damage in a variety of cell
types acts instead as a protective agent against oxidative stress rather than as a source
of mutagenic metabolites (Beeharry et al 2003, Kikugawa et al 2003). The results of
our study have also shown that EPA and DHA protect peripheral and neuroblastoma
cells against oxidative stress induced DNA damage. It is worth noting that in their
study, Kikugawa et al (2003) used fish oil supplemented with vitamin E. Since the
purported health effects of fish oil are questioned by Hooper et al (2006), the
reduction in oxidative stress-induced DNA damage reported by Kikugawa et al
(2003) may well be attributable to the antioxidant rather than the fish oil.
Nevertheless, these authors propose that although lipid peroxidation products formed
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from the use of high concentrations of -3 can damage DNA, the damage caused by
these products may be significantly lower than those caused as a result of direct
oxidative stress resulting from ROS.
Within our study, pure oils without added vitamin E were used as in the study
reported by Beeharry et al (2003). In their study Beeharry et al (2003) suggest that
the DNA-protective effects seen following incubation of human cells with the -6
PUFA linoleic acid may be as a result of the fatty acid acting as a substrate for lipid
peroxidation. In addition, linoleic acid may also inhibit the induced oxidative stress
that causes lipid peroxidation by blocking an early stage in the induction of damage.
Interestingly, a preliminary study carried out by the same group has also shown
DHA to be cytoprotective (Beeharry et al 2003).
7.1.4 Reducing Abilities of Antioxidants in Human Cell Cultures
The reducing ability of a range of antioxidants was assessed and in conjunction, the
efficacy of these antioxidants and a series of polyunsaturated fatty were considered
in affording protection to cellular DNA against an oxidative challenge. Numerous
assays have been described in which antioxidant is added to a reaction mixture in
which free radicals are generated. An example is the ABTS assay in which ABTS is
oxidised by 2,2’azobis(2-amidopropane). Any antioxidant present delays the
appearance of the coloured product of this reaction. Two polyphenolic (EGCG and
resveratrol) and two monophenolic (tyrosol and hydroxytyrosol) compounds were
tested using the ABTS assay. EGCG and hydroxytyrosol were found to be the most
potent radical quenchers examined.
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Structure-activity comparisons suggest that antioxidant activity of phenolic
compounds depends on the number and orientation of hydroxyl groups relative to the
electron-withdrawing CO2H, CH2CO2H or (CH)CO2CH functional groups (Rice-
Evans et al 1996). When considering flavonoid (e.g. EGCG) antioxidant activity, the
B-ring hydroxyl configuration is the most significant determinant of scavenging of
reactive oxygen species. Hydroxyl groups on the B-ring donate hydrogen and an
electron to hydroxyl, peroxyl and peroxynitrite radicals, stabilizing them and giving
rise to a relatively stable flavonoid radical (Heim et al 2002). Functional differences
between hydroxytyrosol and tyrosol have been attributed to the presence of only a
single hydroxyl (reviewed by Quiles et al 2002) which may account for the greater
antioxidant potential of hydroxytyrosol over tyrosol. These structural differences
may explain why hydroxytyrosol and EGCG appear to have a greater antioxidant
potential than tyrosol and resveratrol since Masella et al (1999) suggest that the
phenol chemical structure considerably influences the antioxidant activity as a
consequence of both steric factors and those related to position and type of
functional groups on the phenol ring. Furthermore, the antioxidant activity of
biphenols depends mainly on the number of hydroxyl groups in the molecule
(Masella et al 1999).
7.1.5 DNA Damage in Human Schizophrenia and Control Subjects
Differences in endogenous and H2O2-induced DNA damage in freshly isolated and
cryopreserved peripheral blood lymphocytes from male and female control and
schizophrenic subjects was examined using the comet assay. The results of this study
revealed no significant difference in the level of DNA damage, neither endogenous
nor H2O2-induced in normal and schizophrenic subjects when assessed in freshly
isolated lymphocytes. Furthermore, no significant difference in either endogenous or
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H2O2-induced DNA damage was noted in lymphocytes from control and
schizophrenic subjects that were cryopreserved for up to 12 weeks. These results are
identical to findings observed by Psimadas et al (2004) in their study using
cryopreserved lymphocytes.
Our study sample differed, however, in that the control and patient group consisted
of both male and female schizophrenics. We observed that in the freshly isolated
lymphocytes, the level of DNA damage in male schizophrenic subjects was
significantly greater than in female schizophrenic subjects (p <0.05). Furthermore, a
trend emerged whereby endogenous and H2O2-induced DNA damage in
cryopreserved lymphocytes was greater in male than in female schizophrenic
subjects. In addition, after 5 weeks of cryopreservation, the level of induced DNA
damage at a concentration of 50M H2O2 in the male schizophrenic group was also
statistically significantly (p <0.05) greater than in the female schizophrenic group.
7.1.6 Effect of Cellular Cryopreservation
The effects of cryopreservation on endogenous and induced DNA damage in human
peripheral blood lymphocytes has been measured in various studies (Duthie et al
2002; Visvardis et al 1997) where it was reported that DNA damage was the same as
that in freshly isolated lymphocytes. In addition, long term storage was also shown
to have no effect on endogenous and induced DNA damage. In our investigation,
cryopreservation did not appear to have an effect on the level of DNA damage in
lymphocytes from either group up to 5 weeks storage at -80oC. However, statistical
differences at the level of DNA damage were observed following 12 weeks of
cryopreservation, suggesting that possible changes in lymphocyte environment may
occur following storage for this length of time.
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7.1.7 Gender Differences
The risk of schizophrenia was originally thought to be the same in men and women.
However, more recent studies have reported the risk to be higher in men (reviewed
by Leung and Chue 2000). Furthermore, the existence of gender differences in
schizophrenics has received wide empirical support with respect to age at onset,
premorbid functioning, course of illness and outcome, familial transmission and
neurobiological factors. Uncertainties concerning the gender differences remain
although a number of theories to explain the sex differences in schizophrenia have
been proposed. These include the effects of oestrogen, differential vulnerability to
sub-types of schizophrenia, neurodevelopment and lateralization differences (Leung
and Chue 2000).
We sought to investigate DNA damage in schizophrenia because it had not been
investigated until recently. Psimadas et al (2004) also reported no difference in
levels of H2O2-induced DNA damage in lymphocytes from their schizophrenic
patients and controls, yet our study (Young et al 2007) was the first to report
differences in the level of DNA damage in lymphocytes from male and female
schizophrenic patients. Gender issues in relation to DNA damage were mentioned
earlier but it is important to note that in general, women require lower doses of
medication than men during both acute and maintenance phases of the illness at least
until menopause (reviewed by Afifi 2007). It is worth considering therefore, whether
the difference in the medication dosage might play a role in the differences in levels
of DNA damage reported here. In addition, the type of neuroleptic medication
received by the patient has also been reported as having an effect on levels of lipid
peroxidation. Again, perhaps it is possible that the type of antipsychotic treatment
might also have an effect on the level of DNA damage. In future research
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nevertheless, where gender is being considered in schizophrenia studies, it would be
advisable to ensure that the numbers of male and female volunteers are equally
matched since the significant results reported in our study might be as a result of the
small sample of women volunteers compared to the larger sample of male
volunteers.
7.2 Evaluation of Protein Oxidation in Models of Schizophrenia
7.2.1 Protein Carbonyls in Human Cell Cultures
The evaluation of protein carbonyls as a potential marker of protein oxidation in the
putative cell model for schizophrenia, U937 was undertaken. Treatment with H2O2
alone and following pre-treatment with EPA or DHA had no effect on the levels of
protein carbonyls detected in the cell line by ELISA. Nevertheless, although the
results were not statistically significant, DHA supplementation does appear to reduce
endogenous and H2O2-induced protein carbonylation. Further in vitro and in vivo
work would be merited since evaluation of the effect of fatty acid supplementation
on the levels of protein oxidation in schizophrenia is limited. Indeed, the potential
use of protein carbonyls as a biomarker of schizophrenia has not been widely
examined until now.
The results of our evaluation of the levels of protein carbonyls in cultured human
cells showed that although not statistically significant, pre-treatment of the cultured
cells with DHA might reduce protein oxidation. If this is the case it would appear
that male human schizophrenic patients may benefit from DHA supplementation
since our human study revealed this group to have the highest levels of plasma
protein carbonyls. Since this work was carried out, further studies have shown the
advantages of omega-3 supplementation. In an animal study, male Wistar rats were
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shown to have increased levels of protein carbonyls and MDA following chemically
induced psychosis (Ozyurt et al 2007), while another study by the same group
describes a decrease in protein carbonyls in the rat prefrontal cortex following
omega-3 (EPA and DHA combined) treatment (Ozyurt et al 2007).
7.2.2 Protein Carbonyls in Schizophrenia Patients and Control
Subjects
This study was the first to investigate the use of protein carbonyls as a marker of
oxidative stress in human schizophrenic patients. Observations have revealed no
significant difference in the levels of production of plasma protein carbonyls
between the schizophrenic and control group. Moreover, although a marked increase
of protein carbonyl levels was noted in the male schizophrenic group when
compared to other male and female groups, the increase was not statistically
significant.
The abnormal movements seen in tardive dyskinesia occur as a result of major late-
onset chronic side effect of antipsychotic treatment. Oxidative stress and free
radicals are thought to be associated with dopaminergic malfunctions (Sadan et al
2005) and oxidative stress-induced neurotoxicity in the striatal system is implicated
in tardive dyskinesia (Shamir et al 2001). Several studies have reported that people
with schizophrenia have abnormal levels of essential fatty acids in their blood cells
and similar abnormalities have been recorded in association with the presence of
tardive dyskinesia (reviewed by Vaddadi et al 1996). In their study, Vaddadi et al
(1996) hypothesised that patients with schizophrenia would have lower levels of -3
and -6 EFAs than controls and that this abnormality would be more pronounced in
those schizophrenic patients also suffering with tardive dyskinesia.
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During conditions of oxidative stress protein modification can lead to protein
dysfunction or tissue damage and disease progression. Carbonylation of proteins is
an irreversible oxidative damage, often leading to a loss of protein function, which is
considered a widespread indicator of severe oxidative damage and disease-derived
protein dysfunction (Dalle-Donne 2006). Although moderately carbonylated proteins
are degraded by the proteasomal system, those that have been heavily carbonylated
form high-molecular-weight aggregates that are resistant to degradation and
accumulate as damaged or unfolded proteins while masses of carbonylated proteins
can inhibit proteasome activity. It is widely accepted that a variety of
neurodegenerative diseases are linked to the accumulation of proteolysis-resistant
aggregates of carbonylated proteins in tissues. If this is the case, identification of
specific functionally impaired protein carbonyls and the development of particular
carbonyl inhibitors might result in a better understanding of the role of protein
carbonylation in disease onset and/or progression, possibly providing new
therapeutic approaches (Dalle-Donne 2006). For example, model studies are now
able to reveal the structure of adducts that can be more readily identified in mass
spectrometric studies on proteins exposed to the various pure aldehydes or to
peroxidized PUFAs (Sayre et al 2006).
7.2.3 ROS in Human Cell Cultures
CM-H2DCFDA-sensitive reactive oxygen species of the human U937 cell line along
with the anti- or pro-oxidant effects of EGCG, hydroxytyrosol, -tocopherol and
H2O2 were evaluated by flow cytometry. Results from this study showed that the
pre-treatment with the antioxidant hydroxytyrosol significantly reduced the level of
endogenous ROS in U937 cells, while -tocopherol appears to increase endogenous
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ROS levels. In addition, the beneficial effect of hydroxytyrosol was apparent
following treatment of cells with H2O2 since it was observed that only
hydroxytyrosol was effective in significantly reducing H2O2-induced cellular ROS
Previous studies have suggested that ROS production may play a role in the
pathogenesis of schizophrenia, and more recently, there is an emerging body of data
indicating that schizophrenia may be associated with mitochondrial dysfunction
(Frey et al 2006). Animal studies have established that a global oxidative stress
affects predominantly the brain (Mahadik and Mukherjee 1996). Brain vulnerability
occurs because the brain is under higher oxidative stress than other organs since it
produces very high levels of ROS due to its very high aerobic metabolism and blood
perfusion (reviewed by Mahadik et al 2001). In addition, it is enriched in lipids that
are preferentially susceptible to oxidative damage and the damaged neuronal DNA in
the adult brain can not be effectively repaired since there is no DNA replication. Yet
environmental ROS also attack the brain and inflammation is a major threat to brain
function. Depending on the degree of oxidative stress and the developmental time,
oxidative neuronal injury in the brain may cause abnormal neurodevelopment,
neurodegeneration, or neuronal membrane impairment.
Although the possible potential beneficial effect of hydroxytyrosol in reducing the
level of ROS, and the possible potential beneficial effect of DHA in reducing protein
carbonyls in U937 cells was noted, a number of problems were encountered with
these experiments. The U937 cells were kept under the same cell culture conditions
throughout the experiment and were subjected to limited handling and exposure to
the atmosphere. However it is possible that because of the length of time that the
cells were in use, in particular, the number of passages might have lead to an
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increase in basal oxidative damage. Although cell viability was checked at each
experiment only dead cells would have been highlighted and cells undergoing
damage would not be obvious.
7.3 Evaluation of Lipid Peroxidation in Models of Schizophrenia
7.3.1 Lipid Peroxidation in Human Cell Cultures
In contrast to many other studies whereby increased levels of lipid peroxidation have
been observed in plasma from schizophrenic patients, our study has reported no
significant difference in lipid peroxidation in our models of schizophrenia compared
to the controls, as determined by a range of biomarkers. Furthermore, even after
supplementation with fatty acids, the experiments utilising cultured cells did not
report any clear cut results, particularly in those seeking to evaluate phospholipase
A2 levels.
There are a number of reasons why the results did not draw any concise conclusions
and it is likely that the main limitation of the cell culture experiments was the
maintenance of the cells. During the course of these experiments the cells were
cultured in different laboratories with the risk of bacterial and fungal contamination
being an unfortunate added factor. It is also likely that the number of passages of the
cells might have resulted in them being less viable and hence led to the production of
unexpected results. Nevertheless, the viability of the cells was checked routinely
with the Trypan blue assay and solutions and reagents were freshly made before each
experiment. In addition, the use of the assay kits may have played a role in
producing ambiguous data. Although the kits are quick and relatively straightforward
to use, they can be expensive, have a limited shelf life and the number of
experiments that can be carried out is restricted. Had time and resources permitted, it
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would have been ideal to have repeated the experiments a number of times, not only
using fatty acid supplementation but also with antioxidant treatment. On the other
hand, it was possible to optimise and validate the GC-MS and TBARs methods and
using these methods seemed to be more straightforward and produced more
conclusive data. Whether this was down to the method itself or the cultured cells that
were used with the kits is difficult to pinpoint.
It is now clear that increased lipid peroxidation and failure of antioxidant systems
can lead to neuronal damage in schizophrenic patients and moreover, oxidative stress
may be exacerbated by the treatment with antipsychotics with pro-oxidant properties.
Quantification of MDA still remains the most measured and reliable biomarker of
lipid peroxidation in schizophrenia studies, although there is scope for more breath
analysis to be undertaken, and recent novel work has revealed that increased serum
MDA and 4-hydroxynonenal levels are found in treatment refractory schizophrenic
patients when compared to non-refractory treatment schizophrenics. In addition,
these increased lipoperoxidation products correlated with worsening of some the
psychiatric symptoms (Medina-Hernandez et al 2007). Conversely, short term (6
week) antipsychotic treatment has been shown to have no effect on oxidative-
antioxidative system parameters (Sarandol et al 2007).
7.3.2 Phospholipase A2 in Human Cell Cultures
Recognition of the phospholipid hypothesis of schizophrenia is growing since the
observations made by numerous groups who report increased blood and brain PLA2
activity in schizophrenia (Barbosa et al 2007), while findings from the niacin skin
flush test, PUFA supplementation studies and biochemical studies for the
phospholipid metabolism pathway also suggest a disordered phospholipid
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metabolism in the disease (Liu et al 2007). In addition, a genetic variant of a
cytosolic PLA2 gene has been reported to be associated with schizophrenia. These
data indicate that variants of PLA2 encoding genes are plausible candidates for
increasing the susceptibility for schizophrenia (Barbosa et al 2007).
Initial studies revealed significantly increased total PLA2 levels in the U937 and
IMR-32 cells following 4 hour treatment with H2O2 alone. An increase in total PLA2
activity was also seen in lymphoblastoid cells although this did not reach
significance. However, further experimentation with or without pre-treatment of
cells with -3 fatty acids revealed total PLA2 levels to be similar in all the cell lines
and no change in activity levels was observed following challenge with H2O2. These
findings are in contrast to the reports that H2O2 activates cytosolic phospholipase A2
(van Rossum et al 2004) and it is difficult to provide an explanation for this
discrepancy at present.
In an additional exploratory study, the cPLA2 activity in the three human cell lines
was examined and the basal level of cPLA2 activity was found to be comparable in
the lymphoblastoid and IMR-32 cells but lower than that measured in the U937 cells.
However, because only one study was carried out, the results cannot be deemed
significant since no statistical analysis was undertaken. In this experiment, a high
variance was observed within the untreated cells which lead to the adoption of the
ethanol-treated cells as the control set. In addition, the large error bars recorded in
this experiment in particular may be due to the possible lack of intra-assay precision.
Although our study did not conclude any definitive findings, because of the
importance the PLA2 enzyme plays in the metabolism of fatty acids and its suggested
causal role in the aetiology of schizophrenia, it would be interesting to repeat our
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earlier experiments with human blood samples if possible, and also peripheral blood
cells and neuronal cells, treated with EPA or DHA or a combination of both PUFAs.
An enhanced level of cPLA2 activity in the U937 cell line has been previously
reported by Obajimi et al (2005) and is a feature which has led to the suggestion that
this cell line is a suitable in vitro model for studying cellular mechanisms of
schizophrenia. Supplementation of the U937 cell line with EPA appeared to reduce
cPLA2 activity relative to the vehicle treated control, an outcome which again
appears to mimic some of the biochemical changes reported following EPA
supplementation of Asperger’s syndrome sufferers (Bell et al 2004). Neither EPA
nor DHA supplementation appeared to have any significant effect on either total
PLA2 or cPLA2 activity in IMR-32 or lymphoblastoid cell lines. However, it is also
reported that -3 PUFAs modulate T-cell functions such as T-cell proliferation and
cytokine secretion (Calder 2001). This is important since inflammatory cytokines
such as IL-1, TNF and IFN, play a role in the activation of cPLA2 (Xu et al
2003). A more recent study also reported that IL-2 increased cPLA2 activity in the
shell of the nucleus accumbens but IL-1-induced changes which were significantly
attenuated by EPA treatment (Song et al 2007).
7.3.3 Breath Analysis in Schizophrenia Patients and Control Subjects
Breath analysis is a non-invasive and easy to use method to assess lipid peroxidation.
In the first part of the human trial undertaken during this project, the level of breath
hydrocarbons measured by GC-MS was compared in schizophrenic and control
subjects. Although there were incidences of higher levels of both ethane and pentane
in the patient group, suggesting that these individuals may be subjected to greater
oxidative stress and hence greater levels of lipid peroxidation than individuals in the
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control group, no significant difference was found between the levels of ethane and
pentane in the breath from the schizophrenic patients and control samples on the
whole. In addition, plasma MDA levels were evaluated by TBARs and HPLC in the
schizophrenic patients and controls, but again, there was no significant difference in
the levels of plasma MDA between the two groups. Further analysis of the breath
and MDA data from the schizophrenic group alone was undertaken to determine any
gender differences and although ethane levels and MDA levels were higher in the
male schizophrenic samples the data was not statistically significant. Only the
pentane levels were higher in the female schizophrenic samples when compared to
the male samples but these were not significantly greater. The lack of significance
may be as a result of the small sample sizes, although it is possible that there is just
no definite difference in the levels of oxidative stress between the two groups.
However, any future work that may be carried out would probably benefit from
larger sample sizes.
During the lipid peroxidation chain reaction process, saturated hydrocarbons such as
ethane and pentane are eventually formed from the -3 and -6 fatty acids along
with aldehydes such as MDA and in vitro studies have shown that ethane and
pentane are generated when cell cultures are exposed to ROS (reviewed by Miekisch
et al 2004). As stable end products of lipid peroxidation, hydrocarbons show low
solubility in blood and are excreted into the breath minutes following their formation
in tissues and exhaled concentrations of ethane and pentane therefore can be used to
monitor the degree of oxidative stress within the body (Risby and Sehnert 1999).
Animal and clinical studies have also reported close correlation between clinical
conditions where high levels of lipid peroxidation or inflammation occur and the
exhalation of ethane and pentane generated through ROS attack on lipid membrane
Chapter 7 Discussion .243
structures (Aghdassi et al 2000) while the same authors have also shown that levels
of exhaled pentane and ethane correlate well with other markers of lipid peroxidation
including MDA and TBARs (Aghdassi et al 2003). Although the comparison was
made, we were unable to demonstrate a correlation between the two different
methods of determining lipid peroxidation or plasma MDA levels, or any correlation
between these variables and the clinical rating scales. Furthermore, we did not
observe any differences in the mean population levels of breath hydrocarbons or
MDA between the patient and control group.
As mentioned earlier incidences of higher levels of ethane and pentane were noted in
the patient group, however, only one patient had an ethane level falling outside the
95% reference range for breath ethane levels as determined by Glen et al 2003. Why
this patient appears to produce higher levels of breath ethane is unknown. Volatile
organic compounds (VOCs) such as ethane and pentane may be produced
endogenously ie in the body or they may be exogenously generated ie absorbed as
contaminants from the environment. Furthermore, the composition of VOCs in
breath varies hugely between individuals both qualitatively and quantitatively (Cao
and Duan 2006). Increased levels of oxidative stress might be a cause and perhaps
the type of medication that the patient is receiving may also be a factor. Gama et al
(2006) recently reported serum TBARs to be significantly higher in patients
receiving clozapine than those under haloperidol treatment although it is possible
that the increase in TBARs levels may be as a result of the course of the disease
rather than the medication, as may be the case with our patient.
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7.3.4 LOOH and MDA in Schizophrenia Patients and Control Subjects
The measurement of MDA by the TBARs method is widely debated but although it
has its pitfalls, it is still one of the most commonly reported indices of oxidative
damage. Plasma MDA levels have been found to be elevated in patients with
schizophrenia when compared to normal controls (Zhang et al 2007; Medina-
Hernandez et al 2007; Gama et al 2006; Zhang et al 2006; Khan et al 2002; Kuloglu
et al 2002), while only one recent study (Skinner et al 2005) reported lower levels of
MDA measured by TBARs in CSF from schizophrenic patients compared to
controls. These are in contrast to our study which has shown no difference in the
level of plasma MDA from schizophrenic patients compared to controls, although
the MDA levels in our volunteers appear to be much higher than the reported normal
ranges of <1.0micromol/litre as reported by Kropp et al 2005. Nevertheless, these
results are similar to our earlier findings (Young et al 2007) where we reported no
significant difference in the levels of MDA and hydroxyalkenals in cryopreserved
plasma samples from control and schizophrenic samples. Furthermore, between sex
comparisons of the level of plasma MDA and hydroxynonenal from control and
schizophrenic patients also revealed no statistically significant difference (Young et
al 2007).
7.4 Evaluation of EPUFA Treatment in Cell Models of Schizophrenia
The basal level of -3 fatty acids in the U937 cell line was depleted when compared
to the lymphoblastoid and IMR-32 cell lines and therefore confirmed the validity of
the U937 cell line as an appropriate model for investigating the effects of -3
supplementation on cellular mechanisms in schizophrenia. The -3 and -6 ratio in
the U937 and lymphoblastoid cells lines are highly comparable and significantly
lower than that seen in the IMR-32 cell line. Following treatment with EPA or
Chapter 7 Discussion .245
DHA, the percentage of -3 fatty acid increased in each cell line but the U937 cells
showed the largest increase. In all the cell lines 24h supplementation with EPA
resulted in a decrease in AA and DHA levels when compared to the untreated cells,
but lead to an increase in EPA content in all cell lines. 24h supplementation of the
three cell lines with DHA also revealed an increase in DHA levels with an increase
in all the cell types, compared to DHA content in untreated cells. It has been
suggested that the profile of essential fatty acids in neuronal membranes affects
normal physiological events in the brain and that the fatty acid composition of
neuronal cell membrane phospholipids reflects their intake in the diet (Haag 2003).
Furthermore, the effects of dietary fatty acids may result in changes in
neurophysiological, cognitive and psychophathological parameters (Haag 2003;
Evans et al 2003) although it is thought that oxidative stress may play its part as an
associated event (Mahadik et al 2001). As a major component of brain
phospholipids, DHA has a wide range of biological actions and is also thought to
play an important role in the regulation of cell signalling and in cell proliferation
(Salem et al 2001). Similarly, EPA plays a role in many biological activities and has
a variety of actions. Epidemiological studies have not only reported the beneficial
effects of -3 PUFAs with respect to mortality from heart disease to cancer (Jude et
al 2006) but there is also growing evidence to suggest a beneficial role in mental
health (Peet and Stokes 2005).
Although PUFA supplementation might be expected to increase the possibility of
oxidation in the cells, no differences in the level of DNA damage in the U937 or
IMR-32 cells treated with PUFA was noted when compared to the untreated cells.
Only supplementation with a higher concentration (100M) of DHA for 24h resulted
in an increase in DNA damage compared to the control cells suggesting the expected
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pro-oxidant effect of this fatty acid in this cell line. However, both EPA and DHA
significantly attenuated the DNA damage elicited by an induced oxidative stress in
all cell lines and this protective effect was observed at low concentrations of the fatty
acids than could possibly be achieved through dietary -3 PUFA supplementation to
humans in vivo. Omega-3 intake has also been shown to attenuate inflammatory
cytokine production in various cells which may also be regarded as beneficial to
brain function since the cytokines are reported to induce adverse effects in brain
chemistry (Martin et al 2002).
It is important to note the possible induction of glutathione peroxidase enzymes by
fatty acids and the protective role that these antioxidant enzyme may play in cells
and tissues against oxidative and inflammatory cytokine elicited damage (Crosby et
al 1996). In vitro enrichment of peripheral blood monocytes with low concentrations
of EPA and DHA have also been shown to induce an increase in glutathione
peroxidase (Joulain et al 1994). Indeed schizophrenia may not just be linked to
oxidative events and damage but rather to inflammatory events such as cytokine and
eicosanoid production in the brain elicited by bacterial endotoxins and infections.
For example, a recent study has reported that during critical stages of pregnancy
maternal infection may lead to sensorimotor gating deficits in schizophrenia (Fortier
et al 2007).
7.5 Oxidative Stress, Diet and Schizophrenia
Oxidative stress increases when the level of reactive oxygen species exceeds the
cellular antioxidant defence capacity. The primary antioxidant defence is enzymatic.
However, non-enzymatic antioxidant defence which also plays a significant role in
control of oxidative injury constitutes dietary supplements such as antioxidant
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vitamins (A, C, E and Q), flavones, quinines, lycopenes, -carotene and uric acid
(Mahadik et al 1999). Numerous studies assessing diet in schizophrenic subjects
report the lack of consumption of fruit and vegetables and fibre but increased
consumption of saturated fats and sugar in comparison to controls (Roick et al 2007;
Amani 2007). Conversely, obesity in schizophrenia patients is not solely related to
food consumption, but may be due to other factors including side effects of
medication and reduced physical activity (Henderson et al 2006). However, people
with schizophrenia are at greater risk of obesity, Type 2 diabetes, dyslipidaemia and
hypertension than the general population. This results in an increased incidence of
cardiovascular disease (CVD) and reduced life expectancy, over and above that
imposed by their mental illness through suicide (Barnett et al 2007). Evidence from
data linkage analyses to clinical trials show that treatment-related metabolic
disturbances are widespread in this patient group, and that the use of certain second-
generation antipsychotics may increase the risk of developing the metabolic
syndrome and CVD. In addition, smoking, poor diet, reduced physical activity and
alcohol or drug abuse is prevalent in people with schizophrenia and contribute to the
overall CVD risk (Barnett et al 2007). Had resources permitted, our study may have
benefited from a dietary assessment to gain a better understanding of the role that
dietary choices and the impact on oxidative stress that these choices may play in the
disease.
7.5.1 Vitamin C in Schizophrenia Patients and Control Subjects
The study of plasma vitamin C levels was reported in mentally ill and schizophrenic
patients over two decades ago (Morgan and Hullin 1982; Schorah et al 1983;
Suboticanec et al 1986; Suboticanec et al 1990) where lower levels of vitamin C
were noted in patients compared to control subjects. More recent studies have also
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recorded similar findings (Dakhale et al 2004; Dakhale et al 2005) and these and
other supplementation studies have reported reduction in oxidative stress (Dakhale et
al 2005) and improved outcome in schizophrenia (Arvindakshan 2003; Dakhale et al
2005). Our results recorded a decrease in the level of mean plasma vitamin C in the
schizophrenic group in comparison to the control group but this was not statistically
significant. Further examination of plasma vitamin C between the sexes, revealed a
significantly higher concentration of vitamin C in the female control group than in
the male groups. This pattern was also observed in the schizophrenic group but
statistical analysis revealed no significant difference between the schizophrenic male
and female vitamin C levels.
Vitamin C is the first line of defence against oxygen radicals in the water-soluble
compartment (Nordberg and Arner 2001). This vitamin reacts directly with
superoxide, hydroxyl radical and singlet oxygen and serves to prevent lipid
hydroperoxide formation in plasma lipoproteins by reducing -tocopherol radicals
formed upon reaction with lipid peroxyl radicals. Under conditions of protective
plasma vitamin C concentrations (>50mol/l) significantly lower values of DNA,
protein and lipid oxidative damage have been found in comparison with a vitamin C-
deficient group (<50mol/l) (Krajčovičová-Kudláčková et al 2006). Our results
revealed a parallel between the mean levels of vitamin C and levels of cellular DNA
damage. DNA damage in lymphocytes from schizophrenic male subjects was higher
than in lymphocytes from schizophrenic females. However, mean plasma vitamin C
levels were found to be higher in the female schizophrenic patients (~70mol/l) than
in male schizophrenic patients (~38mol/l).
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In summary, this research aimed to evaluate whether levels of oxidative stress, via a
range of biomarkers are increased in models of schizophrenia and in patients with
schizophrenia compared to the matched controls. With respect to lipid peroxidation
and protein oxidation biomarkers, no significant difference in the levels of oxidative
stress between the human schizophrenic and control groups was detected, while the
results from the cell culture studies were inconclusive. However, treatment of cells
with EPA, DHA and hydroxytyrosol to reduce levels of oxidative damage may
warrant further research. Investigation of DNA damage suggests that hydrogen
peroxide-induced DNA damage can be significantly reduced in vitro by certain -3
fatty acids and phenolic antioxidants while DNA damage in human subjects was not
significantly different between the two study groups. Ultimately, it is important to
investigate a range of biomarkers to determine whether the measurement of
oxidative damage to lipids, proteins and DNA has clinical significance. This will
enable better understanding of the disease of interest and allow these biomarkers to
become potentially useful clinical tools.
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